PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 15138671-0 2004 Effects of dopexamine, dobutamine or dopamine on prolactin and thyreotropin serum concentrations in high-risk surgical patients. Dopamine 37-45 prolactin Homo sapiens 49-58 15138671-2 2004 The objective was to compare endocrine effects of equipotent inotropic doses of dopexamine, dobutamine and dopamine on prolactin and thyreotropin release perioperatively. Dopamine 107-115 prolactin Homo sapiens 119-128 15138671-12 2004 In contrast, dopamine suppressed prolactin and thyreotropin secretion with a maximal effect after 4 h. After dopamine withdrawal, a rebound release of prolactin and thyreotropin was observed. Dopamine 13-21 prolactin Homo sapiens 33-42 15138671-12 2004 In contrast, dopamine suppressed prolactin and thyreotropin secretion with a maximal effect after 4 h. After dopamine withdrawal, a rebound release of prolactin and thyreotropin was observed. Dopamine 13-21 prolactin Homo sapiens 151-160 15138671-12 2004 In contrast, dopamine suppressed prolactin and thyreotropin secretion with a maximal effect after 4 h. After dopamine withdrawal, a rebound release of prolactin and thyreotropin was observed. Dopamine 109-117 prolactin Homo sapiens 151-160 14562140-9 2003 Dopamine-agonist therapy is the first choice treatment for the PRL-induced sexual dysfunctions. Dopamine 0-8 prolactin Homo sapiens 63-66 15006013-2 2004 Prolactin secretion is promoted by various physiological stimuli and pathological processes and is inhibited by the action of dopamine on the lactotroph cells of the hypothalamus. Dopamine 126-134 prolactin Homo sapiens 0-9 14616880-2 2003 DESIGN: Comparison of the TSH and PRL responses to dopamine antagonism with domperidone (10 mg i.v.) Dopamine 51-59 prolactin Homo sapiens 34-37 14616880-6 2003 RESULTS: Patients with macroprolactinaemia showed normal TSH and PRL responses to dopamine antagonism whereas patients with microprolactinomas showed exaggerated TSH responses and reduced PRL responses. Dopamine 82-90 prolactin Homo sapiens 65-68 14870917-1 2004 Prolactin (PRL) secretion by the pituitary is under the control of dopamine. Dopamine 67-75 prolactin Homo sapiens 0-9 14870917-1 2004 Prolactin (PRL) secretion by the pituitary is under the control of dopamine. Dopamine 67-75 prolactin Homo sapiens 11-14 14659314-2 2003 Women undergoing chemotherapy for breast cancer are often administered dopamine antagonist adjuvant medications that may increase levels of prolactin potentially increasing the risk of cancer. Dopamine 71-79 prolactin Homo sapiens 140-149 12966789-5 2003 The application of a dopamine agonist lead to a reduction of serum prolactin level to 0.5% of the initial value and a considerable tumor regression within three months. Dopamine 21-29 prolactin Homo sapiens 67-76 12728300-11 2003 The greater prolactin response to l-tryptophan infusion in depressed subjects may be the result of an increase in dopamine receptor sensitivity, secondary to reduced dopamine levels. Dopamine 114-122 prolactin Homo sapiens 12-21 12763633-1 2003 Physiologic control of prolactin (PRL) secretion is largely dependent upon levels of dopamine accessing the adenohypophysis via the hypophysial portal vessels. Dopamine 85-93 prolactin Homo sapiens 23-32 12763633-1 2003 Physiologic control of prolactin (PRL) secretion is largely dependent upon levels of dopamine accessing the adenohypophysis via the hypophysial portal vessels. Dopamine 85-93 prolactin Homo sapiens 34-37 12824819-12 2003 CONCLUSIONS: These results confirm estradiol"s inhibition of D2 function and provide novel evidence that ethanol, like estradiol, reduces dopamine"s ability to inhibit PRL release by modifying alternative splicing of the dopamine D2 receptor in the pituitary. Dopamine 138-146 prolactin Homo sapiens 168-171 12660899-14 2003 We therefore suggest a drug treatment trial with dopamine agonists in all macroadenoms with hyperprolactinemia, particularly in those with prolactin levels above 2000 mU/l (100 ng/ml). Dopamine 49-57 prolactin Homo sapiens 97-106 12364416-5 2002 Eleven months of dopamine agonist therapy at standard doses lowered PRL levels to 299 micro g/liter. Dopamine 17-25 prolactin Homo sapiens 68-71 12466351-0 2002 Demonstration of enhanced potency of a chimeric somatostatin-dopamine molecule, BIM-23A387, in suppressing growth hormone and prolactin secretion from human pituitary somatotroph adenoma cells. Dopamine 61-69 prolactin Homo sapiens 126-135 12470131-1 2002 BACKGROUND: Although animal studies have raised the possibility that prolactin-elevating dopamine antagonists used to treat psychotic disorders may initiate and promote breast cancers, epidemiologic studies in humans have been limited and inconsistent. Dopamine 89-97 prolactin Homo sapiens 69-78 12470131-7 2002 The increased risk was also seen in women who used prolactin-elevating antiemetic dopamine antagonists despite having different breast cancer risk profiles than antipsychotic dopamine antagonist users. Dopamine 82-90 prolactin Homo sapiens 51-60 12387684-10 2002 However, prolactin is secreted by the anterior pituitary and is under inhibitory control of dopamine released from the tuberoinfundibular neurones. Dopamine 92-100 prolactin Homo sapiens 9-18 12387684-11 2002 Thus, increases in prolactin are due to antipsychotic impact on tuberoinfundibular tract, one of four dopamine-related tracts. Dopamine 102-110 prolactin Homo sapiens 19-28 11942771-1 2002 OBJECTIVE: To investigate whether the serum prolactin (PRL) response to a dopamine antagonist was different in nonobese, euthyroid women with malignant or benign breast tumors in comparison with healthy women, considering their age at first full-term pregnancy or their nulliparity. Dopamine 74-82 prolactin Homo sapiens 44-53 12161478-9 2002 A periodic assessment of PRL levels during BRC (and other dopamine-agonist drugs) withdrawal is recommended to avoid the unnecessary maintenance of therapy in a subset of patients with prolactinomas. Dopamine 58-66 prolactin Homo sapiens 25-28 12585566-7 2002 This paper reviews the published literature regarding prolactin levels in treated and untreated patients with schizophrenia and the relationship of prolactin and dopamine. Dopamine 162-170 prolactin Homo sapiens 148-157 12173917-11 2002 Dopamine agonist therapy was initiated, and the prolactin level and size of the tumor decreased substantially. Dopamine 0-8 prolactin Homo sapiens 48-57 12063637-5 2002 These peptide hormones" ability to decrease circulating prolactin concentrations may be mediated in part by dopamine and in part by their demonstrated ability to decrease corticotropin-releasing hormone concentrations, which stimulate prolactin release. Dopamine 108-116 prolactin Homo sapiens 56-65 11942771-1 2002 OBJECTIVE: To investigate whether the serum prolactin (PRL) response to a dopamine antagonist was different in nonobese, euthyroid women with malignant or benign breast tumors in comparison with healthy women, considering their age at first full-term pregnancy or their nulliparity. Dopamine 74-82 prolactin Homo sapiens 55-58 11944969-9 2002 In parallel studies using a static incubation approach, somatostatin and dopamine, but not vasoactive intestinal polypeptide, were inhibitory to basal prolactin release in goldfish pituitary cells. Dopamine 73-81 prolactin Homo sapiens 151-160 11944969-10 2002 These results suggest that somatostatin and dopamine may serve as negative regulators of basal prolactin secretion and that extracellular Ca(2+) influx and protein kinase C activation may be important signaling events mediating prolactin release in the goldfish. Dopamine 44-52 prolactin Homo sapiens 95-104 11985379-2 2002 Dopamine is the major inhibitory factor of prolactin release and also influences growth hormone (hGH) secretion. Dopamine 0-8 prolactin Homo sapiens 43-52 11684336-3 2001 MPH blocks the reuptake of dopamine, thus enhancing synaptic dopamine which in turn antagonizes the release of prolactin (PL). Dopamine 27-35 prolactin Homo sapiens 111-120 11817505-5 2002 The present study thus suggests that the spectrum of nemonapride-induced side effects is characterized by predominant extrapyramidal symptoms, and that prolactin response as an index of dopamine blockade reflects severity of EPS at least in male patients treated with nemonapride. Dopamine 186-194 prolactin Homo sapiens 152-161 11739329-0 2001 Dopamine as a prolactin (PRL) inhibitor. Dopamine 0-8 prolactin Homo sapiens 25-28 11739329-4 2001 Dopamine reaches the pituitary via hypophysial portal blood from several hypothalamic nerve tracts that are regulated by PRL itself, estrogens, and several neuropeptides and neurotransmitters. Dopamine 0-8 prolactin Homo sapiens 121-124 11739329-6 2001 In addition to inhibiting PRL release by controlling calcium fluxes, dopamine activates several interacting intracellular signaling pathways and suppresses PRL gene expression and lactotroph proliferation. Dopamine 69-77 prolactin Homo sapiens 26-29 11739329-6 2001 In addition to inhibiting PRL release by controlling calcium fluxes, dopamine activates several interacting intracellular signaling pathways and suppresses PRL gene expression and lactotroph proliferation. Dopamine 69-77 prolactin Homo sapiens 156-159 11739329-7 2001 Thus, PRL homeostasis should be viewed in the context of a fine balance between the action of dopamine as an inhibitor and the many hypothalamic, systemic, and local factors acting as stimulators, none of which has yet emerged as a primary PRL releasing factor. Dopamine 94-102 prolactin Homo sapiens 6-9 11739329-8 2001 The generation of transgenic animals with overexpressed or mutated genes expanded our understanding of dopamine-PRL interactions and the physiological consequences of their perturbations. Dopamine 103-111 prolactin Homo sapiens 112-115 11904200-8 2002 Medical treatment with the dopamine agonist cabergoline was given; it was effective in normalizing prolactin levels and inducing tumor shrinkage. Dopamine 27-35 prolactin Homo sapiens 99-108 14558674-11 2002 Furthermore in patients with clinically controlled prolactinomas the presence of PRL variants should be ruled out to avoid an unnecessary increase of dopamine agonist dosage. Dopamine 150-158 prolactin Homo sapiens 81-84 11684336-3 2001 MPH blocks the reuptake of dopamine, thus enhancing synaptic dopamine which in turn antagonizes the release of prolactin (PL). Dopamine 27-35 prolactin Homo sapiens 122-124 11684336-3 2001 MPH blocks the reuptake of dopamine, thus enhancing synaptic dopamine which in turn antagonizes the release of prolactin (PL). Dopamine 61-69 prolactin Homo sapiens 111-120 11684336-3 2001 MPH blocks the reuptake of dopamine, thus enhancing synaptic dopamine which in turn antagonizes the release of prolactin (PL). Dopamine 61-69 prolactin Homo sapiens 122-124 11679501-3 2001 It is suggested that a reduction of the dopamine inhibitory effect might raise both prolactin (PRL) and LH. Dopamine 40-48 prolactin Homo sapiens 84-93 11318782-13 2001 Dopamine agonists (DA) significantly suppressed PRL release in all the cultures, while GH secretion was significantly suppressed in three out of four. Dopamine 0-8 prolactin Homo sapiens 48-51 11680780-5 2001 The dopamine agonist bromocriptine, which inhibits pituitary secretion of prolactin, has been shown in a variety of small animal and human trials to reduce disease activity in SLE. Dopamine 4-12 prolactin Homo sapiens 74-83 11413749-11 2001 Under dopamine agonist therapy prolactin levels rose to a maximum of 6460 ng/ml to decline thereafter to normal values, and the visual disturbances recovered. Dopamine 6-14 prolactin Homo sapiens 31-40 11761431-2 2001 However, their relative incidence in recent surgical series is much less impressive since medical treatment with dopamine agonists is routinely employed, which in many cases leads to tumor shrinkage and normalization of prolactin levels. Dopamine 113-121 prolactin Homo sapiens 220-229 11577979-1 2001 Although dopamine is considered the major hypothalamic controller of prolactin release from the anterior pituitary gland, there is evidence that a yet to be discovered prolactin releasing factor (PRF) also exists in brain. Dopamine 9-17 prolactin Homo sapiens 69-78 11294478-11 2001 Furthermore, PRL has wide intra-interindividual and circadian variations Li-PRL relationship seems to be very complex and probably depends on various interactions among dopamine, serotonin and PRL. Dopamine 169-177 prolactin Homo sapiens 76-79 11163716-10 2001 The higher effect of pimozide upon TRH stimulated PRL and TSH release at day 8 compared to days 0 and 3 indicates a progressive involvement of dopamine on the inhibition of PRL and the sensitivity of the thyrotrophs to TRH during drying off. Dopamine 143-151 prolactin Homo sapiens 173-176 11294478-11 2001 Furthermore, PRL has wide intra-interindividual and circadian variations Li-PRL relationship seems to be very complex and probably depends on various interactions among dopamine, serotonin and PRL. Dopamine 169-177 prolactin Homo sapiens 13-16 11294478-11 2001 Furthermore, PRL has wide intra-interindividual and circadian variations Li-PRL relationship seems to be very complex and probably depends on various interactions among dopamine, serotonin and PRL. Dopamine 169-177 prolactin Homo sapiens 76-79 11167186-2 2001 BACKGROUND: To investigate the role of dopamine on the mechanisms of maternal prolactin secretion during labor and in the first six hours following delivery. Dopamine 39-47 prolactin Homo sapiens 78-87 11721691-3 2001 Most cases of hyperprolactinemia are due to prolactin secreting pituitary tumors or to medications which alter dopamine production. Dopamine 111-119 prolactin Homo sapiens 19-28 11721704-2 2001 It has been hypothesized that bromocriptine, a dopamine analog that suppresses pituitary secretion of prolactin, suppresses circulating prolactin and, through this mechanism, has the potential to suppress autoimmune disease. Dopamine 47-55 prolactin Homo sapiens 102-111 11383480-3 2000 In a 22-year-old man (case 1) with delayed puberty and low testosterone levels, mild hyperprolactinemia was diagnosed and treated with dopamine agonist therapy that reduced the prolactin (PRL) levels to normal. Dopamine 135-143 prolactin Homo sapiens 90-99 11813510-7 2001 Functional diversity among PRL cells is documented in vitro, in terms of basal and synthetic capacity and in respect to responsiveness to dopamine and oestrogen regulation. Dopamine 138-146 prolactin Homo sapiens 27-30 11383480-3 2000 In a 22-year-old man (case 1) with delayed puberty and low testosterone levels, mild hyperprolactinemia was diagnosed and treated with dopamine agonist therapy that reduced the prolactin (PRL) levels to normal. Dopamine 135-143 prolactin Homo sapiens 188-191 11081147-8 2000 An eight-week trial of relatively low dose dopamine agonists led to a reduction of PRL, while the GH- and IGF-1 levels remained unchanged; the tumor showed only little shrinkage. Dopamine 43-51 prolactin Homo sapiens 83-86 11015620-7 2000 Finally, although it is well known that dopamine of hypothalamic origin provides inhibitory control over the secretion of prolactin, other factors within the brain, pituitary gland, and peripheral organs have been shown to inhibit or stimulate prolactin secretion as well. Dopamine 40-48 prolactin Homo sapiens 122-131 11015620-7 2000 Finally, although it is well known that dopamine of hypothalamic origin provides inhibitory control over the secretion of prolactin, other factors within the brain, pituitary gland, and peripheral organs have been shown to inhibit or stimulate prolactin secretion as well. Dopamine 40-48 prolactin Homo sapiens 244-253 10999785-8 2000 All patients had at least one follow-up visit, and the most recent serum PRL measurement after initiating dopamine agonist therapy was reported. Dopamine 106-114 prolactin Homo sapiens 73-76 10892620-7 2000 A significant negative correlation between Animal Naming Test scores and plasma prolactin suggests that a decrement in brain dopamine secretion is related to reduced animal naming ability. Dopamine 125-133 prolactin Homo sapiens 80-89 11069474-2 2000 In all three patients, administration of bromocriptine, a dopamine agonist that suppresses the secretion of prolactin, improved the therapeutic response of the psoriasis. Dopamine 58-66 prolactin Homo sapiens 108-117 10705038-2 2000 Although this pituitary hormone has been long suspected to be involved in the progression of human breast cancer, the failure of clinical improvement by treatment with dopamine agonists (which lower circulating levels of PRL) rapidly reduced the interest of oncologists concerning a potential role of PRL in the development of breast cancer. Dopamine 168-176 prolactin Homo sapiens 221-224 10705038-4 2000 In agreement with a recent epidemiological study, these observations have led to a reconsideration of the role of PRL as an active participant in breast cancer, and are an impetus to redefine the molecular targets of anti-prolactin strategies since dopamine analogs are assumed to be inefficient on extrapituitary PRL synthesis. Dopamine 249-257 prolactin Homo sapiens 222-231 10691808-1 2000 Dopamine modulates cardiovascular function by actions in the central and peripheral nervous system, by altering the secretion/release of prolactin, pro-opiomelanocortin, vasopressin, aldosterone, and renin, and by directly affecting renal function. Dopamine 0-8 prolactin Homo sapiens 137-146 10468974-13 1999 Dopamine agonist therapy resulted in substantial falls in serum PRL and this was associated with improvement or resolution of symptoms in some patients. Dopamine 0-8 prolactin Homo sapiens 64-67 16985734-4 2000 Bromocriptine, a dopamine agonist, is efficacious in lowering elevated prolactin levels and can simultaneously shrink these pituitary tumors. Dopamine 17-25 prolactin Homo sapiens 71-80 10472432-13 1999 Our results suggest that both suppression tests with OCT and BCR, and scintigraphic studies in vivo with 123I-IBZM and 111In-OCT can be predictive for the effectiveness of therapies with dopamine agonists and/or SS-analogs in patients with mixed PRL/GH-secreting pituitary tumors. Dopamine 187-195 prolactin Homo sapiens 246-249 10718101-8 2000 Dopamine agonists are very effective in the treatment of prolactin (PRL)-secreting tumours, with rates of control as high as 80 to 90% for microprolactinomas (< 10 mm) and 60 to 75% for macroprolactinomas (> or = 10 mm). Dopamine 0-8 prolactin Homo sapiens 57-66 10397281-14 1999 The transient effect on prolactin levels may reflect acute changes in opioid and dopamine levels in the hypothalamus. Dopamine 81-89 prolactin Homo sapiens 24-33 10424206-18 1999 However, dopamine agonist (DA) therapy, usually resulting in satisfactory control of PRL levels and in tumor shrinkage, progressively displaced surgery as primary treatment for prolactinomas throughout the study period. Dopamine 9-17 prolactin Homo sapiens 85-88 10420090-0 1999 Potentiation of prolactin secretion following lactotrope escape from dopamine action. Dopamine 69-77 prolactin Homo sapiens 16-25 10420090-3 1999 Hypothalamic dopamine (DA) tonically inhibits prolactin (PRL) release from the anterior pituitary gland. Dopamine 13-21 prolactin Homo sapiens 46-55 10420090-3 1999 Hypothalamic dopamine (DA) tonically inhibits prolactin (PRL) release from the anterior pituitary gland. Dopamine 13-21 prolactin Homo sapiens 57-60 10420090-7 1999 We initially found that in these cells, DA effectively and reversibly inhibited PRL secretion, and reversibly enhanced an inwardly rectifying K(+) current. Dopamine 40-42 prolactin Homo sapiens 80-83 10420090-12 1999 The present results directly demonstrate that dissociation of DA from D(2)-receptors expressed in GH(4)C(1) lactotrope cells causes an increase of high-voltage-activated Ca(2+) channel function, which may play an important role in the cross-talking amplification of endocrine cascades such as that involved in the TRH-induced PRL-release potentiating action of DA withdrawal. Dopamine 62-64 prolactin Homo sapiens 326-329 10420091-0 1999 Potentiation of prolactin secretion following lactotrope escape from dopamine action. Dopamine 69-77 prolactin Homo sapiens 16-25 10420091-5 1999 Prolactin (PRL) secretion is tonically inhibited by dopamine (DA), the escape from which triggers acute episodes of hormone secretion. Dopamine 52-60 prolactin Homo sapiens 0-9 10420091-5 1999 Prolactin (PRL) secretion is tonically inhibited by dopamine (DA), the escape from which triggers acute episodes of hormone secretion. Dopamine 52-60 prolactin Homo sapiens 11-14 10420091-5 1999 Prolactin (PRL) secretion is tonically inhibited by dopamine (DA), the escape from which triggers acute episodes of hormone secretion. Dopamine 62-64 prolactin Homo sapiens 0-9 10420091-5 1999 Prolactin (PRL) secretion is tonically inhibited by dopamine (DA), the escape from which triggers acute episodes of hormone secretion. Dopamine 62-64 prolactin Homo sapiens 11-14 10420091-9 1999 Here we show that the withdrawal from DA potentiates the PRL-releasing action of TRH in GH(4)C(1)/D(2)-DAR cells to the same extent as in enriched lactotropes in primary culture. Dopamine 38-40 prolactin Homo sapiens 57-60 10411322-1 1999 Although prolactin (PRL) has been long suspected to be involved in the progression of human breast cancer, the failure of clinical improvement by treatment with dopamine agonists, which lower circulating levels of PRL, rapidly reduced the interest of oncologists concerning a potential role of this pituitary hormone in the development of breast cancer. Dopamine 161-169 prolactin Homo sapiens 214-217 10338264-10 1999 In most cases, dopamine agonists (bromocriptine, pergolide, cabergoline) are extremely effective in lowering serum prolactin, restoring gonadal function, decreasing tumor size, and improving visual fields. Dopamine 15-23 prolactin Homo sapiens 115-124 10338264-12 1999 The newest dopamine agonist, cabergoline, can be given just once or twice a week, is more effective in normalizing prolactin and restoring menses than bromocriptine, and is significantly better tolerated. Dopamine 11-19 prolactin Homo sapiens 115-124 9833836-4 1998 Hyperprolactinemia, with levels of prolactin as high as 150 ng/ml, is commonly associated with sellar tumors and is attributed to disruption of the normal delivery of dopamine to the adenohypophysis. Dopamine 167-175 prolactin Homo sapiens 5-14 9934942-7 1999 Prolactin response after 1 week of treatment as an index of dopamine blockade may reflect vulnerability to the development of acute dystonia at least in male patients treated with nemonapride. Dopamine 60-68 prolactin Homo sapiens 0-9 10190227-3 1999 These new antipsychotics appear to spare dopamine blockade within the brain"s tubero-infundibular tract, a dopamine pathway that also controls prolactin secretion. Dopamine 107-115 prolactin Homo sapiens 143-152 10190227-4 1999 Since the release of prolactin is tonically inhibited by the hypothalamus, with dopamine acting as the prolactin release-inhibiting factor, any disruption of the connection between the hypothalamus and the pituitary gland is associated with hyperprolactinemia. Dopamine 80-88 prolactin Homo sapiens 103-112 9822800-3 1998 As we have previously shown that vasoactive intestinal peptide (VIP) mediates through an autocrine or paracrine action the PRL release induced by insulin-like growth factor I, thyrotropin-releasing hormone (TRH) and dopamine withdrawal, the aim of the present work was to determine whether 5-HT has a direct action on pituitary secretion and to study the possible role of pituitary VIP in this situation. Dopamine 216-224 prolactin Homo sapiens 123-126 9822660-4 1998 The potential role of ERF in the inhibitory response of the prolactin promoter to dopamine was examined using pituitary tumor cells stably expressing dopamine D2 receptors. Dopamine 82-90 prolactin Homo sapiens 60-69 9822660-5 1998 The inhibitory responses of the prolactin promoter to ERF and dopamine are additive, suggesting that ERF has a complementary role in this hormonal response. Dopamine 62-70 prolactin Homo sapiens 32-41 9451892-2 1997 Bromocriptine (BRC) is a dopamine agonist that suppresses secretion of PRL. Dopamine 25-33 prolactin Homo sapiens 71-74 9593964-1 1998 Dopamine (DA), produced by tubero-infundibular dopaminergic (TIDA) neurons of the arcuate nucleus (ARN) is the established inhibitor of the secretion of prolactin (PRL). Dopamine 0-8 prolactin Homo sapiens 164-167 9593964-1 1998 Dopamine (DA), produced by tubero-infundibular dopaminergic (TIDA) neurons of the arcuate nucleus (ARN) is the established inhibitor of the secretion of prolactin (PRL). Dopamine 10-12 prolactin Homo sapiens 164-167 9593964-2 1998 Changes in dopaminergic (DAergic) neuronal activity in the median eminence-long portal vessels (ME-LPV) and/or the concentration of DA in the anterior lobe (AL) are inversely related to the secretion of PRL. Dopamine 25-27 prolactin Homo sapiens 203-206 9535530-6 1998 However, simple regression analysis of the individual data revealed that the magnitude of the dopamine-induced decrease in serum prolactin was significantly influenced by gestational age (p = 0.006) and birthweight (p = 0.037). Dopamine 94-102 prolactin Homo sapiens 129-138 10806816-1 1998 Dopamine agonists effectively reduce the secretion of prolactin (PRL) in the great majority of prolactinomas and reduce the bulk of the adenomas, as well as have partial therapeutic effect on some patients with acromegaly. Dopamine 0-8 prolactin Homo sapiens 54-63 10806816-1 1998 Dopamine agonists effectively reduce the secretion of prolactin (PRL) in the great majority of prolactinomas and reduce the bulk of the adenomas, as well as have partial therapeutic effect on some patients with acromegaly. Dopamine 0-8 prolactin Homo sapiens 65-68 9648050-1 1998 Dopamine in humans inhibits the secretion of luteinizing hormone (LH), follicular stimulating hormone (FSH), thyroid stimulating hormone (TSH) and prolactin (PRL), and is a stimulator of growth hormone (GH) secretion. Dopamine 0-8 prolactin Homo sapiens 158-161 9545000-11 1998 Prolactin secretion may serve as an extremely sensitive marker for the hypothalamic dopamine content under different therapeutic regimens. Dopamine 84-92 prolactin Homo sapiens 0-9 9535530-0 1998 Developmental regulation of the inhibitory effect of dopamine on prolactin release in the preterm neonate. Dopamine 53-61 prolactin Homo sapiens 65-74 9535530-1 1998 The secretion and release of prolactin from the anterior pituitary is under the tonic inhibitory control of endogenous dopamine produced in the central nervous system. Dopamine 119-127 prolactin Homo sapiens 29-38 9535530-2 1998 Exogenous dopamine inhibits prolactin secretion by reaching the pituitary via the portal circulation, and the hypolactotropic effect of dopamine infusion has been documented in all age groups in humans. Dopamine 10-18 prolactin Homo sapiens 28-37 9535530-5 1998 As expected, dopamine therapy resulted in a decrease in mean serum prolactin from 89.4+/-9.5 to 58.6+/-9.1 microg/l (p < 0.05) with a return of the serum prolactin concentration to the pretreatment level 2-6 h after discontinuation of drug administration (98.3+/-11.7 microg/l, p < 0.05). Dopamine 13-21 prolactin Homo sapiens 67-76 9535530-5 1998 As expected, dopamine therapy resulted in a decrease in mean serum prolactin from 89.4+/-9.5 to 58.6+/-9.1 microg/l (p < 0.05) with a return of the serum prolactin concentration to the pretreatment level 2-6 h after discontinuation of drug administration (98.3+/-11.7 microg/l, p < 0.05). Dopamine 13-21 prolactin Homo sapiens 157-166 9736322-2 1998 The regulation of pituitary prolactin secretion is complex and involves a negative feedback process in the hypothalamus, in which dopamine plays the principal role. Dopamine 130-138 prolactin Homo sapiens 28-37 9110224-1 1997 This experiment was designed to determine 1) the efficacy of daily s.c. injections of a dopamine antagonist, sulpiride, for increasing prolactin secretion in geldings in winter and 2) whether increasing prolactin concentrations would hasten the onset of hair shedding or enhance gonadotropin secretion. Dopamine 88-96 prolactin Homo sapiens 135-144 9396279-3 1997 Dopamine is the major physiologic prolactin inhibiting factor (PIF). Dopamine 0-8 prolactin Homo sapiens 34-43 9211435-6 1997 In contrast, dopamine-induced PRL decrement was significantly lighter in alcoholics than in controls. Dopamine 13-21 prolactin Homo sapiens 30-33 9059216-0 1997 Effect of low-dose dopamine on serum concentrations of prolactin in critically ill patients. Dopamine 19-27 prolactin Homo sapiens 55-64 9059216-1 1997 Dopamine is a naturally occurring catecholamine with actions in the central nervous system and endocrine systems, including inhibition of prolactin release from the pituitary gland. Dopamine 0-8 prolactin Homo sapiens 138-147 9059216-3 1997 We have investigated the effects of low-dose infusion of dopamine 2.5 micrograms kg-1 min-1 on serum concentrations of prolactin in critically ill patients. Dopamine 57-65 prolactin Homo sapiens 119-128 9059216-4 1997 Six hours after commencing the dopamine infusion, mean serum prolactin concentration had decreased from 746.95 to 128.9 mu. Dopamine 31-39 prolactin Homo sapiens 61-70 8888369-1 1996 Prolactin (PRL) and melatonin (ML) secretion are mediated by dopamine (DA) and norepinephrine (NE), respectively. Dopamine 61-69 prolactin Homo sapiens 0-9 9055023-5 1996 This represents one of the highest serum prolactin levels reported in the literature in a patient with a prolactin-secreting pituitary tumour and illustrates the remarkable efficacy of dopamine agonist therapy in patients with large macroprolactinomas. Dopamine 185-193 prolactin Homo sapiens 41-50 9055023-5 1996 This represents one of the highest serum prolactin levels reported in the literature in a patient with a prolactin-secreting pituitary tumour and illustrates the remarkable efficacy of dopamine agonist therapy in patients with large macroprolactinomas. Dopamine 185-193 prolactin Homo sapiens 105-114 8843016-5 1996 One possibility is that melatonin acts at the level of the hypothalamus to modulate the release of the hypothalamic prolactin inhibitory factor, dopamine (7). Dopamine 145-153 prolactin Homo sapiens 116-125 15251513-3 1996 RESULTS: In patients with prolactinomas, medical therapy with a dopamine agonist constitutes the primary treatment and is usually associated with normalization of prolactin levels, tumor shrinkage, and resolution of clinical symptoms. Dopamine 64-72 prolactin Homo sapiens 26-35 21584119-6 1996 Status of prolactin - dopamine relationship and its correlation to neuro - cognition may be another pointer in guiding some of these complex issues. Dopamine 22-30 prolactin Homo sapiens 10-19 8888369-1 1996 Prolactin (PRL) and melatonin (ML) secretion are mediated by dopamine (DA) and norepinephrine (NE), respectively. Dopamine 61-69 prolactin Homo sapiens 11-14 8888369-1 1996 Prolactin (PRL) and melatonin (ML) secretion are mediated by dopamine (DA) and norepinephrine (NE), respectively. Dopamine 71-73 prolactin Homo sapiens 0-9 8888369-1 1996 Prolactin (PRL) and melatonin (ML) secretion are mediated by dopamine (DA) and norepinephrine (NE), respectively. Dopamine 71-73 prolactin Homo sapiens 11-14 8803308-2 1996 Because of its central dopamine antagonist property, it can be a potent stimulant of prolactin release and cause extrapyramidal movement disorders. Dopamine 23-31 prolactin Homo sapiens 85-94 8964874-0 1996 Treatment of prolactin-secreting macroadenomas with the once-weekly dopamine agonist cabergoline. Dopamine 68-76 prolactin Homo sapiens 13-22 8881162-4 1996 Treatment modalities include dopamine agonist therapy such as bromocriptine which allows normalization of prolactin levels, restoration of gonadal functions and tumor shrinkage in most cases. Dopamine 29-37 prolactin Homo sapiens 106-115 8737186-5 1996 Dopamine infusion, compared to saline, caused a significant prolactin decrease in all the three groups of subjects, without significant difference between micro- and macroprolactinoma patients. Dopamine 0-8 prolactin Homo sapiens 60-69 7670564-1 1995 The responsiveness in vivo to dopamine of prolactin (PRL) secretion in patients with prolactinoma was compared with that in vitro of single cells obtained from the same prolactinomas by surgical operations. Dopamine 30-38 prolactin Homo sapiens 42-51 8772480-2 1996 To determine whether the mechanism involved a decrease in the PRL response to dopamine (DA), we infused low doses of DA, finding that the percent inhibition of PRL was not affected by verapamil (max %decrements for 0.003, 0.01, and 0.03 microgram.kg-1.min-1 doses of DA, respectively, 86.7 +/- 19.1, 73.2 +/- 24.8, and 65.2 +/- 20.0% without verapamil and 93.4 +/- 24.6, 79.7 +/- 14.9, and 58.0 +/- 18.1% with verapamil). Dopamine 78-86 prolactin Homo sapiens 62-65 8772480-2 1996 To determine whether the mechanism involved a decrease in the PRL response to dopamine (DA), we infused low doses of DA, finding that the percent inhibition of PRL was not affected by verapamil (max %decrements for 0.003, 0.01, and 0.03 microgram.kg-1.min-1 doses of DA, respectively, 86.7 +/- 19.1, 73.2 +/- 24.8, and 65.2 +/- 20.0% without verapamil and 93.4 +/- 24.6, 79.7 +/- 14.9, and 58.0 +/- 18.1% with verapamil). Dopamine 88-90 prolactin Homo sapiens 62-65 8530591-5 1995 To test these hypotheses, we examined PRL responsiveness to TRH and the dopamine antagonist, perphenazine (PZ), in patients with pituitary macroadenomas who had hypopituitarism and others with intact pituitary function (controls). Dopamine 72-80 prolactin Homo sapiens 38-41 8540286-2 1995 This postpartum prolactin rise can be prevented by administration of dopamine agonists. Dopamine 69-77 prolactin Homo sapiens 16-25 8737186-8 1996 Dopamine infusion induced a significant and comparable increase in the prolactin response to metoclopramide in micro- and macroprolactinoma patients, while it was ineffective in control subjects. Dopamine 0-8 prolactin Homo sapiens 71-80 8530591-16 1995 The mild increase in serum PRL levels in hypopituitary patients and the discordant responses to stimulation with TRH and PZ suggest dopamine deficiency as a cause of hyperprolactinemia. Dopamine 132-140 prolactin Homo sapiens 27-30 7597365-5 1995 Drug therapy with dopamine agonists will almost always decrease prolactin levels, but will rarely cure the disease. Dopamine 18-26 prolactin Homo sapiens 64-73 7670564-1 1995 The responsiveness in vivo to dopamine of prolactin (PRL) secretion in patients with prolactinoma was compared with that in vitro of single cells obtained from the same prolactinomas by surgical operations. Dopamine 30-38 prolactin Homo sapiens 53-56 7670564-7 1995 When the inhibition rates in vitro due to 10(-5) M dopamine in these two parameters were compared with the inhibition rate in vivo in the serum PRL concentration due to bromocriptine, it was found that there was a significant correlation between them. Dopamine 51-59 prolactin Homo sapiens 144-147 7670564-8 1995 These results show that the reverse hemolytic plaque assay can be used to determine in vitro responsiveness to dopamine of PRL secretion from single prolactinoma cells. Dopamine 111-119 prolactin Homo sapiens 123-126 8137548-1 1994 Bromocriptine (BRC), a dopamine type 2 agonist, prevents secretion of pituitary prolactin (PRL). Dopamine 23-31 prolactin Homo sapiens 91-94 7529411-21 1995 NO appears to play little role in the prolactin-releasing action of vasoactive intestinal polypeptide and substance P, but mediates the prolactin-inhibiting activity of dopamine and atrial natriuretic factor. Dopamine 169-177 prolactin Homo sapiens 136-145 7955444-1 1994 OBJECTIVE: Reduced PRL responses to TRH or dopamine antagonists have been described in hyperthyroid patients. Dopamine 43-51 prolactin Homo sapiens 19-22 7714616-0 1995 Prolactin-producing pituitary tumor: resistance to dopamine agonist therapy. Dopamine 51-59 prolactin Homo sapiens 0-9 7529411-15 1995 Dopamine (0.1 microM), an inhibitor of prolactin release, reduced prolactin release, and this inhibitory action was significantly blocked by either hemoglobin (20 micrograms/ml) or NMMA and was completely blocked by 1 mM nitroarginine methyl ester. Dopamine 0-8 prolactin Homo sapiens 39-48 7529411-15 1995 Dopamine (0.1 microM), an inhibitor of prolactin release, reduced prolactin release, and this inhibitory action was significantly blocked by either hemoglobin (20 micrograms/ml) or NMMA and was completely blocked by 1 mM nitroarginine methyl ester. Dopamine 0-8 prolactin Homo sapiens 66-75 7977731-0 1994 Stimulation of prolactin release by dopamine withdrawal: role of membrane hyperpolarization. Dopamine 36-44 prolactin Homo sapiens 15-24 7977731-1 1994 Hypothalamic dopamine (DA) tonically inhibits prolactin (PRL) release from the anterior pituitary gland, whereas removal of DA markedly augments its release to values exceeding pre-DA rates. Dopamine 13-21 prolactin Homo sapiens 46-55 7977731-1 1994 Hypothalamic dopamine (DA) tonically inhibits prolactin (PRL) release from the anterior pituitary gland, whereas removal of DA markedly augments its release to values exceeding pre-DA rates. Dopamine 23-25 prolactin Homo sapiens 46-55 7969823-1 1994 The most prominent previously reported clinical features of growth hormone (GH) and prolactin (PRL)-secreting pituitary adenomas associated with acromegaly have included the high incidence of galactorrhea in women and a generally more favorable response to dopamine agonist therapy. Dopamine 257-265 prolactin Homo sapiens 84-93 7907340-1 1994 Dopamine, acting via its specific receptor (DRD2) in the anterior pituitary, tonically inhibits pituitary prolactin secretion and lactotroph proliferation. Dopamine 0-8 prolactin Homo sapiens 106-115 7907340-2 1994 In addition, dopamine agonist therapy for pituitary prolactinomas results in reduction of prolactin secretion and tumor regression. Dopamine 13-21 prolactin Homo sapiens 52-61 7907340-3 1994 These observations lead to the speculation that functional dopamine uncoupling may release lactotrophs from the inhibitory effects of dopamine and contribute to the development of prolactin (PRL)-secreting pituitary tumors. Dopamine 59-67 prolactin Homo sapiens 180-189 7890021-2 1994 Pharmacological reduction of Prl release by dopamine agonists or treatment with extracts of Agnus castus (AC) improve the clinical situation of patients with such premenstrual symptoms. Dopamine 44-52 prolactin Homo sapiens 29-32 8167201-3 1994 More severe impairment on these summary measures was significantly associated with greater biological evidence of dopamine blockade (more severe extrapyramidal side effects and higher serum prolactin levels). Dopamine 114-122 prolactin Homo sapiens 190-199 8284103-0 1993 Dopamine inhibits growth hormone and prolactin secretion in the human newborn. Dopamine 0-8 prolactin Homo sapiens 37-46 8266982-2 1993 Inhibition of prolactin secretion by a dopamine agonist restores menses and reduces tumor size. Dopamine 39-47 prolactin Homo sapiens 14-23 8284103-4 1993 We observed strikingly low serum concentrations of growth hormone (GH) and prolactin (PRL) during a therapeutic, standardized, isovolumetric, partial exchange transfusion (blood sampling every 20 min for 6 h) in two polycythemic neonates requiring intensive therapy, including continuous dopamine infusion. Dopamine 288-296 prolactin Homo sapiens 86-89 8284103-9 1993 During the dopamine infusion, GH secretion was virtually abolished and PRL release was reduced by at least 50%. Dopamine 11-19 prolactin Homo sapiens 71-74 8284103-10 1993 Dopamine withdrawal was associated with a rebound release of GH and PRL. Dopamine 0-8 prolactin Homo sapiens 68-71 8284103-13 1993 Within 2 h after dopamine withdrawal, GH and PRL levels increased a median 3-fold and 10-fold respectively. Dopamine 17-25 prolactin Homo sapiens 45-48 8284103-14 1993 These data concord to indicate that dopamine is a potent inhibitor of GH and PRL secretion in the human newborn. Dopamine 36-44 prolactin Homo sapiens 77-80 8254926-6 1993 Estrogen coupled with the receptors in the cytoplasma goes directly to the DNA region -1713-->-1495 being upstream to the starting site of prolactin transcription and differing from the region on which dopamine acts. Dopamine 205-213 prolactin Homo sapiens 142-151 8162388-4 1993 Among several possible regulators, inhibitory dopamine and stimulatory thyrotropin-releasing hormone (TRH) may take part in the regulation of prolactin levels in connection with epileptic activity. Dopamine 46-54 prolactin Homo sapiens 142-151 8258642-1 1993 To test the hypothesis that PRL is able to feedback negatively on its own secretion (short-loop feedback) in humans via augmentation of the turnover of tuberoinfundibular dopamine (TIDA), the effects of the administration of purified hPRL on endogenous LH, FSH and TSH were assessed. Dopamine 171-179 prolactin Homo sapiens 28-31 8103956-2 1993 True prolactinomas, usually characterized by pituitary lesions and circulating levels of prolactin in excess of 2 U/l (100 micrograms/l), are best treated with a dopamine agonist such as bromocriptine. Dopamine 162-170 prolactin Homo sapiens 5-14 8103956-5 1993 Patients with macroadenomas treated successfully with dopamine agonists should be given pituitary radiotherapy to provide long-term ablation of the prolactin-secreting cells and facilitate a gradual cessation of drug. Dopamine 54-62 prolactin Homo sapiens 148-157 8372607-5 1993 The portal concentration of dopamine and oxytocin (a prolactin stimulatory substance) may be increased in hyperprolactinaemia. Dopamine 28-36 prolactin Homo sapiens 53-62 8103956-7 1993 Pseudoprolactinomas usually associated with circulating prolactin levels < 2 U/l (100 micrograms/l) are caused by a peripituitary tumour which obstructs the flow of dopamine into the pituitary. Dopamine 168-176 prolactin Homo sapiens 6-15 8103956-8 1993 Treatment with dopamine agonists reduces prolactin levels but does not result in tumour shrinkage and so the treatment of choice is trans-sphenoidal surgery. Dopamine 15-23 prolactin Homo sapiens 41-50 8329652-2 1993 Control of prolactin secretion is complex and involves inhibition by dopamine and possibly endothelins, as well as stimulation by serotoninergic and opioidergic pathways, gonadotropin-releasing hormone, and possibly galanin. Dopamine 69-77 prolactin Homo sapiens 11-20 7678802-7 1993 Since dopamine inhibition of PRL release is mediated by several second messager pathways, including cAMP, inositol phosphates, and Ca2+, we investigated whether PKC depletion was able to interact with direct stimulation of these pathways. Dopamine 6-14 prolactin Homo sapiens 29-32 8097192-6 1993 This article discusses behavioral response to psychostimulant tests and pituitary hormone levels, particularly growth hormone and prolactin response to dopamine antagonist stimulation. Dopamine 152-160 prolactin Homo sapiens 130-139 8341771-10 1993 These data confirm the indirect pharmacologic evidence of increased dopaminergic activity in schizophrenic patients that relates to dopamine"s precursors and to the neuroendocrine regulation of prolactin. Dopamine 68-76 prolactin Homo sapiens 194-203 8474497-0 1993 Function of dopamine receptors in young-onset Parkinson"s disease: prolactin response. Dopamine 12-20 prolactin Homo sapiens 67-76 7678802-1 1993 The role of protein kinase C (PKC) on dopamine inhibition of PRL messenger RNA (mRNA) levels was studied in anterior pituitary cells kept in primary culture. Dopamine 38-46 prolactin Homo sapiens 61-64 7678802-12 1993 The data indicate that endogenous PKC can interfere with the regulation of PRL gene expression induced by both cAMP and Ca2+ pathways, two second messengers associated with the action of dopamine in lactotroph cells. Dopamine 187-195 prolactin Homo sapiens 75-78 8130181-2 1993 Plasma prolactin elevation was induced by administration of a dopamine antagonist drug domperidone (Motilium 10 mg orally, 9 subjects) and 2 h later the oral glucose tolerance test was performed. Dopamine 62-70 prolactin Homo sapiens 7-16 8299703-2 1993 Since it is known that endogenous opiates and dopamine interact in modulating PRL secretion, we have studied the effect of an opiate receptor blockade (with Naloxone, NAL, 1.6 mg/h as a continuous infusion) on anterior pituitary hormones and on PRL responsiveness to metoclopramide (MCP), in 10 premenopausal normoprolactinemic patients with PES, studied in follicular phase, in order to investigate neurotransmitter abnormalities present in such a syndrome. Dopamine 46-54 prolactin Homo sapiens 78-81 1458939-12 1992 MAIN RESULTS: Serum prolactin concentrations decreased > 90% (p < .001) within hours in all patients receiving dopamine infusions at study dose limit or above. Dopamine 117-125 prolactin Homo sapiens 20-29 8128789-6 1993 The persistence of elevated prolactin serum level gave necessity of dopamine agonist therapy postoperatively. Dopamine 68-76 prolactin Homo sapiens 28-37 1458939-14 1992 Dopamine infusions in medical ICU patients produced an immediate and profound reduction in serum prolactin concentrations in both males and females. Dopamine 0-8 prolactin Homo sapiens 97-106 1369597-0 1992 Influence of dopamine on the altered release of prolactin, luteinizing hormone, and follicle-stimulating hormone induced by interleukin-2 in vitro. Dopamine 13-21 prolactin Homo sapiens 48-57 1369597-3 1992 Since dopamine (DA) is a powerful inhibitor of PRL release, in the present experiments were evaluated possible dose dependent effects of DA on IL-2-induced alterations of the release of PRL, LH, and FSH. Dopamine 6-14 prolactin Homo sapiens 47-50 1369597-3 1992 Since dopamine (DA) is a powerful inhibitor of PRL release, in the present experiments were evaluated possible dose dependent effects of DA on IL-2-induced alterations of the release of PRL, LH, and FSH. Dopamine 6-14 prolactin Homo sapiens 186-189 1369597-3 1992 Since dopamine (DA) is a powerful inhibitor of PRL release, in the present experiments were evaluated possible dose dependent effects of DA on IL-2-induced alterations of the release of PRL, LH, and FSH. Dopamine 16-18 prolactin Homo sapiens 47-50 1369597-3 1992 Since dopamine (DA) is a powerful inhibitor of PRL release, in the present experiments were evaluated possible dose dependent effects of DA on IL-2-induced alterations of the release of PRL, LH, and FSH. Dopamine 137-139 prolactin Homo sapiens 186-189 1369597-5 1992 DA induced a dose-related, significant lowering of the basal PRL release with a minimal effective dose (MED) of less than 19 nM. Dopamine 0-2 prolactin Homo sapiens 61-64 1369597-14 1992 The effects of DA on PRL, LH, and FSH at all doses tested were blocked by the DA receptor blocker, haloperidol which by itself at the concentration tested (1 x 10(-5) M) had no effect. Dopamine 15-17 prolactin Homo sapiens 21-24 1352703-0 1992 The effects of a dopamine antagonist on luteinizing hormone and prolactin release in women with anorexia nervosa and in normal controls. Dopamine 17-25 prolactin Homo sapiens 64-73 1323636-5 1992 Prolactin levels increased 10-fold after metoclopramide with placebo infusion, and about 50% of this stimulation was abolished by preinfusion with dopamine. Dopamine 147-155 prolactin Homo sapiens 0-9 1350936-1 1992 We report the case of a 27-year-old woman with a prolactin-secreting macroadenoma of the pituitary gland who was under treatment with a new dopamine agonist, Sandoz CV 205-502. Dopamine 140-148 prolactin Homo sapiens 49-58 1618163-0 1992 Dissociation of dopamine from its receptor as a signal in the pleiotropic hypothalamic regulation of prolactin secretion. Dopamine 16-24 prolactin Homo sapiens 101-110 1618163-1 1992 We have reviewed the literature, which supports an important role for dopamine withdrawal in the regulation of PRL secretion. Dopamine 70-78 prolactin Homo sapiens 111-114 1618163-2 1992 Concentrations of dopamine in the hypophyseal portal circulation are sufficient to occupy the majority of dopamine receptors (1) and tonically suppress PRL secretion (20-26). Dopamine 18-26 prolactin Homo sapiens 152-155 1618163-4 1992 Therefore, dopamine regulates secretion of PRL both by occupancy of, as well as dissociation from, specific D2 dopamine receptors. Dopamine 11-19 prolactin Homo sapiens 43-46 1618163-7 1992 The removal of dopamine results directly in the release of PRL (37-41). Dopamine 15-23 prolactin Homo sapiens 59-62 1618163-8 1992 Furthermore, the brief removal of dopamine results in the long-term potentiation of the PRL-releasing action of TRH (38-40). Dopamine 34-42 prolactin Homo sapiens 88-91 1411301-1 1992 Dopamine inhibits prolactin release from pituitary cells and seems to affect the release of several other hormones as well. Dopamine 0-8 prolactin Homo sapiens 18-27 1411301-5 1992 When two of the hormones known to be under dopamine control, i.e. prolactin (PRL) and thyrotropin (TSH), were tested, they were able to prevent dopamine-induced cell death if combined with heparin. Dopamine 43-51 prolactin Homo sapiens 66-75 1411301-5 1992 When two of the hormones known to be under dopamine control, i.e. prolactin (PRL) and thyrotropin (TSH), were tested, they were able to prevent dopamine-induced cell death if combined with heparin. Dopamine 144-152 prolactin Homo sapiens 66-75 1351839-20 1992 Therefore, the contribution of the PR-positive periventricular dopamine neurons to progestin-stimulated PRL secretion may be important. Dopamine 63-71 prolactin Homo sapiens 104-107 1594706-6 1992 Plasma PRL and plasma HVA may reflect different elements of dopamine function in the central nervous system during maintenance treatment; plasma PRL may be the useful marker under these conditions. Dopamine 60-68 prolactin Homo sapiens 7-10 1564425-0 1992 Differential dopamine-induced prolactin mRNA levels in various prolactin-secreting cell (sub)populations. Dopamine 13-21 prolactin Homo sapiens 30-39 1564425-0 1992 Differential dopamine-induced prolactin mRNA levels in various prolactin-secreting cell (sub)populations. Dopamine 13-21 prolactin Homo sapiens 63-72 1564425-1 1992 We have examined the effects of dopamine on prolactin gene expression using quantitative in-situ hybridization histochemistry in different pituitary cell (sub)populations separated according to their density on a discontinuous Percoll gradient. Dopamine 32-40 prolactin Homo sapiens 44-53 1564425-2 1992 Administration of dopamine resulted in a drastic reduction in hybridization of 35S-labelled DNA probe complementary to prolactin mRNA in total pituitary cells and in lactotrophs with low density. Dopamine 18-26 prolactin Homo sapiens 119-128 1564425-3 1992 In contrast, dopamine significantly stimulated mRNA accumulation in prolactin-secreting cells with high density compared with other cell layers. Dopamine 13-21 prolactin Homo sapiens 68-77 1564425-5 1992 Prolactin-secreting cells with high and low density clearly show functional heterogeneity in their response to dopamine. Dopamine 111-119 prolactin Homo sapiens 0-9 1594711-5 1992 The results also suggest that drug-free schizophrenic patients may have a different pattern of prolactin variants than normal subjects and that this difference could be secondary to a disordered tuberoinfundibular dopamine system or long-term effects of neuroleptic drugs. Dopamine 214-222 prolactin Homo sapiens 95-104 11941158-0 1992 The Role of Dopamine in Seizure-Induced Prolactin Release in Humans. Dopamine 12-20 prolactin Homo sapiens 40-49 11941158-7 1992 The data suggest that the PRL plasma rise after ECT involves dopamine as it is not seen when the dopaminergic inhibitory tone, exerted by the hypothalamus on the pituitary lactotroph, has been removed. Dopamine 61-69 prolactin Homo sapiens 26-29 2068891-3 1991 Histamine stimulates the secretion of ACTH, beta-endorphin (mediated by CRH and AVP), alpha-MSH (mediated by dopamine and peripheral catecholamines), and PRL (mediated by dopamine, serotonin and AVP), and participates in the stress-induced release of these hormones and possibly in the suckling- and estrogen-induced PRL release. Dopamine 171-179 prolactin Homo sapiens 154-157 1684803-1 1991 CV 205-502, a benzoquinoline, is a new nonergot dopamine agonist compound which has been shown to be effective in lowering PRL levels in normal volunteers and in hyperprolactinemic women. Dopamine 48-56 prolactin Homo sapiens 123-126 1912121-0 1991 Prolactin response to the dopamine antagonist, metoclopramide, in depression. Dopamine 26-34 prolactin Homo sapiens 0-9 1687293-2 1991 Consequently new dopamine agonists have been developed, including the long acting non-ergot agonist CV205-502 which has been shown to date to be consistently effective in reducing serum PRL levels and causing tumour shrinkage. Dopamine 17-25 prolactin Homo sapiens 186-189 18411177-1 1991 Macroprolactinomas will usually shrink with dopamine agonist therapy, often to within the pituitary fossa; definitive treatment with radiotherapy can then achieve eventual normalization of serum prolactin in the majority of patients. Dopamine 44-52 prolactin Homo sapiens 5-14 1685014-1 1991 The ability of low concentrations of dopamine (DA) to stimulate the secretion of prolactin (PRL) was examined in perifused or monolayer cultures of anterior pituitary cells. Dopamine 37-45 prolactin Homo sapiens 81-90 1685014-1 1991 The ability of low concentrations of dopamine (DA) to stimulate the secretion of prolactin (PRL) was examined in perifused or monolayer cultures of anterior pituitary cells. Dopamine 37-45 prolactin Homo sapiens 92-95 1685014-1 1991 The ability of low concentrations of dopamine (DA) to stimulate the secretion of prolactin (PRL) was examined in perifused or monolayer cultures of anterior pituitary cells. Dopamine 47-49 prolactin Homo sapiens 81-90 1685014-1 1991 The ability of low concentrations of dopamine (DA) to stimulate the secretion of prolactin (PRL) was examined in perifused or monolayer cultures of anterior pituitary cells. Dopamine 47-49 prolactin Homo sapiens 92-95 1685014-2 1991 In cultures perifused with media containing 100 nM DA, changing the DA concentration to either 1 or 100 pM caused a significant dose-dependent stimulatory PRL secretory response within 6 min when compared to the PRL secretory response to removal of DA altogether. Dopamine 51-53 prolactin Homo sapiens 155-158 1685014-2 1991 In cultures perifused with media containing 100 nM DA, changing the DA concentration to either 1 or 100 pM caused a significant dose-dependent stimulatory PRL secretory response within 6 min when compared to the PRL secretory response to removal of DA altogether. Dopamine 68-70 prolactin Homo sapiens 155-158 1685014-2 1991 In cultures perifused with media containing 100 nM DA, changing the DA concentration to either 1 or 100 pM caused a significant dose-dependent stimulatory PRL secretory response within 6 min when compared to the PRL secretory response to removal of DA altogether. Dopamine 68-70 prolactin Homo sapiens 212-215 1685014-3 1991 Picomolar concentrations of DA caused a biphasic PRL secretory response. Dopamine 28-30 prolactin Homo sapiens 49-52 1671361-9 1991 Additionally, dopamine and Fenoldopam have opposite effects on PRL secretion, the latter increasing PRL levels. Dopamine 14-22 prolactin Homo sapiens 63-66 1674531-1 1991 The full dopamine agonist R-(-)-N-n-propylnorapomorphine (NPA) completely suppressed (ED50 0.12 micrograms/kg) serum prolactin (PRL) levels elevated by pretreatment with gamma-butyrolactone (750 mg/kg). Dopamine 9-17 prolactin Homo sapiens 117-126 1674531-1 1991 The full dopamine agonist R-(-)-N-n-propylnorapomorphine (NPA) completely suppressed (ED50 0.12 micrograms/kg) serum prolactin (PRL) levels elevated by pretreatment with gamma-butyrolactone (750 mg/kg). Dopamine 9-17 prolactin Homo sapiens 128-131 1903236-4 1991 Patients showing a therapeutic motor improvement over 50% on the WRS (dopamine-dependent or "responder") showed lower PRL and TSH and higher GH responses than the non-responders. Dopamine 70-78 prolactin Homo sapiens 118-121 1671361-9 1991 Additionally, dopamine and Fenoldopam have opposite effects on PRL secretion, the latter increasing PRL levels. Dopamine 14-22 prolactin Homo sapiens 100-103 1901539-6 1991 Secretion of PRL was reduced (P less than .05) by treatment with DA and NE but not 5-HT. Dopamine 65-67 prolactin Homo sapiens 13-16 19215442-1 1991 Abstract The relative potencies of dopamine and somatostatin to inhibit prolactin secretion by pituitary cells in primary culture were compared. Dopamine 35-43 prolactin Homo sapiens 72-81 19215442-4 1991 Dopamine markedly inhibited basal as well as thyrotropin-releasing hormone-, vasoactive intestinal peptide-, forskolin- and BAY-K-8644-stimulated release of prolactin. Dopamine 0-8 prolactin Homo sapiens 157-166 2035258-0 1991 Effect of dopamine agonist medication on prolactin producing pituitary adenomas. Dopamine 10-18 prolactin Homo sapiens 41-50 2035258-3 1991 Dopamine agonist therapy resulted in decrease of serum PRL, clinical improvement and tumour shrinkage. Dopamine 0-8 prolactin Homo sapiens 55-58 2035258-7 1991 The large cells contained immunoreactive PRL and expressed the PRL gene indicating resistance to dopamine agonists. Dopamine 97-105 prolactin Homo sapiens 63-66 2035258-11 1991 The formation of irreversibly suppressed PRL cells may explain why some PRL-producing adenomas do not recur after withdrawal of dopamine agonists. Dopamine 128-136 prolactin Homo sapiens 41-44 2126309-15 1990 Hypothalamic regulation of prolactin mainly involves tonic inhibition via portal dopamine. Dopamine 81-89 prolactin Homo sapiens 27-36 2280212-3 1990 The role of dopamine in the control of beta-endorphin and prolactin was investigated in a series of experiments, conducted under both long and short days, in which rams were treated with dopamine receptor agonists (dopamine and bromocriptine) and antagonists (pimozide and sulpiride). Dopamine 12-20 prolactin Homo sapiens 58-67 2174755-0 1990 Dopamine-mediated effects induced by metoclopramide simultaneously on adrenocorticotropic hormone and prolactin in patients with pituitary and/or hypothalamic disorders. Dopamine 0-8 prolactin Homo sapiens 102-111 2286281-16 1990 These results indicated that the pulsatility and circadian secretion of prolactin were preserved during pregnancy and puerperium and also suggested that prolactin secretion during pregnancy, delivery and puerperium was regulated by at least 3 factors: estradiol, dopamine and LH-hCG. Dopamine 263-271 prolactin Homo sapiens 72-81 2286281-16 1990 These results indicated that the pulsatility and circadian secretion of prolactin were preserved during pregnancy and puerperium and also suggested that prolactin secretion during pregnancy, delivery and puerperium was regulated by at least 3 factors: estradiol, dopamine and LH-hCG. Dopamine 263-271 prolactin Homo sapiens 153-162 2112813-4 1990 Dopamine infusion (4 micrograms.kg-1.min-1 for 180 min) did not affect gonadotropins and greatly reduced serum PRL. Dopamine 0-8 prolactin Homo sapiens 111-114 2234477-3 1990 In fact many neurotransmitters (dopamine) and peptides can modulate prolactin release from anterior pituitary lactotrophs. Dopamine 32-40 prolactin Homo sapiens 68-77 2243892-1 1990 Plasma prolactin (PRL) and growth hormone (GH) levels are determined, in part, by the effects of dopamine (DA) at pituitary and hypothalamic DA receptors, respectively. Dopamine 97-105 prolactin Homo sapiens 18-21 2118609-5 1990 IAP also blocked the inhibitions by DA of the releases of PRL by 5 microM AA and by 5 microM 5-hydroxyeicosatetraenoic acid. Dopamine 36-38 prolactin Homo sapiens 58-61 2118609-2 1990 The inhibitions by 1 microM DA of the stimulations of prolactin (PRL) release by 100 nM thyrotropin-releasing hormone and by 10 microM calcium ionophore A23187 were blocked by 100 ng/ml IAP. Dopamine 28-30 prolactin Homo sapiens 65-68 1973867-6 1990 Both dopamine agonists adequately suppressed PRL. Dopamine 5-13 prolactin Homo sapiens 45-48 2333989-6 1990 We examined endogenous prolactin secretion after administration of the dopamine antagonist metoclopramide. Dopamine 71-79 prolactin Homo sapiens 23-32 2385731-4 1990 In vitro studies of tissue from this prolactinoma showed that although prolactin secretion was reduced by both bromocriptine and dopamine, neither agent affected cytoplasmic levels of prolactin mRNA, suggesting relative autonomy of prolactin synthesis. Dopamine 129-137 prolactin Homo sapiens 71-80 2385731-4 1990 In vitro studies of tissue from this prolactinoma showed that although prolactin secretion was reduced by both bromocriptine and dopamine, neither agent affected cytoplasmic levels of prolactin mRNA, suggesting relative autonomy of prolactin synthesis. Dopamine 129-137 prolactin Homo sapiens 71-80 2352119-10 1990 An alternative explanation of our findings could be based on the fact that melatonin influences dopamine metabolism, which in turn alters prolactin secretion. Dopamine 96-104 prolactin Homo sapiens 138-147 2129295-5 1990 Many evidences indicate that dopamine acts as a physiological inhibitor on mammalian PRL secreting cells. Dopamine 29-37 prolactin Homo sapiens 85-88 2128416-6 1990 The different patterns of PRL response to DOM and TRH throughout male puberty might be due to differences in pituitary thresholds for sex steroids between the dopamine- and TRH-dependent intracellular pools. Dopamine 159-167 prolactin Homo sapiens 26-29 34540295-0 2021 Prolactin-Secreting Leiomyoma Causing Hyperprolactinaemia Unresponsive to Dopamine Agonist Therapy and Resolution following Myomectomy. Dopamine 74-82 prolactin Homo sapiens 0-9 2374967-5 1990 Therapy with dopamine agonists (lisenyl, parlodel) was found most effective in Type I hyperprolactinemia syndrome, associated with essential prolactin hypersecretion and oligospermia. Dopamine 13-21 prolactin Homo sapiens 91-100 33234470-13 2020 Prolactin (whose secretion is inhibited by dopamine) levels were elevated in several patients with PTPS deficiency and inversely correlated with the z-scores for height (p < 0.01) and weight (p < 0.05). Dopamine 43-51 prolactin Homo sapiens 0-9 34967003-6 2022 Dopamine receptor agonists, which suppress pituitary prolactin release, are an effective migraine treatment in a subset of patients. Dopamine 0-8 prolactin Homo sapiens 53-62 34173929-12 2021 CONCLUSIONS: Addition of an aromatase inhibitor (ANA) to the dopamine agonist therapy improved the control of prolactin levels and induced tumour regression. Dopamine 61-69 prolactin Homo sapiens 110-119 34261980-1 2021 BACKGROUND: Dopamine agonists such as bromocriptine and cabergoline have been found to be an effective treatment for hyperprolactinemia, not only inducing adenoma shrinkage but also lowering serum prolactin levels. Dopamine 12-20 prolactin Homo sapiens 197-206 34446277-5 2021 However, the physiologic decline of prolactin levels during menopause and the lack of fertility concerns, which represent specific indications for medical treatment with dopamine agonists, might require a careful reassessment of therapeutic management in such patients. Dopamine 170-178 prolactin Homo sapiens 36-45 34106485-7 2021 Atremorine also influences the levels of other neurotransmitters (adrenaline, noradrenaline) and hormones which are regulated by DA (e.g., prolactin, PRL), with no effect on serotonin or histamine. Dopamine 129-131 prolactin Homo sapiens 139-148 34106485-7 2021 Atremorine also influences the levels of other neurotransmitters (adrenaline, noradrenaline) and hormones which are regulated by DA (e.g., prolactin, PRL), with no effect on serotonin or histamine. Dopamine 129-131 prolactin Homo sapiens 150-153 34864772-1 2022 PURPOSE/BACKGROUND: Antipsychotic drugs are well established to alter circulating prolactin levels by blocking dopamine D2 receptors in the pituitary. Dopamine 111-119 prolactin Homo sapiens 82-91 2516707-6 1989 Dopamine caused a 50.2% and 60.4% MD in prolactin (PRL) in the PCOS and control groups, respectively, the difference being statistically non-significant. Dopamine 0-8 prolactin Homo sapiens 51-54 2689208-3 1989 Bromocriptine is a dopamine agonist, dopamine being a natural inhibitor of PRL-secretion. Dopamine 37-45 prolactin Homo sapiens 75-78 2576397-1 1989 CV 205-502 (Sandoz), an octahydrobenzol [g]quinoline, is a long-acting dopamine agonist which inhibits prolactin secretion. Dopamine 71-79 prolactin Homo sapiens 103-112 2777190-6 1989 DA infusion caused a significant reduction in serum prolactin (PRL) levels both in hyperprolactinaemic patients (P less than 0.001) and normal women (P less than 0.02), but the PRL suppression was significantly (P less than 0.05) less pronounced in the hyperprolactinaemic patients, compared to normal women. Dopamine 0-2 prolactin Homo sapiens 63-66 2544414-3 1989 Dopamine (DA) attenuated IL6-induced PRL release. Dopamine 0-8 prolactin Homo sapiens 37-40 2544414-3 1989 Dopamine (DA) attenuated IL6-induced PRL release. Dopamine 10-12 prolactin Homo sapiens 37-40 2512041-5 1989 During perifusion with dopamine (DA, 5 mumol/l) untreated prolactinomas had a higher PRL secretion rate (19.3 +/- 2.7 microU/mg tissue/min, mean +/- SEM) than BC-treated (3.9 +/- 0.7, P = 0.005). Dopamine 23-31 prolactin Homo sapiens 85-88 2512041-5 1989 During perifusion with dopamine (DA, 5 mumol/l) untreated prolactinomas had a higher PRL secretion rate (19.3 +/- 2.7 microU/mg tissue/min, mean +/- SEM) than BC-treated (3.9 +/- 0.7, P = 0.005). Dopamine 33-35 prolactin Homo sapiens 85-88 2777190-6 1989 DA infusion caused a significant reduction in serum prolactin (PRL) levels both in hyperprolactinaemic patients (P less than 0.001) and normal women (P less than 0.02), but the PRL suppression was significantly (P less than 0.05) less pronounced in the hyperprolactinaemic patients, compared to normal women. Dopamine 0-2 prolactin Homo sapiens 177-180 2723131-4 1989 A drug effect upon serotonin-modulated prolactin release or on the tubero-infundibular dopamine axis (prolactin; growth hormone) was negligible at clinically effective dosages of buspirone. Dopamine 87-95 prolactin Homo sapiens 102-111 2601863-5 1989 L-sulpiride is an antagonist of dopamine on D2 receptors therefore inhibits the action of dopamine increasing the secretion of prolactin. Dopamine 32-40 prolactin Homo sapiens 127-136 2601863-5 1989 L-sulpiride is an antagonist of dopamine on D2 receptors therefore inhibits the action of dopamine increasing the secretion of prolactin. Dopamine 90-98 prolactin Homo sapiens 127-136 2499519-1 1989 The main aim of this study was to evaluate the effect of dopamine infusion on plasma luteinizing hormone (LH), follicle-stimulating hormone, (FSH) and prolactin (PRL) after acute (1 week postovariectomy) and chronic (postmenopausal women) estrogen withdrawal. Dopamine 57-65 prolactin Homo sapiens 151-160 2506942-0 1989 Prolactin response to dopamine and valproate administration in breast cancer patients. Dopamine 22-30 prolactin Homo sapiens 0-9 2499519-1 1989 The main aim of this study was to evaluate the effect of dopamine infusion on plasma luteinizing hormone (LH), follicle-stimulating hormone, (FSH) and prolactin (PRL) after acute (1 week postovariectomy) and chronic (postmenopausal women) estrogen withdrawal. Dopamine 57-65 prolactin Homo sapiens 162-165 2722137-1 1989 In most of human prolactin (PRL)-secreting adenomas, dopamine and dopamine agonists normally suppress the excessive PRL secretion. Dopamine 53-61 prolactin Homo sapiens 17-26 2722137-1 1989 In most of human prolactin (PRL)-secreting adenomas, dopamine and dopamine agonists normally suppress the excessive PRL secretion. Dopamine 53-61 prolactin Homo sapiens 28-31 2722137-1 1989 In most of human prolactin (PRL)-secreting adenomas, dopamine and dopamine agonists normally suppress the excessive PRL secretion. Dopamine 53-61 prolactin Homo sapiens 116-119 2722137-1 1989 In most of human prolactin (PRL)-secreting adenomas, dopamine and dopamine agonists normally suppress the excessive PRL secretion. Dopamine 66-74 prolactin Homo sapiens 17-26 2722137-1 1989 In most of human prolactin (PRL)-secreting adenomas, dopamine and dopamine agonists normally suppress the excessive PRL secretion. Dopamine 66-74 prolactin Homo sapiens 28-31 2499519-5 1989 In all groups of patients, dopamine significantly inhibited plasma PRL levels. Dopamine 27-35 prolactin Homo sapiens 67-70 2722137-1 1989 In most of human prolactin (PRL)-secreting adenomas, dopamine and dopamine agonists normally suppress the excessive PRL secretion. Dopamine 66-74 prolactin Homo sapiens 116-119 2485823-2 1989 In this communication, evidence is presented to suggest that the striatal dopamine receptor supersensitivity in TS may be mediated by alterations in the release and function of dopamine supersensitive factors including prolactin, estrogens, beta-endorphin, melanocyte stimulating hormone (MSH), and adrenal corticotrophic hormone (ACTH). Dopamine 74-82 prolactin Homo sapiens 219-228 2485823-2 1989 In this communication, evidence is presented to suggest that the striatal dopamine receptor supersensitivity in TS may be mediated by alterations in the release and function of dopamine supersensitive factors including prolactin, estrogens, beta-endorphin, melanocyte stimulating hormone (MSH), and adrenal corticotrophic hormone (ACTH). Dopamine 177-185 prolactin Homo sapiens 219-228 2682729-3 1989 These PRL results are consistent with the observation that clozapine may increase DA release. Dopamine 82-84 prolactin Homo sapiens 6-9 2675278-4 1989 Prolactin secretion is regulated by both an inhibitory hormone (dopamine), and by one or more releasing factors. Dopamine 64-72 prolactin Homo sapiens 0-9 3234595-0 1988 Effect of dopamine on plasma growth hormone and prolactin concentrations under anaesthesia. Dopamine 10-18 prolactin Homo sapiens 48-57 2517609-4 1989 In the past decade, many studies in neuroendocrinology revealed that Tubero-infundibular dopamine (TIDA) neurons of hypothalamus play a major modulating role in PRL secretion. Dopamine 89-97 prolactin Homo sapiens 161-164 2908364-6 1988 The in vitro potency of EGYT-2509 to block dopamine-mediated inhibition of prolactin release was weaker by three orders of magnitude than that of haloperidol. Dopamine 43-51 prolactin Homo sapiens 75-84 3229037-6 1988 Dopamine infusion significantly (p = 0.015) reduced the mean plasma prolactin levels in hyperprolactinemic patients and normal women. Dopamine 0-8 prolactin Homo sapiens 68-77 3229037-10 1988 They also suggest that in these patients, the decrease in prolactin response to metoclopramide may be explained by the relative refractoriness to endogenous dopamine. Dopamine 157-165 prolactin Homo sapiens 58-67 3149403-10 1988 The same was shown in vitro: Pituitary cells cultured in vitro with 10(-6) M dopamine showed an increase of prolactin secretion after coincubation with 10(-7) M TRH. Dopamine 77-85 prolactin Homo sapiens 108-117 3149403-11 1988 There was a linear increase of the prolactin concentration during the incubation period in dopamine-free cell cultures. Dopamine 91-99 prolactin Homo sapiens 35-44 3149403-13 1988 The in vivo and in vitro results are in agreement with the hypothesis of a rapid, dopamine-independent effect of TRH on the secretion of stored prolactin in the pituitary. Dopamine 82-90 prolactin Homo sapiens 144-153 2908233-0 1988 Actions of pertussis toxin on the inhibitory effects of dopamine and somatostatin on prolactin and growth hormone release from ovine anterior pituitary cells. Dopamine 56-64 prolactin Homo sapiens 85-94 2908233-2 1988 Dopamine and somatostatin inhibit release of prolactin and GH respectively, after stimulation by these agents, but without effects on intracellular cyclic AMP concentrations. Dopamine 0-8 prolactin Homo sapiens 45-54 3661064-4 1987 Serum prolactin was normalized in 4 patients during dopamine, and in 6 patients 12-48 h following depot bromocriptine. Dopamine 52-60 prolactin Homo sapiens 6-15 3417848-11 1988 In the case of PRL-secreting cells, which are tonically inhibited by the hypothalamic hormone dopamine, this would result in hypertrophy, hyperplasia, and possibly tumorigenesis. Dopamine 94-102 prolactin Homo sapiens 15-18 3137253-8 1988 A relative dopamine deficiency might cause hypersecretion of PRL and LH in patients with PCOS and hyperprolactinemia. Dopamine 11-19 prolactin Homo sapiens 61-64 21927277-3 1988 Prolactin (PRL), Lutenising hormone (LH) and Growth hormone (GH) have definite link with Dopamine (DA), the latter being implicated in the pathogenesis of schizophrenia. Dopamine 99-101 prolactin Homo sapiens 0-9 21927277-3 1988 Prolactin (PRL), Lutenising hormone (LH) and Growth hormone (GH) have definite link with Dopamine (DA), the latter being implicated in the pathogenesis of schizophrenia. Dopamine 99-101 prolactin Homo sapiens 11-14 3140665-6 1988 All doses of dopamine achieved some degree of prolactin suppression, but doses that achieved nanomolar circulating concentrations did not significantly affect luteinizing hormone secretion. Dopamine 13-21 prolactin Homo sapiens 46-55 21927277-3 1988 Prolactin (PRL), Lutenising hormone (LH) and Growth hormone (GH) have definite link with Dopamine (DA), the latter being implicated in the pathogenesis of schizophrenia. Dopamine 89-97 prolactin Homo sapiens 0-9 21927277-3 1988 Prolactin (PRL), Lutenising hormone (LH) and Growth hormone (GH) have definite link with Dopamine (DA), the latter being implicated in the pathogenesis of schizophrenia. Dopamine 89-97 prolactin Homo sapiens 11-14 3692700-3 1987 Serum prolactin levels fell approximately four months prior to onset of the psychotic episode and thus may have provided a predictive indicator of changing dopamine activity in both the tubero-infundibular and the mesolimbic-mesocortical dopaminergic systems. Dopamine 156-164 prolactin Homo sapiens 6-15 3116800-9 1987 Dopamine agonist therapy led to suppression of serum PRL with few exceptions in patients with PRL-positive and -negative tumours, whereas shrinkage was only observed in PRL-immunostainable tumours with high serum PRL levels (over 18,000 mU/l). Dopamine 0-8 prolactin Homo sapiens 53-56 3116800-9 1987 Dopamine agonist therapy led to suppression of serum PRL with few exceptions in patients with PRL-positive and -negative tumours, whereas shrinkage was only observed in PRL-immunostainable tumours with high serum PRL levels (over 18,000 mU/l). Dopamine 0-8 prolactin Homo sapiens 94-97 3116800-9 1987 Dopamine agonist therapy led to suppression of serum PRL with few exceptions in patients with PRL-positive and -negative tumours, whereas shrinkage was only observed in PRL-immunostainable tumours with high serum PRL levels (over 18,000 mU/l). Dopamine 0-8 prolactin Homo sapiens 94-97 3116800-9 1987 Dopamine agonist therapy led to suppression of serum PRL with few exceptions in patients with PRL-positive and -negative tumours, whereas shrinkage was only observed in PRL-immunostainable tumours with high serum PRL levels (over 18,000 mU/l). Dopamine 0-8 prolactin Homo sapiens 94-97 3116800-10 1987 All patients with PRL-negative tumours showed no change or even growth of the tumour despite dopamine agonist therapy. Dopamine 93-101 prolactin Homo sapiens 18-21 3116800-12 1987 Dopamine agonist therapy is effective in PRL suppression and tumour shrinkage in most of these patients. Dopamine 0-8 prolactin Homo sapiens 41-44 3123284-5 1987 The plasma PRL responses to dopaminergic agents (L-dopa, CB-154, dopamine) were greater in responders than in non-responders (% of basal: L-dopa, 33.7 +/- 3.7% vs 51.6 +/- 5.6% at 150 min, P less than 0.05; CB-154, 16.5 +/- 2.6% vs 30.9 +/- 2.8% at 6 hr, P less than 0.05; dopamine, 31.7 +/- 5.6% vs 44.9 +/- 4.3% at 90 min, P less than 0.05). Dopamine 28-36 prolactin Homo sapiens 11-14 3658111-0 1987 Vasoactive intestinal polypeptide and dopamine: effect on prolactin secretion in normal women and patients with microprolactinomas. Dopamine 38-46 prolactin Homo sapiens 58-67 3658111-1 1987 In order to investigate the influence of dopamine (DA) in modulating prolactin (PRL) response to vasoactive intestinal polypeptide (VIP), VIP (75 micrograms i.v. Dopamine 51-53 prolactin Homo sapiens 69-78 3658111-1 1987 In order to investigate the influence of dopamine (DA) in modulating prolactin (PRL) response to vasoactive intestinal polypeptide (VIP), VIP (75 micrograms i.v. Dopamine 51-53 prolactin Homo sapiens 80-83 3658111-4 1987 DA infusion lowered serum PRL by 67 and 58.2% at 120 min in normal women and in patients with microprolactinomas, respectively, and abolished VIP-induced PRL response in normal women without influencing PRL response in patients with microprolactinomas. Dopamine 0-2 prolactin Homo sapiens 26-29 3658111-4 1987 DA infusion lowered serum PRL by 67 and 58.2% at 120 min in normal women and in patients with microprolactinomas, respectively, and abolished VIP-induced PRL response in normal women without influencing PRL response in patients with microprolactinomas. Dopamine 0-2 prolactin Homo sapiens 154-157 3658111-4 1987 DA infusion lowered serum PRL by 67 and 58.2% at 120 min in normal women and in patients with microprolactinomas, respectively, and abolished VIP-induced PRL response in normal women without influencing PRL response in patients with microprolactinomas. Dopamine 0-2 prolactin Homo sapiens 154-157 3310494-3 1987 When cells were incubated with dopamine (10 nmol/l), a significant inhibition in PRL secretion was observed in all the experiments, which was blocked by co-incubation with haloperidol. Dopamine 31-39 prolactin Homo sapiens 81-84 3310494-4 1987 In mixed GH- and PRL-secreting adenoma cells, dopamine likewise decreased GH secretion. Dopamine 46-54 prolactin Homo sapiens 17-20 3123284-5 1987 The plasma PRL responses to dopaminergic agents (L-dopa, CB-154, dopamine) were greater in responders than in non-responders (% of basal: L-dopa, 33.7 +/- 3.7% vs 51.6 +/- 5.6% at 150 min, P less than 0.05; CB-154, 16.5 +/- 2.6% vs 30.9 +/- 2.8% at 6 hr, P less than 0.05; dopamine, 31.7 +/- 5.6% vs 44.9 +/- 4.3% at 90 min, P less than 0.05). Dopamine 65-73 prolactin Homo sapiens 11-14 3115863-1 1987 Dopamine has already been recognized as an inhibiting factor of prolactin. Dopamine 0-8 prolactin Homo sapiens 64-73 3597709-4 1987 In five normal men whose endogenous PRL secretion was suppressed by dopamine, a loading dose of hPRL (70-90 micrograms) followed by a constant infusion (1.39-2.9 ng/min) produced steady state serum PRL levels of 15.2-25.4 ng/mL by 30-60 min. Dopamine 68-76 prolactin Homo sapiens 96-100 3597709-4 1987 In five normal men whose endogenous PRL secretion was suppressed by dopamine, a loading dose of hPRL (70-90 micrograms) followed by a constant infusion (1.39-2.9 ng/min) produced steady state serum PRL levels of 15.2-25.4 ng/mL by 30-60 min. Dopamine 68-76 prolactin Homo sapiens 97-100 3119696-7 1987 These results suggest that a reduction of an inhibitory influence of hypothalamic dopamine might be a cause of inappropriately elevated LH and PRL levels found in patients with polycystic ovary syndrome and hyperprolactinemia. Dopamine 82-90 prolactin Homo sapiens 143-146 3114114-2 1987 Enhanced GABA activity may either reduce basal prolactin levels whilst allowing a normal pituitary response to TRH stimulation, or may overcome the inhibitory effects of dopamine on pituitary prolactin release. Dopamine 170-178 prolactin Homo sapiens 192-201 3327498-13 1987 The prolactin rise is brought about by either a decrease in dopamine activity, an increased secretion of a hypothetical PRF, or by both mechanisms. Dopamine 60-68 prolactin Homo sapiens 4-13 2980713-0 1987 Light microscopical morphometry of prolactin secreting adenomas under treatment with dopamine agonists. Dopamine 85-93 prolactin Homo sapiens 35-44 3297633-2 1987 Different neurotransmitters (Dopamine, serotonin, GABA...) and hormones (TRH, oestrogenes...) are involved in the central regulation of prolactin synthesis and release. Dopamine 29-37 prolactin Homo sapiens 136-145 3583091-3 1987 Among hypothalamic neurotransmitters regulating the anterior pituitary function, dopamine (DA) is currently considered to correspond to the PRL-inhibiting factor. Dopamine 81-89 prolactin Homo sapiens 140-143 3106094-1 1987 Infertile women with normal serum prolactin (PRL) levels have been known to establish a pregnancy after the use of bromocriptine, a dopamine agonist. Dopamine 132-140 prolactin Homo sapiens 45-48 3104097-3 1987 The maximal response of PRL to the dopamine antagonist metoclopramide was increased (P less than 0.01), whereas the maximal responses of luteinizing hormone (P less than 0.025) and follicle-stimulating hormone (P less than 0.001) to gonadotropin-releasing hormone were lowered in the treatment cycles. Dopamine 35-43 prolactin Homo sapiens 24-27 3108134-7 1987 Dopamine infusion induced parallel decreases in TSH and PRL concentrations, without modifying hormonal secretory patterns in response to domperidone. Dopamine 0-8 prolactin Homo sapiens 56-59 3812533-1 1987 Several investigators have suggested that prolactin secretion in some subjects with hyperprolactinemia associated with pituitary macroadenomas may have a resistance to the prolactin inhibitory hormone, dopamine. Dopamine 202-210 prolactin Homo sapiens 42-51 3812533-2 1987 This report describes a male subject with a prolactinoma whose preoperative evaluation demonstrated a resistance of prolactin release to inhibition by dopamine. Dopamine 151-159 prolactin Homo sapiens 44-53 3812533-3 1987 Evaluation of prolactin secretion from monolayer culture of his tumor also revealed a resistance to inhibition by dopamine. Dopamine 114-122 prolactin Homo sapiens 14-23 3812533-4 1987 Four months postoperatively, normal serum prolactin levels and a normal maximal inhibition of prolactin to a dopamine infusion of 0.04 microgram/kg/minute suggested surgical cure. Dopamine 109-117 prolactin Homo sapiens 94-103 3812533-5 1987 However, a 24-hour prolactin sampling revealed blunted nocturnal augmentation of prolactin release, an early escape of inhibition of prolactin release at 150 minutes from a 0.04 microgram/kg/minute dopamine infusion, and abnormal prolactin response to a low-dose (0.004 microgram/kg/minute) dopamine infusion. Dopamine 198-206 prolactin Homo sapiens 81-90 3812533-5 1987 However, a 24-hour prolactin sampling revealed blunted nocturnal augmentation of prolactin release, an early escape of inhibition of prolactin release at 150 minutes from a 0.04 microgram/kg/minute dopamine infusion, and abnormal prolactin response to a low-dose (0.004 microgram/kg/minute) dopamine infusion. Dopamine 198-206 prolactin Homo sapiens 81-90 3812533-5 1987 However, a 24-hour prolactin sampling revealed blunted nocturnal augmentation of prolactin release, an early escape of inhibition of prolactin release at 150 minutes from a 0.04 microgram/kg/minute dopamine infusion, and abnormal prolactin response to a low-dose (0.004 microgram/kg/minute) dopamine infusion. Dopamine 198-206 prolactin Homo sapiens 81-90 3812533-8 1987 Thus, resistance of prolactin secretion to inhibition by dopamine was present in this patient with a prolactinoma. Dopamine 57-65 prolactin Homo sapiens 20-29 3812533-9 1987 Additionally, an abnormal prolactin response to dopamine was noted to precede the development of hyperprolactinemia with tumor recurrence. Dopamine 48-56 prolactin Homo sapiens 26-35 3103387-0 1987 Dopamine receptor function in Parkinson"s disease--in vivo studies with prolactin responses. Dopamine 0-8 prolactin Homo sapiens 72-81 3799691-6 1987 If the serum prolactin concentration is less than 3,000 mU/liter in the presence of significant pituitary enlargement, surgical removal is essential for both diagnosis and treatment since only prolactin-secreting adenomas are likely to shrink with dopamine agonist therapy. Dopamine 248-256 prolactin Homo sapiens 13-22 2888653-7 1987 Chronic treatment with drugs affecting dopamine transmission had a profound effect on PRL secretion, and a dose-dependent significant increase in PRL with neuroleptics was observed. Dopamine 39-47 prolactin Homo sapiens 86-89 2888653-7 1987 Chronic treatment with drugs affecting dopamine transmission had a profound effect on PRL secretion, and a dose-dependent significant increase in PRL with neuroleptics was observed. Dopamine 39-47 prolactin Homo sapiens 146-149 3583091-3 1987 Among hypothalamic neurotransmitters regulating the anterior pituitary function, dopamine (DA) is currently considered to correspond to the PRL-inhibiting factor. Dopamine 91-93 prolactin Homo sapiens 140-143 3099236-2 1987 The absence of PRL secretory response to dopamine or TRH in prolactinoma patients also may be an effect of the disease. Dopamine 41-49 prolactin Homo sapiens 15-18 3114361-1 1987 Bromocriptine, a dopamine agonist, is well known for its inhibitory action on prolactin secretion. Dopamine 17-25 prolactin Homo sapiens 78-87 3546358-5 1986 The authors recommend that dopaminergic drugs should be the primary therapies for prolactin-secreting adenomas and idiopathic hyperprolactinaemia, and surgery should be reserved for dopamine-resistant conditions. Dopamine 27-35 prolactin Homo sapiens 82-91 3792121-0 1986 Chronobiologic quantification of nocturnal low-dose dopamine effect on circadian rhythms of thyroid-related hormones and prolactin (PRL). Dopamine 52-60 prolactin Homo sapiens 132-135 3755608-0 1986 Description of the time course of the prolactin suppressant effect of the dopamine agonist CQP201-403 by an integrated pharmacokinetic-pharmacodynamic model. Dopamine 74-82 prolactin Homo sapiens 38-47 3792121-7 1986 Dopamine Rx produced a statistically-significant increase in amplitude for PRL and T4 and an advance in acrophase for TSH, T3 and T4, but a delay for PRL. Dopamine 0-8 prolactin Homo sapiens 75-78 3792121-7 1986 Dopamine Rx produced a statistically-significant increase in amplitude for PRL and T4 and an advance in acrophase for TSH, T3 and T4, but a delay for PRL. Dopamine 0-8 prolactin Homo sapiens 150-153 3725261-1 1986 The effect of a dopamine antagonist on prolactin concentrations was studied in maternal, fetal plasma, and amniotic fluid in term gestation. Dopamine 16-24 prolactin Homo sapiens 39-48 3757769-3 1986 In this study serum prolactin (PRL) was used as an indicator of central dopamine activity since dopamine is the most important factor in the control of prolactin secretion from the pituitary. Dopamine 96-104 prolactin Homo sapiens 152-161 3757769-3 1986 In this study serum prolactin (PRL) was used as an indicator of central dopamine activity since dopamine is the most important factor in the control of prolactin secretion from the pituitary. Dopamine 72-80 prolactin Homo sapiens 20-29 3757769-3 1986 In this study serum prolactin (PRL) was used as an indicator of central dopamine activity since dopamine is the most important factor in the control of prolactin secretion from the pituitary. Dopamine 72-80 prolactin Homo sapiens 31-34 3757769-3 1986 In this study serum prolactin (PRL) was used as an indicator of central dopamine activity since dopamine is the most important factor in the control of prolactin secretion from the pituitary. Dopamine 96-104 prolactin Homo sapiens 20-29 3757769-3 1986 In this study serum prolactin (PRL) was used as an indicator of central dopamine activity since dopamine is the most important factor in the control of prolactin secretion from the pituitary. Dopamine 96-104 prolactin Homo sapiens 31-34 3748874-0 1986 Ultrastructural morphometry of prolactin secreting adenomas treated with dopamine agonists. Dopamine 73-81 prolactin Homo sapiens 31-40 3755462-8 1986 In view of the effect of bromocriptine on plasma prolactin concentrations in late lactation and the demonstration that domperidone (a dopamine antagonist) significantly increases plasma prolactin concentrations, it would seem that dopamine can act as a prolactin inhibitory hormone in this as in other mammalian species. Dopamine 134-142 prolactin Homo sapiens 186-195 3755462-8 1986 In view of the effect of bromocriptine on plasma prolactin concentrations in late lactation and the demonstration that domperidone (a dopamine antagonist) significantly increases plasma prolactin concentrations, it would seem that dopamine can act as a prolactin inhibitory hormone in this as in other mammalian species. Dopamine 134-142 prolactin Homo sapiens 186-195 3755462-8 1986 In view of the effect of bromocriptine on plasma prolactin concentrations in late lactation and the demonstration that domperidone (a dopamine antagonist) significantly increases plasma prolactin concentrations, it would seem that dopamine can act as a prolactin inhibitory hormone in this as in other mammalian species. Dopamine 231-239 prolactin Homo sapiens 49-58 3755462-8 1986 In view of the effect of bromocriptine on plasma prolactin concentrations in late lactation and the demonstration that domperidone (a dopamine antagonist) significantly increases plasma prolactin concentrations, it would seem that dopamine can act as a prolactin inhibitory hormone in this as in other mammalian species. Dopamine 231-239 prolactin Homo sapiens 186-195 3755462-8 1986 In view of the effect of bromocriptine on plasma prolactin concentrations in late lactation and the demonstration that domperidone (a dopamine antagonist) significantly increases plasma prolactin concentrations, it would seem that dopamine can act as a prolactin inhibitory hormone in this as in other mammalian species. Dopamine 231-239 prolactin Homo sapiens 186-195 3748874-12 1986 The results display the influence of dopamine agonist on the hormone synthesis, release and degradation in PRL secreting adenoma cells. Dopamine 37-45 prolactin Homo sapiens 107-110 3516535-5 1986 On the contrary, plasma prolactin levels, previously suppressed during water immersion alone, were significantly stimulated during water immersion plus domperidone, thus indirectly suggesting a role of dopamine in mediating the blunted natriuresis seen during water immersion. Dopamine 202-210 prolactin Homo sapiens 24-33 3716756-1 1986 In the adult, dopamine inhibits prolactin (Prl) secretion and less so thyrotropin (TSH) release. Dopamine 14-22 prolactin Homo sapiens 32-41 3716756-1 1986 In the adult, dopamine inhibits prolactin (Prl) secretion and less so thyrotropin (TSH) release. Dopamine 14-22 prolactin Homo sapiens 43-46 3789642-6 1986 Dopamine-blocking activity was related more closely to dose of drug and to serum prolactin level than was serum chlorpromazine level measured by HPLC. Dopamine 0-8 prolactin Homo sapiens 81-90 3698093-1 1986 Prolactin (PRL) responses to dopamine (DA) blockers and to direct and indirect DA agonists have been studied in 23 healthy women, 17 women with catamenial migraine and 17 with non-catamenial migraine in both their follicular and luteal phases. Dopamine 29-37 prolactin Homo sapiens 0-9 3742834-6 1986 At this stage treatment with a second dopamine agonist, pergolide, was effective in reducing the prolactin concentration to normal within four months. Dopamine 38-46 prolactin Homo sapiens 97-106 3742834-7 1986 Serial CT scans at 1, 6 and 12 months on dopamine agonist therapy showed a progressive decrease in tumour size, which seemed to be maintained even during the period of rising prolactin concentrations due to bromocriptine resistance. Dopamine 41-49 prolactin Homo sapiens 175-184 3742834-8 1986 This case illustrates that during dopamine agonist therapy a discrepancy may exist in the clinical response as judged by reduction in tumour size and decrease in the circulating prolactin level. Dopamine 34-42 prolactin Homo sapiens 178-187 3084318-2 1986 Also the effect of including dopamine (DA) at 1 X 10(-7) mol/1 in these different in vitro systems on the release of LH, FSH and Prl was investigated. Dopamine 29-37 prolactin Homo sapiens 129-132 3084318-2 1986 Also the effect of including dopamine (DA) at 1 X 10(-7) mol/1 in these different in vitro systems on the release of LH, FSH and Prl was investigated. Dopamine 39-41 prolactin Homo sapiens 129-132 3084318-7 1986 Inclusion of 1 X 10(-7) M DA in the incubation medium stimulated the release of LH (80%) but inhibited the release of Prl (71%) by PHC. Dopamine 26-28 prolactin Homo sapiens 118-121 3081830-0 1986 Function of dopamine receptors in Parkinson"s disease: prolactin responses. Dopamine 12-20 prolactin Homo sapiens 55-64 3956568-0 1986 Inhibition of prolactin and aldosterone secretion by the dopamine derivative ibopamine. Dopamine 57-65 prolactin Homo sapiens 14-23 3699687-1 1986 To examine the previous suggestion that the endogenous dopaminergic activity would be increased in patients with primary aldosteronism, dose-response curves of aldosterone and prolactin stimulation by the dopamine antagonist metoclopramide were established in a pilot study by injecting metoclopramide 1, 2.5, and 10 mg i.v. Dopamine 55-63 prolactin Homo sapiens 176-185 3472433-1 1986 An exaggerated, early prolactin response (p less than 0.01) was observed in ten patients with untreated essential hypertension (148 +/- 4/97 +/- 1 mmHg, means +/- SE) compared with ten healthy normotensive men of the same age (124 +/- 3/78 +/- 2 mmHg) after administration of metoclopramide, a competitive dopamine antagonist. Dopamine 306-314 prolactin Homo sapiens 22-31 3956568-1 1986 In 7 patients with congestive heart failure acute oral administration of ibopamine, a new dopamine derivative, induced a significant decrease in serum prolactin and aldosterone without affecting serum growth hormone or cortisol. Dopamine 90-98 prolactin Homo sapiens 151-160 3894101-1 1985 The clinical use of anti-dopaminergic drugs to stimulate plasma PRL levels, to induce lactogenesis and maintain an adequate lactation has been widely suggested, taking into consideration the main inhibitory role of hypothalamic dopamine on PRL secretion. Dopamine 25-33 prolactin Homo sapiens 64-67 3938732-2 1985 Plasma PRL values showed clear decreases during the infusion of DA (5 micrograms/kg/min for 90 min) in both 6 normal and 7 PRL-oma subjects (%decrease: 43.8 +/- 3.9% vs. 53.9 +/- 5.6%; NS) and postinhibitory increases after the termination. Dopamine 64-66 prolactin Homo sapiens 7-10 3938732-5 1985 The maximal increments in plasma PRL in the combination test of DA plus domperidone were significantly larger in PRL-oma patients, but were almost the same in normal controls, compared to the single domperidone test. Dopamine 64-66 prolactin Homo sapiens 33-36 4042883-4 1985 Of those patients in whom the operation was less successful, a normal prolactin level could be achieved in 77% by additional therapy with dopamine agonists. Dopamine 138-146 prolactin Homo sapiens 70-79 4042883-5 1985 Of 57 patients handled exclusively with drugs, the prolactin level was normalised by dopamine agonists in 78%. Dopamine 85-93 prolactin Homo sapiens 51-60 4072731-8 1985 Dopamine depresses PRL and TSH secretion. Dopamine 0-8 prolactin Homo sapiens 19-22 3931942-0 1985 Prolactin and TSH responses to both domperidone and TRH in normal and hyperprolactinaemic women after dopamine synthesis blockade. Dopamine 102-110 prolactin Homo sapiens 0-9 3931943-0 1985 Effect of low-dose dopamine infusion on basal and stimulated TSH and prolactin concentrations in man. Dopamine 19-27 prolactin Homo sapiens 69-78 3931943-2 1985 The effect of low-dose DA infusion (0.1 microgram/kg/min) on TSH and prolactin (PRL) concentrations during stimulation with thyrotrophin releasing hormone (TRH) in normal male subjects is reported. Dopamine 23-25 prolactin Homo sapiens 69-78 2995431-10 1985 The binding of kappa-1 type opioid ligands modulates the inhibitory effect of dopamine upon PRL release. Dopamine 78-86 prolactin Homo sapiens 92-95 3930984-8 1985 Short-photoperiod exposure increased the ability of DA to suppress PRL secretion, and this effect could be reversed by the presence of an ectopic pituitary graft. Dopamine 52-54 prolactin Homo sapiens 67-70 3901563-1 1985 Because of the decreased dopamine concentration in the elderly brain an alteration of the dopaminergic suppression of aldosterone and prolactin incretion was postulated. Dopamine 25-33 prolactin Homo sapiens 134-143 3894101-1 1985 The clinical use of anti-dopaminergic drugs to stimulate plasma PRL levels, to induce lactogenesis and maintain an adequate lactation has been widely suggested, taking into consideration the main inhibitory role of hypothalamic dopamine on PRL secretion. Dopamine 25-33 prolactin Homo sapiens 240-243 3159606-5 1985 A23187 at 400 nM or 2 ng/ml maitotoxin, a Ca2+ channel activator, did not affect prolactin release by themselves, but enhanced the release of prolactin induced by DG, PMA or phospholipase C. The stimulatory effects of DG, PMA and phospholipase C on prolactin release were reduced by co-incubation with dopamine. Dopamine 302-310 prolactin Homo sapiens 142-151 2858494-12 1985 In prolactinoma cells, somatostatin and dopamine unequivocally suppressed PRL secretion; however, other stimuli including GHRH, VIP, and CRF were ineffective. Dopamine 40-48 prolactin Homo sapiens 74-77 3159606-5 1985 A23187 at 400 nM or 2 ng/ml maitotoxin, a Ca2+ channel activator, did not affect prolactin release by themselves, but enhanced the release of prolactin induced by DG, PMA or phospholipase C. The stimulatory effects of DG, PMA and phospholipase C on prolactin release were reduced by co-incubation with dopamine. Dopamine 302-310 prolactin Homo sapiens 142-151 3159606-7 1985 Dopamine appears to inhibit prolactin release at a point distal to the DG-enhanced stimulation of the process. Dopamine 0-8 prolactin Homo sapiens 28-37 3976764-4 1985 Dopamine infusion rates as low as 0.004 micrograms/kg/min, which were associated with physiologic serum dopamine levels, produced significant (p less than 0.01) suppression of prolactin in normal women and in normal males (p less than 0.05). Dopamine 0-8 prolactin Homo sapiens 176-185 4042986-0 1985 Disturbed prolactin responses to dopamine-related substances in patients with acromegaly and hyperprolactinemia. Dopamine 33-41 prolactin Homo sapiens 10-19 4042986-2 1985 In order to clarify the dopaminergic regulation of PRL secretion in patients with acromegaly and hyperprolactinemia, the effects of nomifensine, a central dopamine agonist, FK 33-824, a centrally antidopaminergically acting agent, and domperidone, a peripheral dopamine antagonist, on plasma PRL in these patients were studied. Dopamine 24-32 prolactin Homo sapiens 51-54 3976764-4 1985 Dopamine infusion rates as low as 0.004 micrograms/kg/min, which were associated with physiologic serum dopamine levels, produced significant (p less than 0.01) suppression of prolactin in normal women and in normal males (p less than 0.05). Dopamine 104-112 prolactin Homo sapiens 176-185 3976764-5 1985 In contrast, a 10-fold increase in the dopamine infusion rate, 0.04 micrograms/kg/min, was required in the hyperprolactinemic subjects to produce prolactin suppression similar to that found in the control subjects. Dopamine 39-47 prolactin Homo sapiens 112-121 3976764-6 1985 Hence, prolactin secretion in both tumors and other hyperprolactinemic states is associated with a resistance to suppression by dopamine. Dopamine 128-136 prolactin Homo sapiens 7-16 2579087-0 1985 Mechanism of the inhibitory action of dopamine and somatostatin on prolactin secretion from human lactotrophs in culture. Dopamine 38-46 prolactin Homo sapiens 67-76 2579087-2 1985 High K+ and the divalent cation ionophore A23187 both elevated PRL secretion, which was blocked by dopamine and somatostatin. Dopamine 99-107 prolactin Homo sapiens 63-66 2579087-4 1985 The addition of dopamine or somatostatin to low calcium medium further decreased PRL release. Dopamine 16-24 prolactin Homo sapiens 81-84 2579087-6 1985 Theophylline and isobutylmethylxanthine, when added to the incubation medium, increased PRL secretion, and dopamine as well as somatostatin again inhibited PRL release induced by phosphodiesterase inhibitors. Dopamine 107-115 prolactin Homo sapiens 156-159 2579087-9 1985 Exposure of the cells to dopamine or somatostatin resulted in a parallel decrease in intracellular cAMP content and PRL secretion. Dopamine 25-33 prolactin Homo sapiens 116-119 2579087-10 1985 The inhibitory effect of dopamine on PRL secretion and cAMP accumulation was blocked by coincubation of the cells with haloperidol. Dopamine 25-33 prolactin Homo sapiens 37-40 2579087-11 1985 These results suggest that an increase in cytosol calcium caused by either mobilization from intracellular calcium pools or influx from the extracellular compartment and intracellular cAMP accumulation may be involved in the mechanism of PRL secretion from human lactotrophs, and dopamine and somatostatin may influence these two messengers to suppress PRL secretion. Dopamine 280-288 prolactin Homo sapiens 238-241 3917966-1 1985 Dopamine infusion 4 micrograms/kg/min over 4 h, administered to six subjects with diagnosis of polycystic ovarian disease laparoscopically confirmed, produced a significant decrease in serum LH, FSH and PRL, suggesting a reduced dopamine activity in these subjects. Dopamine 0-8 prolactin Homo sapiens 203-206 3977547-4 1985 High correlations existed between baseline PRL level and any subsequent absolute measure of PRL after administration of a dopamine agonist or placebo. Dopamine 122-130 prolactin Homo sapiens 43-46 3977547-4 1985 High correlations existed between baseline PRL level and any subsequent absolute measure of PRL after administration of a dopamine agonist or placebo. Dopamine 122-130 prolactin Homo sapiens 92-95 3977547-9 1985 Prolactin responses after dopamine or levodopa-carbidopa did not differ; however, placebo correction was not possible. Dopamine 26-34 prolactin Homo sapiens 0-9 3965110-5 1985 This is the third reported case of prolactin cell carcinoma that metastasized despite high-dose dopamine agonist therapy. Dopamine 96-104 prolactin Homo sapiens 35-44 4027295-0 1985 Effect of low-dose dopamine infusion on prolactin and thyrotropin secretion in preterm infants with hyaline membrane disease. Dopamine 19-27 prolactin Homo sapiens 40-49 4027295-1 1985 The effect of low-dose (2-4 micrograms/kg/min) and long-term (greater than or equal to 46 h) dopamine infusion on serum prolactin and thyrotropin concentrations was investigated in 8 preterm infants with hyaline membrane disease. Dopamine 93-101 prolactin Homo sapiens 120-129 4027295-4 1985 Our data indicate that exogenous dopamine exerts an inhibitory effect on the secretion of prolactin and thyrotropin even in the sick preterm neonate. Dopamine 33-41 prolactin Homo sapiens 90-99 3977547-0 1985 Evaluating prolactin response to dopamine agonists in schizophrenia. Dopamine 33-41 prolactin Homo sapiens 11-20 3157511-8 1985 Dopamine in doses of 0.1 microgram/kg/min and 1.0 microgram/kg/min was administered to six subjects with PRL levels greater than 1000 mU/l and six subjects with PRL levels less than 500 mU/l. Dopamine 0-8 prolactin Homo sapiens 105-108 3157511-8 1985 Dopamine in doses of 0.1 microgram/kg/min and 1.0 microgram/kg/min was administered to six subjects with PRL levels greater than 1000 mU/l and six subjects with PRL levels less than 500 mU/l. Dopamine 0-8 prolactin Homo sapiens 161-164 3834948-3 1985 In parallel with these findings, bromocriptine, a dopamin agonist inhibiting PRL secretion has been used in the clinic for the treatment of hyperprolactinemic states and the positive results obtained confirmed the role of PRL in human reproduction. Dopamine 50-57 prolactin Homo sapiens 77-80 4047382-2 1985 Bromocriptine, a potent dopamine agonist, appears to effectively reduce the serum prolactin level. Dopamine 24-32 prolactin Homo sapiens 82-91 6441763-3 1984 The inhibitory effect of various doses of dopamine on serum PRL levels was assessed in both normal cycling women and patients with tumoral hyperprolactinemia before and after endogenous catecholamine synthesis inhibition by alpha-methyl-p-tyrosine, a strong and specific tyrosine-hydroxylase inhibitor. Dopamine 42-50 prolactin Homo sapiens 60-63 6441763-4 1984 Dopamine infusion induced a significant decrease in the serum PRL levels in both normal cycling and hyperprolactinemic subjects. Dopamine 0-8 prolactin Homo sapiens 62-65 6441763-5 1984 The mean percent inhibition of baseline PRL induced by the various dopamine infusion rates (0.1, 0.5, 1.0 and 2.0 micrograms/kg/min) was similar in regularly cycling women and in patients with tumoral hyperprolactinemia both before and after endogenous catecholamine synthesis inhibition by alpha-methyl-p-tyrosine. Dopamine 67-75 prolactin Homo sapiens 40-43 6441763-8 1984 These data indicate that reduced dopamine delivery to the adenomatous lactotroph, either due to a primary hypothalamic abnormality or to a deranged vascular pituitary arrangement, rather than a reduced PRL sensitivity to dopamine inhibition, is the main event accounting for PRL hypersecretion in women with PRL-secreting pituitary tumors. Dopamine 33-41 prolactin Homo sapiens 275-278 6441763-8 1984 These data indicate that reduced dopamine delivery to the adenomatous lactotroph, either due to a primary hypothalamic abnormality or to a deranged vascular pituitary arrangement, rather than a reduced PRL sensitivity to dopamine inhibition, is the main event accounting for PRL hypersecretion in women with PRL-secreting pituitary tumors. Dopamine 33-41 prolactin Homo sapiens 275-278 6096765-6 1984 In particular the variation of PRL synthesis and secretion due to dopamine deficiency during basal conditions and after pharmacological treatment is discussed. Dopamine 66-74 prolactin Homo sapiens 31-34 6512754-1 1984 Incubation with high concentrations of dopamine (greater than or equal to 10(-3) mol/l) depressed the ability of goat placental lactogen, human placental lactogen, ovine prolactin and human growth hormone to compete with labelled hormone in radioreceptor assays for lactogenic activity, with the greatest effects on placental lactogen. Dopamine 39-47 prolactin Homo sapiens 170-179 6480809-10 1984 Pharmacological studies of TSH, TSH-alpha, and PRL release using thyroid hormones (T3), dopamine agonist (bromocriptine), TRH, and cholera toxin yielded the following results: 1) T3 after 3 days of incubation produced a dose-dependent inhibition of TSH, TSH-alpha, and PRL release. Dopamine 88-96 prolactin Homo sapiens 47-50 6746862-2 1984 Dopamine regulation of prolactin secretion. Dopamine 0-8 prolactin Homo sapiens 23-32 6434684-4 1984 Dopamine inhibited the release of prolactin stimulated by hypothalamic tissue or TRH, in a concentration-dependent fashion. Dopamine 0-8 prolactin Homo sapiens 34-43 6434684-7 1984 Both basal and TRH-stimulated release of prolactin from the oestrogen-primed pituitary glands was inhibited by dopamine, an effect blocked by pimozide. Dopamine 111-119 prolactin Homo sapiens 41-50 6434684-12 1984 These results suggest that dopamine inhibits release of prolactin directly from the pituitary gland only when prolactin secretion is high. Dopamine 27-35 prolactin Homo sapiens 56-65 6434684-12 1984 These results suggest that dopamine inhibits release of prolactin directly from the pituitary gland only when prolactin secretion is high. Dopamine 27-35 prolactin Homo sapiens 110-119 6434684-14 1984 Dopamine may also play an inhibitory role in the regulation of secretion of the prolactin-releasing factor. Dopamine 0-8 prolactin Homo sapiens 80-89 6480800-0 1984 Twenty four-hour prolactin profiles and prolactin responses to dopamine in long distance running women. Dopamine 63-71 prolactin Homo sapiens 40-49 6746862-3 1984 Previous studies demonstrated that high doses of dopamine administered as a constant infusion were capable of suppressing PRL secretion in both normal and hyperprolactinemic individuals. Dopamine 49-57 prolactin Homo sapiens 122-125 6746862-4 1984 The present study was designed to examine the dose-response relationship of PRL suppression to low doses of dopamine (between 0.06 and 4 micrograms/kg X min) infused in a step-wise fashion. Dopamine 108-116 prolactin Homo sapiens 76-79 6146654-0 1984 Effects of synthetic mammalian thyrotrophin releasing hormone, somatostatin and dopamine on the secretion of prolactin and growth hormone from amphibian and reptilian pituitary glands incubated in vitro. Dopamine 80-88 prolactin Homo sapiens 109-118 6438614-0 1984 [Effect of dopamine on gonadotropin and prolactin secretion in patients with polycystic ovary syndrome]. Dopamine 11-19 prolactin Homo sapiens 40-49 6429989-1 1984 In the first part of this study, we have demonstrated that, in 7 patients with untreated thyrotoxicosis, a 7 day regime of the long acting dopamine antagonist metoclopramide (10 mg orally 8 hourly) produces more adequate dopaminergic blockade at pituitary level than a single oral 10 mg dose of the compound as assessed by serum prolactin responses. Dopamine 139-147 prolactin Homo sapiens 329-338 6146654-5 1984 Dopamine had little effect alone, but inhibited HE- and TRH-stimulated release of prolactin, but not GH, in both amphibia and reptiles. Dopamine 0-8 prolactin Homo sapiens 82-91 6475464-3 1984 This dopamine agonist is very effective in normalizing raised prolactin levels. Dopamine 5-13 prolactin Homo sapiens 62-71 6547344-2 1984 In the anterior pituitary gland, dopamine controls the release of prolactin from the mammotrophs. Dopamine 33-41 prolactin Homo sapiens 66-75 6738811-1 1984 Results of previous studies have revealed that prolactin causes a delayed (12-16 h) increase in the rate of synthesis and turnover of dopamine (DA) in terminals of tuberoinfundibular (TI) neurons in the median eminence. Dopamine 134-142 prolactin Homo sapiens 47-56 6738811-1 1984 Results of previous studies have revealed that prolactin causes a delayed (12-16 h) increase in the rate of synthesis and turnover of dopamine (DA) in terminals of tuberoinfundibular (TI) neurons in the median eminence. Dopamine 144-146 prolactin Homo sapiens 47-56 6738811-6 1984 Hypophysectomy or treatment with bromocriptine (a DA agonist) reduce circulating levels of prolactin and reduce the rate of DA synthesis in the median eminence. Dopamine 50-52 prolactin Homo sapiens 91-100 6721674-2 1984 The responses of serum prolactin (PRL) and growth hormone (GH) to the dopamine agonist apomorphine hydrochloride (0.75 mg subcutaneously) were studied in a large group of unmedicated hospitalized patients with functional psychoses. Dopamine 70-78 prolactin Homo sapiens 23-32 6203789-3 1984 Dopamine (DA) inhibited PRL release in a dose-dependent manner within a physiological range, and this inhibition was reversed by the stereospecific DA receptor antagonist (+)-butaclamol. Dopamine 0-8 prolactin Homo sapiens 24-27 6203789-3 1984 Dopamine (DA) inhibited PRL release in a dose-dependent manner within a physiological range, and this inhibition was reversed by the stereospecific DA receptor antagonist (+)-butaclamol. Dopamine 10-12 prolactin Homo sapiens 24-27 6374346-0 1984 Stimulation of spontaneous and dopamine-inhibited prolactin release from anterior pituitary reaggregate cell cultures by angiotensin peptides. Dopamine 31-39 prolactin Homo sapiens 50-59 6374346-1 1984 In superfused anterior pituitary reaggregate cell cultures angiotensin II (AII) stimulated both spontaneous and dopamine-inhibited prolactin (PRL) release from subnanomolar concentrations. Dopamine 112-120 prolactin Homo sapiens 131-140 6330783-4 1984 The diminished increase in serum prolactin after morphine in depressed patients may reflect anterior pituitary dysfunction or abnormalities in central endogenous opioid, dopamine, serotonin, or other neuroregulatory systems. Dopamine 170-178 prolactin Homo sapiens 33-42 6141070-0 1984 Effects of growth hormone-releasing factor, somatostatin and dopamine on growth hormone and prolactin secretion from cultured ovine pituitary cells. Dopamine 61-69 prolactin Homo sapiens 92-101 6713309-3 1984 Their development has yielded valuable information on the pharmacology of dopamine receptors involved in the regulatory mechanisms of prolactin secretion and in striatal functions. Dopamine 74-82 prolactin Homo sapiens 134-143 6366415-2 1984 This finding has been used to support the concept of a central dopamine mediated mechanism for LRF-induced PRL release. Dopamine 63-71 prolactin Homo sapiens 107-110 6141070-5 1984 Dopamine (0.1 microM) inhibition of basal prolactin secretion was not affected by GRF (1 nM). Dopamine 0-8 prolactin Homo sapiens 42-51 6421041-6 1984 Dopamine (5 X 10(-7) M) suppressed Prl secretion from adenoma tissue in 5 of 7 patients tested but had no effect in the remaining two adenomas. Dopamine 0-8 prolactin Homo sapiens 35-38 6420095-15 1984 We conclude that the inhibitory action of dopamine on PRL release restores LH secretion by removing central dopaminergic inhibition through hypothalamic feedback of PRL. Dopamine 42-50 prolactin Homo sapiens 165-168 6151431-0 1984 Dopamine control of prolactin secretion in multiple endocrine neoplasia type I. Dopamine 0-8 prolactin Homo sapiens 20-29 6151431-3 1984 Dopamine (2 micrograms/kg/min) was less effective in reducing serum prolactin in the prolactinoma group than in the other three groups studied; serum prolactin also showed little rebound in prolactin comparable to controls. Dopamine 0-8 prolactin Homo sapiens 68-77 6151431-3 1984 Dopamine (2 micrograms/kg/min) was less effective in reducing serum prolactin in the prolactinoma group than in the other three groups studied; serum prolactin also showed little rebound in prolactin comparable to controls. Dopamine 0-8 prolactin Homo sapiens 85-94 6730927-6 1984 The study indicates that the degree of autonomy of PRL secretion reflected by both the fluctuations in basal levels and the response to a dopamine antagonist, may be used to evaluate whether or not slightly elevated PRL levels are of clinical significance in relation to fertility. Dopamine 138-146 prolactin Homo sapiens 51-54 6388911-4 1984 The serum PRL concentration showed a significant correlation with DA in the urine (gamma = 0.447, n = 24, p less than 0.05). Dopamine 66-68 prolactin Homo sapiens 10-13 6420095-6 1984 Dopamine infusion (0.5 microgram/kg/min) resulted in suppression of PRL (min 19 +/- 3% of basal) but not of LH or FSH. Dopamine 0-8 prolactin Homo sapiens 68-71 6151431-3 1984 Dopamine (2 micrograms/kg/min) was less effective in reducing serum prolactin in the prolactinoma group than in the other three groups studied; serum prolactin also showed little rebound in prolactin comparable to controls. Dopamine 0-8 prolactin Homo sapiens 85-94 6420206-8 1984 The addition of dopamine, pergolide, or bromocriptine resulted in a depression of PRL during the treatment period. Dopamine 16-24 prolactin Homo sapiens 82-85 6420095-7 1984 A rebound of PRL (peak 188 +/- 68% of basal) but not LH or FSH occurred on cessation of dopamine. Dopamine 88-96 prolactin Homo sapiens 13-16 6420095-10 1984 The responses to MIT show that dopamine functions as an inhibitor of PRL but not of LH or FSH in normal subjects. Dopamine 31-39 prolactin Homo sapiens 69-72 6420095-14 1984 In PHP patients, PRL feedback results in increased hypothalamic dopamine activity which in turn inhibits LH release. Dopamine 64-72 prolactin Homo sapiens 17-20 6420095-15 1984 We conclude that the inhibitory action of dopamine on PRL release restores LH secretion by removing central dopaminergic inhibition through hypothalamic feedback of PRL. Dopamine 42-50 prolactin Homo sapiens 54-57 6538844-1 1984 Prolactin (PRL) secretion is stimulated by serotonin (5-HT) and inhibited by dopamine (DA). Dopamine 77-85 prolactin Homo sapiens 0-9 6538844-1 1984 Prolactin (PRL) secretion is stimulated by serotonin (5-HT) and inhibited by dopamine (DA). Dopamine 77-85 prolactin Homo sapiens 11-14 6538844-1 1984 Prolactin (PRL) secretion is stimulated by serotonin (5-HT) and inhibited by dopamine (DA). Dopamine 87-89 prolactin Homo sapiens 0-9 6538844-1 1984 Prolactin (PRL) secretion is stimulated by serotonin (5-HT) and inhibited by dopamine (DA). Dopamine 87-89 prolactin Homo sapiens 11-14 6140273-2 1984 When dopamine (0.01-0.1 microM) or bromocriptine (0.01-0.1 microM) was added to the culture media, a significant inhibition of GH and PRL secretion from adenoma cells from acromegalic patients was observed. Dopamine 5-13 prolactin Homo sapiens 134-137 6425187-6 1984 DA infusion after endogenous catecholamine synthesis inhibition by AMPT, induced an appreciable decline in PRL levels in both normal and hyperprolactinemic subjects. Dopamine 0-2 prolactin Homo sapiens 107-110 6436160-2 1984 Restoration of the prolactin response to thyrotropin-releasing hormone by low-dose dopamine infusion in women with pathological hyperprolactinemia. Dopamine 83-91 prolactin Homo sapiens 19-28 6140273-4 1984 Similarly, dopamine suppressed GH and PRL release by nonadenomatous pituitary cells in a dose-dependent manner, which was again blocked by D2 receptor blockade. Dopamine 11-19 prolactin Homo sapiens 38-41 6140273-5 1984 The minimum effective concentration of dopamine required for a significant inhibition of PRL secretion (0.01 microM) was lower than that for GH release (0.1 microM). Dopamine 39-47 prolactin Homo sapiens 89-92 6140273-9 1984 Coincubation of TRH and dopamine resulted in variable effects on GH and PRL secretion. Dopamine 24-32 prolactin Homo sapiens 72-75 6624968-3 1983 The elevation of serum prolactin during treatment in three patients suggests that postsynaptic dopamine blockade occurs with amoxapine treatment. Dopamine 95-103 prolactin Homo sapiens 23-32 6645503-0 1983 Mineralocorticoid and prolactin response to the dopamine antagonist metoclopramide in patients with primary aldosteronism. Dopamine 48-56 prolactin Homo sapiens 22-31 6627697-0 1983 The participation of hypothalamic dopamine in morphine-induced prolactin release in man. Dopamine 34-42 prolactin Homo sapiens 63-72 6689678-6 1984 Upon cessation of DA infusion, there was a rapid rebound in PRL release, which was significantly greater (P less than 0.05) in patients (155 +/- 15%) than in normal subjects (118 +/- 13%). Dopamine 18-20 prolactin Homo sapiens 60-63 6699448-6 1984 The effects of the oral administration of two serotonin antagonist (cyproheptadine and metergoline) and the dopamine infusion on plasma PRL levels and the response to suckling were investigated during the 1st week postpartum. Dopamine 108-116 prolactin Homo sapiens 136-139 6699448-7 1984 Metergoline and dopamine suppressed basal PRL levels and abolished the response to suckling, whereas cyproheptadine suppressed the response less effectively without modifying the basal levels. Dopamine 16-24 prolactin Homo sapiens 42-45 6229562-2 1983 Clinically, an increase in serum prolactin occurs during neuroleptic treatment secondary to post-synaptic dopamine blockade. Dopamine 106-114 prolactin Homo sapiens 33-42 6643309-0 1983 Effects of ovarian secretions and dopamine on secretion of luteinizing hormone and prolactin in ewes. Dopamine 34-42 prolactin Homo sapiens 83-92 6643309-9 1983 Infusion of DA inhibited release of PRL, but there was no effect of method of progesterone withdrawal. Dopamine 12-14 prolactin Homo sapiens 36-39 6138009-5 1983 The increase in PRL secretion could be due to a dopamine antagonist effect at the pituitary gland. Dopamine 48-56 prolactin Homo sapiens 16-19 6580661-0 1983 Serum prolactin response to chlorpromazine and psychopathology in schizophrenics: implications for the dopamine hypothesis. Dopamine 103-111 prolactin Homo sapiens 6-15 6580661-3 1983 The PRL response to the 12.5 mg dose only was significantly correlated with baseline PRL levels for both males and females, suggesting that endogenous dopamine release from tuberoinfundibular neurons has a much greater effect upon the PRL response to the 12.5 mg dose of CPZ than to the 25 mg dose. Dopamine 151-159 prolactin Homo sapiens 4-7 6580661-3 1983 The PRL response to the 12.5 mg dose only was significantly correlated with baseline PRL levels for both males and females, suggesting that endogenous dopamine release from tuberoinfundibular neurons has a much greater effect upon the PRL response to the 12.5 mg dose of CPZ than to the 25 mg dose. Dopamine 151-159 prolactin Homo sapiens 85-88 6580661-3 1983 The PRL response to the 12.5 mg dose only was significantly correlated with baseline PRL levels for both males and females, suggesting that endogenous dopamine release from tuberoinfundibular neurons has a much greater effect upon the PRL response to the 12.5 mg dose of CPZ than to the 25 mg dose. Dopamine 151-159 prolactin Homo sapiens 85-88 6403331-11 1983 These data suggest that there is persistent dopaminergic inhibition of PRL secretion in the fetus after complete stalk section, and that the source of this dopamine is extrahypothalamic. Dopamine 44-52 prolactin Homo sapiens 71-74 6861440-1 1983 The effects of oral doses (100, 200, and 400 mg) of a dopamine derivative, ibopamine, on serum prolactin (PRL) and growth hormone (GH) levels were evaluated in hyperprolactinemic patients, some of whom also were acromegalic. Dopamine 54-62 prolactin Homo sapiens 95-104 6404923-0 1983 Are fasting-induced effects on thyrotropin and prolactin secretion mediated by dopamine? Dopamine 79-87 prolactin Homo sapiens 47-56 6403331-3 1983 The administration of a dopamine antagonist, haloperidol, to the ovine fetus in late gestation elevates plasma concentrations of PRL, suggesting tonic dopaminergic inhibition of fetal PRL secretion. Dopamine 24-32 prolactin Homo sapiens 129-132 6420004-5 1983 In these women, PRL increases when VIP is administered at the 200th minute of DA infusion (1 microgram X kg/min.). Dopamine 78-80 prolactin Homo sapiens 16-19 6403331-3 1983 The administration of a dopamine antagonist, haloperidol, to the ovine fetus in late gestation elevates plasma concentrations of PRL, suggesting tonic dopaminergic inhibition of fetal PRL secretion. Dopamine 24-32 prolactin Homo sapiens 184-187 6403331-8 1983 The dopamine agonist apomorphine (100 micrograms/kg, iv) induced a similar suppression of fetal PRL concentrations in CON (n = 4) and SS (n = 2) fetuses. Dopamine 4-12 prolactin Homo sapiens 96-99 6343157-3 1983 Elevated plasma prolactin levels, induced by pituitary transplants, resulted in increased in vitro biosynthesis of medial basal hypothalamic (MBH) dopamine (DA), but not norepinephrine (NE). Dopamine 147-155 prolactin Homo sapiens 16-25 6343157-8 1983 Gonadotroph responsiveness to LHRH was significantly increased, while the inhibition of prolactin by dopamine was not altered. Dopamine 101-109 prolactin Homo sapiens 88-97 6838618-1 1983 The ability of 2-Hydroxyestradiol, a catecholestrogen, and 17 beta Estradiol to interact with the dopamine inhibition of prolactin and with dopamine receptors has been tested on dispersed human prolactin-secreting cells obtained from ten pituitary adenomas. Dopamine 98-106 prolactin Homo sapiens 121-130 6838618-2 1983 There is a 80% inhibition of prolactin secretion obtained by addition of dopamine in a superfusion system. Dopamine 73-81 prolactin Homo sapiens 29-38 6133737-5 1983 Some of the above classes of drugs (e.g. the indirect-acting dopamine agonists, dopamine receptor antagonists, GABA-mimetic drugs, dopamine receptor blocking drugs, and H2-antagonists) may be useful for selecting among hyperprolactinaemic patients those with a prolactin-secreting tumour in an early stage of the disease. Dopamine 61-69 prolactin Homo sapiens 224-233 6833458-0 1983 Prolactin response to dopamine synthesis inhibition using monoiodotyrosine in subjects on oral contraceptives and patients with pathological hyperprolactinemia. Dopamine 22-30 prolactin Homo sapiens 0-9 6822635-0 1983 Differential effects of a low dose dopamine infusion on prolactin secretion in normal and hyperprolactinemic subjects. Dopamine 35-43 prolactin Homo sapiens 56-65 6872271-0 1983 Inhibition of prolactin secretion by low-dose dopamine infusion in patients with hyperprolactinaemia. Dopamine 46-54 prolactin Homo sapiens 14-23 6872271-1 1983 Dopamine inhibits the secretion of prolactin from the pituitary. Dopamine 0-8 prolactin Homo sapiens 35-44 6872271-2 1983 We have examined the relation between plasma dopamine and serum prolactin in 12 patients with hyperprolactinaemia during the infusion of dopamine at low doses (0.01, 0.1 and 1 microgram/kg/min). Dopamine 45-53 prolactin Homo sapiens 64-73 6872271-6 1983 Serum prolactin levels returned to values similar to or greater than basal on cessation of dopamine infusion. Dopamine 91-99 prolactin Homo sapiens 6-15 6872271-7 1983 Infusion of dopamine at doses much lower than previously used in man exposes the pituitary to a concentration of dopamine sufficient to suppress prolactin secretion. Dopamine 12-20 prolactin Homo sapiens 145-154 6872271-7 1983 Infusion of dopamine at doses much lower than previously used in man exposes the pituitary to a concentration of dopamine sufficient to suppress prolactin secretion. Dopamine 113-121 prolactin Homo sapiens 145-154 6308959-3 1983 The stress induced reduction of DA turnover in MPZ may mediate the stress induced increase of prolactin secretion. Dopamine 32-34 prolactin Homo sapiens 94-103 6661508-3 1983 Prolactin rebound after the arrest of dopamine infusion and during domperidone are + 400% and + 2,300% in normal subjects. Dopamine 38-46 prolactin Homo sapiens 0-9 6617716-0 1983 Effect of the orally absorbed dopamine analogue N-methyldopamine diisobutyric ester on plasma prolactin levels. Dopamine 30-38 prolactin Homo sapiens 94-103 6133307-0 1983 Dopamine, serotonin and alpha-adrenergic receptor blocking activities in serum and their relationships to prolactin level in schizophrenic patients receiving long-term chlorpromazine treatment. Dopamine 0-8 prolactin Homo sapiens 106-115 6642291-0 1983 Prolactin response to the dopamine antagonists sulpiride and domperidone. Dopamine 26-34 prolactin Homo sapiens 0-9 6642291-7 1983 Since the PRL response to dopamine antagonists depends on the presence of an endogenous dopaminergic tone, it is suggested that these figures reflect the incidence of major dopamine deficiency at pituitary lactotrophs in different hyperprolactinemic states. Dopamine 26-34 prolactin Homo sapiens 10-13 6642291-7 1983 Since the PRL response to dopamine antagonists depends on the presence of an endogenous dopaminergic tone, it is suggested that these figures reflect the incidence of major dopamine deficiency at pituitary lactotrophs in different hyperprolactinemic states. Dopamine 88-96 prolactin Homo sapiens 10-13 7132736-0 1982 Impaired prolactin responsiveness to dopamine antagonists in acromegaly. Dopamine 37-45 prolactin Homo sapiens 9-18 6408670-0 1983 A preliminary study of sex-related differences in prolactin responses to dopamine blockade and insulin hypoglycemia and in penfluridol plasma levels in schizophrenic patients. Dopamine 73-81 prolactin Homo sapiens 50-59 7158225-5 1982 This potent long-lasting inhibition of Prl secretion should enhance the efficacy and acceptability of the chronic treatment of hyperprolactinaemia with this new dopamine agonist and, for example, allow drug intake only once every other day. Dopamine 161-169 prolactin Homo sapiens 39-42 6130077-4 1982 Buspirone also blocked the inhibitory effect of dopamine on PRL secretion in vitro, which is consistent with the action of a DA antagonist. Dopamine 48-56 prolactin Homo sapiens 60-63 7069345-6 1982 These results are interpreted as evidence that the raised concentrations of prolactin characteristic of late pregnancy in the ewe are due to a reduced responsiveness of the pituitary gland to inhibitory stimuli, or to a decreased secretion of endogenous dopamine into the hypophysial portal blood system or to both. Dopamine 254-262 prolactin Homo sapiens 76-85 7096541-5 1982 In comparison to prior studies with PRL-secreting adenomas, several differences were apparent: 1) the maximum inhibition of GH release by DA is lower than that of PRL (50% vs. 80%), 2) the maximum number of binding sites is much lower (5-20 times) in GH-secreting adenomas than in PRL-secreting adenomas, and 3) [3H]domperidone does not show specific binding on GH-secreting adenomas but does on PRL-secreting adenomas. Dopamine 138-140 prolactin Homo sapiens 36-39 6804483-6 1982 We have previously suggested that thyroid hormones inhibit PRL secretion by stimulating the hypothalamic secretion of dopamine. Dopamine 118-126 prolactin Homo sapiens 59-62 7093595-3 1982 These findings are discussed in relation to the role of dopamine in the release of prolactin and growth hormone, and in the pathogenesis of mania. Dopamine 56-64 prolactin Homo sapiens 83-92 7308513-5 1981 The release of prolactin to AS was blunted by higher-dose of opioid and by dopamine antagonists. Dopamine 75-83 prolactin Homo sapiens 15-24 7035483-6 1982 min) begun 60 min before the administration of metoclopramide markedly decreased the 18-OHB as well as the aldosterone and PRL responses to the dopamine antagonist. Dopamine 144-152 prolactin Homo sapiens 123-126 6818826-7 1982 Furthermore, the low prolactin and LH levels despite a low estradiol-17 beta concentration may suggest an increased hypothalamic dopamine activity in patients with diabetes mellitus and secondary amenorrhea. Dopamine 129-137 prolactin Homo sapiens 21-30 7054227-0 1982 Dynamic tests of prolactin secretion in hyperprolactinemic states: carbidopa-L-dopa and indirectly acting dopamine agonists. Dopamine 106-114 prolactin Homo sapiens 17-26 6223322-2 1982 Evidence for autoreceptors on the tuberoinfundibular dopamine neurones which participate in the regulation of prolactin and growth hormone secretion is lacking. Dopamine 53-61 prolactin Homo sapiens 110-119 7293666-4 1981 It is speculated that the inhibitory effect of Ca infusion or serum Prl may be due to dopamine release from nerve tracts in the hypothalamus. Dopamine 86-94 prolactin Homo sapiens 68-71 6795296-0 1981 Evidence for the involvement of hypothalamic dopamine and thyrotrophin-releasing hormone in suckling-induced release of prolactin. Dopamine 45-53 prolactin Homo sapiens 120-129 7301051-0 1981 Effect of two indirectly acting dopamine agonists on prolactin secretion in normo- and hyperprolactinemic subjects: comparison with the effect of nomifensine. Dopamine 32-40 prolactin Homo sapiens 53-62 6802092-7 1981 The data of the present study suggest that dopamine blockade at pituitary (or median eminence) level is able to stimulate maximally the lactotrophs and emphasize the important role of the dopaminergic system in the interrelated regulation of TSH and PRL secretion at the pituitary level. Dopamine 43-51 prolactin Homo sapiens 250-253 7246736-0 1981 Resumption of prolactin secretion after dopaminergic inhibition: differential effects of dopamine and its agonists. Dopamine 40-48 prolactin Homo sapiens 14-23 7023253-2 1981 Because the monoamines dopamine and serotonin are important in the control of its secretion, prolactin has been the subject of much psychoendocrine research in recent years. Dopamine 23-31 prolactin Homo sapiens 93-102 6944708-4 1981 The fact that reserpine was found to be a potent releaser of PRL--significantly greater than haloperidol--suggests a major role of storage pool dopamine in regulating PRL Secretion. Dopamine 144-152 prolactin Homo sapiens 167-170 7246736-2 1981 PRL secretion over 4 h was inhibited comparably by 10(-6) M dopamine (DA), 10(-7) M apomorphine (APO), and 10(-10) M bromocriptine (45%, 42%, 51%, respectively) with reciprocal increases in intracellular hormone content. Dopamine 60-68 prolactin Homo sapiens 0-3 7246736-2 1981 PRL secretion over 4 h was inhibited comparably by 10(-6) M dopamine (DA), 10(-7) M apomorphine (APO), and 10(-10) M bromocriptine (45%, 42%, 51%, respectively) with reciprocal increases in intracellular hormone content. Dopamine 70-72 prolactin Homo sapiens 0-3 7246736-3 1981 After drug removal, the PRL secretion rate in the cultures that had been treated with DA was 208% of the control cultures by the 2nd h but returned to control values by 4 h, whereas the secretion rate after APO was 131-142% of control throughout the 4-h recovery period. Dopamine 86-88 prolactin Homo sapiens 24-27 6261178-12 1981 It is concluded that TRH and dopamine regulate PRL release at sites which are not under corticosteroid regulation, while corticosteroids modulate PRL secretion in response to stress. Dopamine 29-37 prolactin Homo sapiens 47-50 6261178-8 1981 However, in the presence of dexamethasone modulation of PRL release by TRH and dopamine remained unaltered. Dopamine 79-87 prolactin Homo sapiens 56-59 7238264-2 1981 Therefore, we measured plasma prolactin, a known sensitive indicator of functional dopamine activity in man, in an attempt to evaluate dopaminergic function in 21 patients with alcoholic liver disease and PSE and several control groups. Dopamine 83-91 prolactin Homo sapiens 30-39 7460842-4 1981 The effect of PRL on the amounts of DA and NE released during exposure to a submaximal stimulus of 30 mM K+ was evaluated. Dopamine 36-38 prolactin Homo sapiens 14-17 7460842-5 1981 PRL in concentrations of 50-5000 ng/ml augmented the K+-induced release of DA and NE in a concentration-dependent manner. Dopamine 75-77 prolactin Homo sapiens 0-3 7460842-6 1981 The PRL augmentation of the release of both DA and NE was prevented by the addition of anti-PRL gamma-globulin to the superfusion medium. Dopamine 44-46 prolactin Homo sapiens 4-7 7460842-6 1981 The PRL augmentation of the release of both DA and NE was prevented by the addition of anti-PRL gamma-globulin to the superfusion medium. Dopamine 44-46 prolactin Homo sapiens 92-95 7460842-7 1981 In view of the inhibitory effect of DA on PRL secretion, these findings are consistent with the conclusion that PRL can influence its own secretion by stimulating the release of hypothalamic DA. Dopamine 36-38 prolactin Homo sapiens 42-45 7460842-7 1981 In view of the inhibitory effect of DA on PRL secretion, these findings are consistent with the conclusion that PRL can influence its own secretion by stimulating the release of hypothalamic DA. Dopamine 36-38 prolactin Homo sapiens 112-115 7226569-0 1980 Effect of dopamine infusion on serum prolactin concentration in normal and hyperprolactinaemic subjects. Dopamine 10-18 prolactin Homo sapiens 37-46 7226569-1 1980 The serum prolactin response to intravenous dopamine infusion (5 micrograms . Dopamine 44-52 prolactin Homo sapiens 10-19 7226569-7 1980 Since intravenously infused dopamine is believed to inhibit prolactin secretion by acting at pituitary level, it is suggested that a normal functioning of pituitary dopamine receptors is maintained in most human prolactinomas. Dopamine 28-36 prolactin Homo sapiens 60-69 6893323-6 1980 Dopamine, ergocryptine, and bromoergocryptine (also a dopamine agonist) all inhibited prolactin synthesis while epinephrine and norepinephrine had little effect. Dopamine 54-62 prolactin Homo sapiens 86-95 6893323-6 1980 Dopamine, ergocryptine, and bromoergocryptine (also a dopamine agonist) all inhibited prolactin synthesis while epinephrine and norepinephrine had little effect. Dopamine 0-8 prolactin Homo sapiens 86-95 7234451-3 1980 Several unexpected findings related to neuroleptic-induced prolactin response and its suppression by dopamine infusion have been observed. Dopamine 101-109 prolactin Homo sapiens 59-68 6105975-0 1980 Dopamine, PIF, and other regulators of prolactin secretion. Dopamine 0-8 prolactin Homo sapiens 39-48 6105975-1 1980 Considerable evidence now exists that dopamine is a physiological prolactin inhibiting factor (PIF); however, it may not represent the only PIF. Dopamine 38-46 prolactin Homo sapiens 66-75 6105975-2 1980 Amphetamine, which releases newly synthesized dopamine and blocks prolactin release, caused an increased in dopamine levels in the pituitaryb gloand. Dopamine 108-116 prolactin Homo sapiens 66-75 7190256-2 1980 Nine of 12 patients had a suppression of prolactin with oral L-dopa, and all of 4 patients undergoing dopamine infusion had suppression of prolactin. Dopamine 102-110 prolactin Homo sapiens 139-148 6773972-3 1980 However, medical therapy with bromocriptine, a dopamine agonist, not only suppresses PRL levels, but may also lead to a reduction in tumor size. Dopamine 47-55 prolactin Homo sapiens 85-88 7411481-9 1980 3 degrees Morphinomimetic peptides had no effect on prolactin secretion in vitro, but blocked the dopamine inhibition of prolactin secretion. Dopamine 98-106 prolactin Homo sapiens 121-130 7378822-0 1980 Relationship of prolactin secretion to dopamine release into hypophysial portal blood and dopamine turnover in the median eminence. Dopamine 39-47 prolactin Homo sapiens 16-25 6250393-4 1980 Dopamine inhibition of PRL secretion (> 80% at 1, 2, 3 h) resulted in accumulation of secretory granules in all stages of maturation and dilation of Golgi saccules at 2 and 3 h, accompanied by increased mitochondria antimonate and increased Golgi-associated antimonate. Dopamine 0-8 prolactin Homo sapiens 23-26 6769714-2 1980 Dopamine may be a physiological prolactin inhibiting factor (PIF), while norepinephrine and possibly epinephrine regulate prolactin release at the level of the hypothalamus. Dopamine 0-8 prolactin Homo sapiens 32-41 7372794-0 1980 Functional studies of dopamine control of prolactin secretion in normal women and women with hyperprolactinemic pituitary microadenoma. Dopamine 22-30 prolactin Homo sapiens 42-51 7376792-1 1980 Prolactin (Prl) release, both in the experimental animal and in man, is stimulated by serotonin (5HT) and inhibited by dopamine (DA). Dopamine 119-127 prolactin Homo sapiens 0-9 7376792-7 1980 These data indicate that DA inhibits both LH and Prl release in normal women, and that 5HT stimulates Prl release but is not involved in the regulation of LH secretion. Dopamine 25-27 prolactin Homo sapiens 49-52 7376792-1 1980 Prolactin (Prl) release, both in the experimental animal and in man, is stimulated by serotonin (5HT) and inhibited by dopamine (DA). Dopamine 119-127 prolactin Homo sapiens 11-14 7376792-1 1980 Prolactin (Prl) release, both in the experimental animal and in man, is stimulated by serotonin (5HT) and inhibited by dopamine (DA). Dopamine 129-131 prolactin Homo sapiens 0-9 7376792-1 1980 Prolactin (Prl) release, both in the experimental animal and in man, is stimulated by serotonin (5HT) and inhibited by dopamine (DA). Dopamine 129-131 prolactin Homo sapiens 11-14 6774864-1 1980 Some investigators have reported that plasma prolactin levels are elevated in hypertensive men and that both their hyperprolactinemia and hypertension were controlled by bromocriptine, a dopamine agonist. Dopamine 187-195 prolactin Homo sapiens 45-54 7421220-0 1980 Sex steroids interact with dopamine at the hypothalamic and pituitary levels to modulate prolactin secretion. Dopamine 27-35 prolactin Homo sapiens 89-98 7355667-7 1980 The observed prolactin increase fits with the hypothesis that a diminution of the inhibitory effect of dopamine at the pituitary and/or at the median eminence levels may occur in connection to the pharmacologically impaired monoamine synthesis. Dopamine 103-111 prolactin Homo sapiens 13-22 7379313-0 1980 Size reduction of a prolactin secreting adenoma during long-term treatment with the dopamine agonist lisuride. Dopamine 84-92 prolactin Homo sapiens 20-29 117385-0 1979 Dopamine inhibition of action potentials in a prolactin secreting cell line is modulated by oestrogen. Dopamine 0-8 prolactin Homo sapiens 46-55 43786-2 1979 The serum prolactin response to cimetidine was abolished by dopamine infusion and almost completely suppressed by L-dopa plus carbidopa administration. Dopamine 60-68 prolactin Homo sapiens 10-19 583048-10 1979 Dopamine infusion decreased RPL PR from 270 to 66 micrograms/d per m2 indicating that its effect was on pituitary PRL secretion and not PRL metabolism. Dopamine 0-8 prolactin Homo sapiens 114-117 317700-3 1979 This study thus demonstrates that a quite specific and unexpected change occurs in the regulation of hypothalamic-median eminence dopamine when iproniazid is administered chronically and provides an explanation of previous observations in human subjects where raised serum prolactin levels are observed after chronic therapy with monoamine oxidase inhibitors. Dopamine 130-138 prolactin Homo sapiens 273-282 572372-1 1979 The suppressive action of dopamine (DA) on circulating gonadotropin and PRL levels is found to be positively correlated with their basal serum concentrations. Dopamine 26-34 prolactin Homo sapiens 72-75 467339-0 1979 Independent inhibition of prolactin secretion by dopamine and gamma-aminobutyric acid in vitro. Dopamine 49-57 prolactin Homo sapiens 26-35 489713-4 1979 When pooling the results of the PRL-secreting adenomas, the mean levels of PRL with dopamine, L-dopa, and bromocriptine were, respectively, 49%, 55%, and 60% of the control levels. Dopamine 84-92 prolactin Homo sapiens 75-78 489713-10 1979 1) Dopamine acts directly on PRL and GH release from human pituitary adenomas; in vitro, L-dopa effects are similar (its action probably occurs after conversion to catecholamines). Dopamine 3-11 prolactin Homo sapiens 29-39 223069-0 1979 Endogenous opiates block dopamine inhibition of prolactin secretion in vitro. Dopamine 25-33 prolactin Homo sapiens 48-57 572372-1 1979 The suppressive action of dopamine (DA) on circulating gonadotropin and PRL levels is found to be positively correlated with their basal serum concentrations. Dopamine 36-38 prolactin Homo sapiens 72-75 572372-5 1979 These findings indicate that castration and estrogen treatment significantly influence the inhibitory effect of DA on gonadotropin and PRL release. Dopamine 112-114 prolactin Homo sapiens 135-138 288372-6 1979 This was suggested by the inhibitory effect of pretreatment with the dopamine antagonist spiroperidol or with sulpiride on the prolactin-lowering effect of lisuride. Dopamine 69-77 prolactin Homo sapiens 127-136 29592-1 1978 It has been suggested that, if dopamine antagonism is a necessary condition for the antischizophrenic action of neuroleptics, the prolactin response, as an index of dopamine blockade, would correlate with clinical response. Dopamine 165-173 prolactin Homo sapiens 130-139 43550-2 1979 This study evaluated with dopamine antagonists the possibility that such dopamine hypersensitivity extends to the tuberoinfundibular dopamine (TIDA) system, which regulates, by inhibition, pituitary prolactin secretion. Dopamine 26-34 prolactin Homo sapiens 199-208 43550-2 1979 This study evaluated with dopamine antagonists the possibility that such dopamine hypersensitivity extends to the tuberoinfundibular dopamine (TIDA) system, which regulates, by inhibition, pituitary prolactin secretion. Dopamine 73-81 prolactin Homo sapiens 199-208 43550-2 1979 This study evaluated with dopamine antagonists the possibility that such dopamine hypersensitivity extends to the tuberoinfundibular dopamine (TIDA) system, which regulates, by inhibition, pituitary prolactin secretion. Dopamine 73-81 prolactin Homo sapiens 199-208 720494-1 1978 The addition of dopamine to anterior pituitary incubations resulted in a marked decrease (88% for 3H prolactin and 69% for RIA prolactin) in prolactin release. Dopamine 16-24 prolactin Homo sapiens 101-110 720494-1 1978 The addition of dopamine to anterior pituitary incubations resulted in a marked decrease (88% for 3H prolactin and 69% for RIA prolactin) in prolactin release. Dopamine 16-24 prolactin Homo sapiens 127-136 720494-1 1978 The addition of dopamine to anterior pituitary incubations resulted in a marked decrease (88% for 3H prolactin and 69% for RIA prolactin) in prolactin release. Dopamine 16-24 prolactin Homo sapiens 127-136 760734-0 1979 Failure of cimetidine to antagonise dopamine-induced suppression of prolactin in vitro. Dopamine 36-44 prolactin Homo sapiens 68-77 122409-1 1978 The influence of endogenous estradiol (E2) levels on gonadotropin and PRL sensitivity to dopamine (DA) infusion (4 micrograms/kg/min) was assessed at different stages of the follicular phase of the menstrual cycle. Dopamine 89-97 prolactin Homo sapiens 70-73 45469-0 1978 Effect of dopamine agonist (Lergotrile mesylate) therapy on twenty-four hour secretion of prolactin in treated Parkinson"s disease. Dopamine 10-18 prolactin Homo sapiens 90-99 45469-6 1978 The addition of a dopamine agonist (Lergotrile mesylate) resulted in a significant (P less than 0.01) suppression of the 24-h mean PRL levels and abolition of the normal sleep augmentation after 2 weeks of therapy. Dopamine 18-26 prolactin Homo sapiens 131-134 45469-9 1978 These results suggest a dichotomy between the PRL and GH responses to combined L-dopa-carbidopa and dopamine agonist therapy. Dopamine 100-108 prolactin Homo sapiens 46-49 122409-1 1978 The influence of endogenous estradiol (E2) levels on gonadotropin and PRL sensitivity to dopamine (DA) infusion (4 micrograms/kg/min) was assessed at different stages of the follicular phase of the menstrual cycle. Dopamine 99-101 prolactin Homo sapiens 70-73 122409-7 1978 The inhibition of PRL release by DA is correlated with endogenous E2 levels (r equal 0.685) as well as basal PRL levels (r = 0.878). Dopamine 33-35 prolactin Homo sapiens 18-21 122409-7 1978 The inhibition of PRL release by DA is correlated with endogenous E2 levels (r equal 0.685) as well as basal PRL levels (r = 0.878). Dopamine 33-35 prolactin Homo sapiens 109-112 233660-4 1978 The ingestion of L-dopa 2 h before parathyroid hormone infusion suppressed the PRL response, suggesting that dopamine and parathyroid hormone interact at a common site. Dopamine 109-117 prolactin Homo sapiens 79-82 665840-0 1978 Suppression of prolactin by dopamine agonists in schizophrenics and controls. Dopamine 28-36 prolactin Homo sapiens 15-24 665840-3 1978 Suppression of prolactin levels after each dopamine agonist was highly significant. Dopamine 43-51 prolactin Homo sapiens 15-24 744072-0 1978 The biphasic regulation of prolactin secretion by dopamine agonist-antagonists. Dopamine 50-58 prolactin Homo sapiens 27-36 744072-1 1978 The in vitro secretion of PRL by the pituitary gland is inhibited by low concentrations of dopamine. Dopamine 91-99 prolactin Homo sapiens 26-29 744072-2 1978 Dopamine receptor-blocking agents, haloperidol and pimozide, in concentrations between 10-100 nM, neutralize virtually completely the dopamine-mediated inhibition of PRL secretion. Dopamine 134-142 prolactin Homo sapiens 166-169 672445-0 1978 Prolactin in CSF selectively increases dopamine turnover in the median eminence. Dopamine 39-47 prolactin Homo sapiens 0-9 122292-1 1978 Our previous studies suggest that increased serum PRL, secondary to haloperidol-induced dopamine blockade, augments serum testosterone (T) levels in normal men. Dopamine 88-96 prolactin Homo sapiens 50-53 26606-2 1978 The locus of action of dopamine and dopaminergic agents such as the ergot alkaloids inhibiting prolactin secretion appears to be primarily at the pituitary level, though a hypothalamic action to increase secretion of prolactin inhibitory factor may also contribute. Dopamine 23-31 prolactin Homo sapiens 95-104 26606-2 1978 The locus of action of dopamine and dopaminergic agents such as the ergot alkaloids inhibiting prolactin secretion appears to be primarily at the pituitary level, though a hypothalamic action to increase secretion of prolactin inhibitory factor may also contribute. Dopamine 23-31 prolactin Homo sapiens 217-226 744042-0 1978 In vitro supersensitivity of the anterior pituitary to dopamine inhibition of prolactin secretion. Dopamine 55-63 prolactin Homo sapiens 78-87 638883-2 1978 Both dopamine and norepinephrine caused long lasting inhibition of prolactin release from either an isolated hemipituitary or a hemipituitary coincubated with a hypothalamus. Dopamine 5-13 prolactin Homo sapiens 67-76 637104-2 1978 Since hypothalamic dopamine functions as an inhibitor for the secretion of both prolactin and gonadotropin, we postulate that sequential EB-P stimulation for simultaneous release of gonadotropin and prolactin may be mediated by a reduction of hypothalamic dopamine in response to progesterone. Dopamine 19-27 prolactin Homo sapiens 80-89 659585-7 1978 Comparable suppression of PRL levels in response to a dopamine infusion (4 mug/kg per min for 3 h) was observed in controls and tumor patients. Dopamine 54-62 prolactin Homo sapiens 26-29 637104-2 1978 Since hypothalamic dopamine functions as an inhibitor for the secretion of both prolactin and gonadotropin, we postulate that sequential EB-P stimulation for simultaneous release of gonadotropin and prolactin may be mediated by a reduction of hypothalamic dopamine in response to progesterone. Dopamine 19-27 prolactin Homo sapiens 199-208 704750-0 1978 Effect of dopamine and neuroleptics on plasma growth hormone and prolactin in normal men. Dopamine 10-18 prolactin Homo sapiens 65-74 27267-2 1978 This is followed by the presentation of the evidence that dopamine is the inhibitory hypothalamic transducer controlling hormone release by prolactin cells. Dopamine 58-66 prolactin Homo sapiens 140-149 27267-5 1978 Although the dopamine concept of an inhibitory control of prolactin secretion seems quite satisfactory, the possibility of another unrelated inhibitory control system is not excluded. Dopamine 13-21 prolactin Homo sapiens 58-67 638883-6 1978 Results confirm that dopamine and norepinephrine directly inhibit prolactin release from pituitary and suggest that the hypothalamic mechanism inhibiting prolactin involves dopamine but not norepinephrine. Dopamine 21-29 prolactin Homo sapiens 66-75 638883-6 1978 Results confirm that dopamine and norepinephrine directly inhibit prolactin release from pituitary and suggest that the hypothalamic mechanism inhibiting prolactin involves dopamine but not norepinephrine. Dopamine 21-29 prolactin Homo sapiens 154-163 638883-6 1978 Results confirm that dopamine and norepinephrine directly inhibit prolactin release from pituitary and suggest that the hypothalamic mechanism inhibiting prolactin involves dopamine but not norepinephrine. Dopamine 173-181 prolactin Homo sapiens 154-163 418418-0 1978 Prolactin secretion from clonal pituitary cells following incubation with estradiol, progesterone, thyrotrophin releasing hormone and dopamine. Dopamine 134-142 prolactin Homo sapiens 0-9 579527-0 1978 The effects of the dopamine agonist, lergotrile mesylate, on prolactin secretion in women. Dopamine 19-27 prolactin Homo sapiens 61-70 659585-8 1978 The results indicate that although peripheral conversion of exogenous dopa to dopamine can suppress PRL secretion, in normals, the central nervous system conversion of dopa to dopamine in the presence of peripheral dopa decarboxylase inhibition is sufficient to account for its PRL-suppressive effects. Dopamine 78-86 prolactin Homo sapiens 100-103 410826-1 1977 In eleven normal women dopamine infusion (5 microgram/Kg/min) significantly lowered plasma prolactin levels but failed to suppress the PRL response to sulpiride (10 or 100 mg i.v. Dopamine 23-31 prolactin Homo sapiens 91-100 23087-1 1978 The prolactin response to neuroleptics can serve as an index of dopamine blockade in humans. Dopamine 64-72 prolactin Homo sapiens 4-13 573767-0 1978 Inhibition of thyrotropin and prolactin secretion by dopamine in man. Dopamine 53-61 prolactin Homo sapiens 30-39 573767-1 1978 The effect of dopamine on thyrotropin (TSH) and prolactin (PRL) levels was studied in 5 normal subjects, 7 women with galactorrhea, 9 acromegalics and 4 patients with primary hypothyroidism. Dopamine 14-22 prolactin Homo sapiens 48-57 573767-2 1978 Dopamine infused at the rate of 280 micrograms/min produced significant decrease in plasma TSH and PRL levels in all four groups, though a lower fall in TSH was noted in acromegalics. Dopamine 0-8 prolactin Homo sapiens 99-102 573767-3 1978 A similar reduction in PRL was also noted after 28 micrograms/min dopamine. Dopamine 66-74 prolactin Homo sapiens 23-26 410826-2 1977 ), while the same dose of dopamine was effective in abolishing the PRL response to TRH (200 microgram i.v.). Dopamine 26-34 prolactin Homo sapiens 67-70 410826-3 1977 In four hyperprolactinemic women showing an impaired PRL response to sulpiride, dopamine infusion was effective both in lowering PRL circulating levels and in restoring an evident response to sulpiride. Dopamine 80-88 prolactin Homo sapiens 53-56 410826-3 1977 In four hyperprolactinemic women showing an impaired PRL response to sulpiride, dopamine infusion was effective both in lowering PRL circulating levels and in restoring an evident response to sulpiride. Dopamine 80-88 prolactin Homo sapiens 129-132 410827-0 1977 Effects of CNS dopamine augmentation on stimulated prolactin secretion. Dopamine 15-23 prolactin Homo sapiens 51-60 410827-2 1977 Consequently, the effect of central dopamine (DA) augmentation on stimulated PRL release was determined in 5 healthy men. Dopamine 36-44 prolactin Homo sapiens 77-80 410827-2 1977 Consequently, the effect of central dopamine (DA) augmentation on stimulated PRL release was determined in 5 healthy men. Dopamine 46-48 prolactin Homo sapiens 77-80 891746-0 1977 Influence of dopamine infusion on plasma prolactin released by kidney capsule transplanted anterior pituitaries. Dopamine 13-21 prolactin Homo sapiens 41-50 69827-4 1977 It is proposed that in the hypertensive patients the raised prolactin levels reflect a defect in central dopamine control which is normalised by bromocriptine. Dopamine 105-113 prolactin Homo sapiens 60-69 20170-4 1977 Since dopamine does not penetrate the blood-brain barrier, the enhanced PRL decrease observed during pyridoxine infusion might be explained only on the basis of a mechanism of action exerted by dopamine on extra blood-brain barrier sites. Dopamine 194-202 prolactin Homo sapiens 72-75 20170-4 1977 Since dopamine does not penetrate the blood-brain barrier, the enhanced PRL decrease observed during pyridoxine infusion might be explained only on the basis of a mechanism of action exerted by dopamine on extra blood-brain barrier sites. Dopamine 6-14 prolactin Homo sapiens 72-75 891746-1 1977 The infusion of dopamine into the renal artery resulted in decreased prolactin release from 3 anterior pituitary glands transplanted under the kidney capsule. Dopamine 16-24 prolactin Homo sapiens 69-78 329643-0 1977 Regulation of prolactin secretion through dopamine, serotonin, and the cerebrospinal fluid. Dopamine 42-50 prolactin Homo sapiens 14-23 408065-6 1977 Neurotransmitter therapy, with dopamine agonists which act as functional analogues of PIF, restores prolactin levels to normal and leads to a return of normal gonadal function. Dopamine 31-39 prolactin Homo sapiens 100-109 402375-4 1977 Following dexamethasone administration, the PRL response to metoclopramide, a dopamine antagonist which acts at the hypothalamicpituitary level to stimulate PRL secretion, was blunted in 7 normal men. Dopamine 78-86 prolactin Homo sapiens 44-47 62213-0 1976 Dopamine-induced inhibition of prolactin secretion in amenorrhea-galactorrhea. Dopamine 0-8 prolactin Homo sapiens 31-40 53377-3 1975 It is suggested that dopamine may modulate the normal secretion of aldosterone either directly, or indirectly, possible by inhibition of prolactin secretion. Dopamine 21-29 prolactin Homo sapiens 137-146 947942-4 1976 Since the tuberoinfundibular dopamine nerve terminals lie outside the blood brain barrier, this study suggests that these neurons are involved in prolactin but not in growth hormone or cortisol regulation. Dopamine 29-37 prolactin Homo sapiens 146-155 947942-5 1976 Findings are compatible with two alternate hypotheses--either that dopamine is a physiologic prolactin inhibiting factor (PIF) or that tuberoinfundibular dopamine neurons regulate the release of PIF. Dopamine 67-75 prolactin Homo sapiens 93-102 1259521-4 1976 There was a lag between clinical response and dopamine blockade, as indicated by serum prolactin levels in most patients. Dopamine 46-54 prolactin Homo sapiens 87-96 1249179-6 1976 Mean PRL levels rose promptly and significantly in a dose-related manner in response to the haloperidol, which has strong dopamine blocking effects. Dopamine 122-130 prolactin Homo sapiens 5-8 956350-1 1976 Dopamine, infused at a rate of 4 mug/kg/min for 3-4 h unaccompanied by any significant changes in cardiovascular dynamics, induced a prompt and sustained suppression of circulating prolactin (PRL) levels in normal men and women as well as in patients with hyperprolactinemia. Dopamine 0-8 prolactin Homo sapiens 181-190 777023-4 1976 Pre-treatment with 500 mg L-dopa inhibited the early metoclopramide-induced prolactin increase, which is consistent with the possibility that metoclopramide acts by inhibiting dopamine-mediated hypothalamic secretion of prolactin inhibitory factor. Dopamine 176-184 prolactin Homo sapiens 76-85 777023-4 1976 Pre-treatment with 500 mg L-dopa inhibited the early metoclopramide-induced prolactin increase, which is consistent with the possibility that metoclopramide acts by inhibiting dopamine-mediated hypothalamic secretion of prolactin inhibitory factor. Dopamine 176-184 prolactin Homo sapiens 220-229 55749-0 1976 Letter: Dopamine-induced inhibition of prolactin and growth hormone secretion in acromegaly. Dopamine 8-16 prolactin Homo sapiens 39-48 33914699-1 2021 CONTEXT: Prolactinomas frequently cause amenorrhoea, galactorrhoea and infertility and require dopamine agonist (DA) treatment to normalize prolactin levels and hence restore ovulation. Dopamine 95-103 prolactin Homo sapiens 140-149 4818768-0 1974 Studies on the mechanism of the dopamine-mediated inhibition of prolactin secretion. Dopamine 32-40 prolactin Homo sapiens 64-73 5061810-0 1972 Effects of prolactin and ergot alkaloids on the tubero-infundibular dopamine (DA) neurons. Dopamine 68-76 prolactin Homo sapiens 11-20 33358454-10 2021 Erectile dysfunction caused by pituitary neoplasms is a multifactorial disease and elevated prolactin has consequences on testosterone, LH, FSH, and dopamine precursor levels. Dopamine 149-157 prolactin Homo sapiens 92-101 33961352-10 2021 Especially in the female AUD patients under remission, alcohol use trait-related factors were better predictors of the level of prolactin than the alcohol use state-related factors, indicating that individuals might characteristically have varying degree of dopamine reactivity. Dopamine 258-266 prolactin Homo sapiens 128-137 33902531-11 2021 CONCLUSIONS: Reasons for the association between prolactin and metabolic parameters include direct effects of prolactin on adipose tissue, hyperprolactinaemia-triggered hypogonadism and dopamine-agonist therapy per se. Dopamine 186-194 prolactin Homo sapiens 49-58 33706313-2 2022 The preferred first-line therapy is a medical treatment with dopamine agonists (DA), mainly cabergoline, to reduce serum prolactin levels, tumor volume, and mass effect. Dopamine 61-69 prolactin Homo sapiens 121-130 32857272-3 2020 We present the rare case of a patient who had prolactin elevation typical of a prolactin-secreting pituitary macroadenoma,with a normal cranial MRI, and in whom the prolactin rose further with dopamine agonist treatment. Dopamine 193-201 prolactin Homo sapiens 79-88 32857272-3 2020 We present the rare case of a patient who had prolactin elevation typical of a prolactin-secreting pituitary macroadenoma,with a normal cranial MRI, and in whom the prolactin rose further with dopamine agonist treatment. Dopamine 193-201 prolactin Homo sapiens 79-88 32781144-4 2020 She was initially treated with dopamine agonists with normalization of prolactin levels but no changes on the size of the lesion. Dopamine 31-39 prolactin Homo sapiens 71-80 32737582-2 2020 In addition to its role in the regulation of HPT axis, TRH is a potent regulator of prolactin (PRL) secretion by stimulating PRL secretion either directly from lactotrophs or indirectly via its action on the tuberoinfundibular dopamine (TIDA) neurons. Dopamine 227-235 prolactin Homo sapiens 84-93 33254515-3 2020 It has been reported that by controlled enhancement of blood PRL level (within the physiological limit and in some cases a little elevated above the normal to induce mild hyperprolactinemia) using dopamine antagonists such immune-stimulatory advantage can led to survival of the patients in many critical conditions. Dopamine 197-205 prolactin Homo sapiens 61-64 33254515-4 2020 Here it is hypothesized that through controlled augmentation of blood PRL level using dopamine antagonists like domperidone/metoclopramide, which are commonly used drugs for the treatment of nausea and vomiting, both innate and adaptive immunity can be boosted to evade or tone down COVID-19. Dopamine 86-94 prolactin Homo sapiens 70-73 32654174-11 2020 CONCLUSIONS: The obtained results suggest that dopamine agonist-induced hypoprolactinemia impairs sexual functioning and well-being in young women, as well as that these disturbances are secondary to low prolactin levels, not to specific properties of cabergoline. Dopamine 47-55 prolactin Homo sapiens 76-85 32737582-2 2020 In addition to its role in the regulation of HPT axis, TRH is a potent regulator of prolactin (PRL) secretion by stimulating PRL secretion either directly from lactotrophs or indirectly via its action on the tuberoinfundibular dopamine (TIDA) neurons. Dopamine 227-235 prolactin Homo sapiens 95-98 32508315-2 2020 Dopamine agonists stimulate the dopamine D2 receptor, resulting in a decrease in prolactin (PRL) levels and in prolactinoma size but action on dopamine receptors in the meso-limbic system may rarely cause psychosis and more commonly cause impulse control disorders. Dopamine 32-40 prolactin Homo sapiens 81-90 32508315-2 2020 Dopamine agonists stimulate the dopamine D2 receptor, resulting in a decrease in prolactin (PRL) levels and in prolactinoma size but action on dopamine receptors in the meso-limbic system may rarely cause psychosis and more commonly cause impulse control disorders. Dopamine 0-8 prolactin Homo sapiens 81-90 32741482-1 2020 Dopamine agonist therapy is the primary therapy for prolactin-secreting adenomas and usually results in normoprolactinemia, eugonadism, and tumor reduction. Dopamine 0-8 prolactin Homo sapiens 52-61 32508315-2 2020 Dopamine agonists stimulate the dopamine D2 receptor, resulting in a decrease in prolactin (PRL) levels and in prolactinoma size but action on dopamine receptors in the meso-limbic system may rarely cause psychosis and more commonly cause impulse control disorders. Dopamine 0-8 prolactin Homo sapiens 92-95 32508315-2 2020 Dopamine agonists stimulate the dopamine D2 receptor, resulting in a decrease in prolactin (PRL) levels and in prolactinoma size but action on dopamine receptors in the meso-limbic system may rarely cause psychosis and more commonly cause impulse control disorders. Dopamine 32-40 prolactin Homo sapiens 92-95 33072650-3 2020 Conversely, dopamine antagonist drugs increase prolactin in patients with simultaneous schizophrenia. Dopamine 12-20 prolactin Homo sapiens 47-56 32508315-5 2020 In those who require dopamine agonists for PRL and tumor size control, the introduction of antipsychotics may blunt this effect, so that higher doses of the dopamine agonists may be needed. Dopamine 21-29 prolactin Homo sapiens 43-46 31686376-6 2020 Although most prolactin secreting adenomas diagnosed during menopause are large, they respond well to dopamine agonist treatment. Dopamine 102-110 prolactin Homo sapiens 14-23 32760348-4 2020 Despite the continuation of dopamine agonist after surgery, serum prolactin level progressively increased to above 8,000 ng/ml in 5 years. Dopamine 28-36 prolactin Homo sapiens 66-75 32760348-14 2020 This case suggests that highly sustained serum prolactin levels during the dopamine agonist may indicate prolactin-producing pituitary carcinomas with hidden metastases. Dopamine 75-83 prolactin Homo sapiens 47-56 32760348-14 2020 This case suggests that highly sustained serum prolactin levels during the dopamine agonist may indicate prolactin-producing pituitary carcinomas with hidden metastases. Dopamine 75-83 prolactin Homo sapiens 105-114 32243999-4 2020 Almost all antipsychotics lead to hyperprolactinemia by blocking dopamine D2 receptors in the anterior pituitary gland, which counteracts dopamine"s inhibitory action on prolactin secretion. Dopamine 65-73 prolactin Homo sapiens 39-48 32793702-2 2020 Dopamine receptor agonists (DAs) are effective in reducing prolactin levels and tumor mass, but some prolactinoma patients are resistant to DAs. Dopamine 0-8 prolactin Homo sapiens 59-68 32413670-9 2020 RESULTS: Methyldopa alterate neurotrophic factors levels, impairs cerebral blood flow, and through dopamine level reduction it impairs reward system and increase prolactin release. Dopamine 99-107 prolactin Homo sapiens 162-171 32429916-8 2020 We identified four significant predictors of dopamine agonist resistance: male gender, a large tumour volume, prolonged time to prolactin normalization and presence of a cystic, hemorrhagic and/or necrotic component. Dopamine 45-53 prolactin Homo sapiens 128-137 31853893-5 2020 She was successfully managed with cabergoline, a dopamine agonist, with a reduction in the size of the tumor and normalization of serum prolactin levels. Dopamine 49-57 prolactin Homo sapiens 136-145 31802331-3 2020 RESULTS: Medical treatment with the dopamine agonist, cabergoline, became the preferred first-line treatment for male prolactinomas as well as for giant tumors, leading to prolactin normalization in ~ 80% of treated men, and tumor shrinkage, improved visual fields and recovery of hypogonadism in most patients. Dopamine 36-44 prolactin Homo sapiens 118-127 33305662-9 2020 CONCLUSIONS: PRL involvement in GE pathogenesis and more intense therapeutic impact on pain syndrome in case of combined administration of dopamine and standard hormone therapy prove cabergoline application in clinical practice. Dopamine 139-147 prolactin Homo sapiens 13-16 32392109-4 2020 The hypothalamus-pituitary system, the most important endocrine system in the body, regulates prolactin secretion mainly through dopamine released from tuberoinfundibular dopaminergic neurons. Dopamine 129-137 prolactin Homo sapiens 94-103 32597492-11 2020 Dopamine receptors were positively immunostained in all the investigated PRL-immunopositive and all PRL-immunonegative adenomas. Dopamine 0-8 prolactin Homo sapiens 73-76 32597492-11 2020 Dopamine receptors were positively immunostained in all the investigated PRL-immunopositive and all PRL-immunonegative adenomas. Dopamine 0-8 prolactin Homo sapiens 100-103 32082942-1 2019 The inverse relationship between prolactin and dopamine is important in the context of treatment with antipsychotic medications in men and nonpregnant women with thought disorders. Dopamine 47-55 prolactin Homo sapiens 33-42 31319705-1 2019 Prolactin (PRL) levels can usually be controlled by PRL-inhibiting psychiatric drugs that include anti-dopamine agents. Dopamine 103-111 prolactin Homo sapiens 0-9 31319705-1 2019 Prolactin (PRL) levels can usually be controlled by PRL-inhibiting psychiatric drugs that include anti-dopamine agents. Dopamine 103-111 prolactin Homo sapiens 11-14 31319705-1 2019 Prolactin (PRL) levels can usually be controlled by PRL-inhibiting psychiatric drugs that include anti-dopamine agents. Dopamine 103-111 prolactin Homo sapiens 52-55 32082942-4 2019 Our previously published paper, "Placental Barrier and Autism Spectrum Disorders: The Role of Prolactin and Dopamine on the Developing Fetal Brain," summarized evidence for dysregulated dopamine and prolactin levels in the etiology of ASDs and suggested a possible method for assessing whether such aberrations increase the risk of ASDs. Dopamine 108-116 prolactin Homo sapiens 199-208 32082942-4 2019 Our previously published paper, "Placental Barrier and Autism Spectrum Disorders: The Role of Prolactin and Dopamine on the Developing Fetal Brain," summarized evidence for dysregulated dopamine and prolactin levels in the etiology of ASDs and suggested a possible method for assessing whether such aberrations increase the risk of ASDs. Dopamine 186-194 prolactin Homo sapiens 94-103 31523679-9 2019 However, the inhibitory effects of dopamine on prolactin by caffeine remain to be elucidated. Dopamine 35-43 prolactin Homo sapiens 47-56 31167164-0 2019 Confirmation of a new therapeutic option for aggressive or dopamine agonist-resistant prolactin pituitary neuroendocrine tumors. Dopamine 59-67 prolactin Homo sapiens 86-95 30986806-1 2019 Dopamine agonists (DAs, especially cabergoline) are recommended as first-line treatment in patients with prolactin-secreting pituitary adenomas, to reduce hormone secretion and tumor size. Dopamine 0-8 prolactin Homo sapiens 105-114 31106995-7 2019 Results: Risperidone, paliperidone, and amisulpride are associated with higher prolactin levels than would be anticipated from striatal dopamine receptor occupancy studies. Dopamine 136-144 prolactin Homo sapiens 79-88 30967134-4 2019 Moreover, the activity of prolactin-producing lactotrophs also depends on other hormones which are regulated by the extra-pituitary activity of dopamine receptors, dopamine transporters, enzymes of neurotransmitter metabolism and other factors. Dopamine 144-152 prolactin Homo sapiens 26-35 29940665-5 2019 Dopamine agonist represented an efficient method to control PRL concentrations (98.8%) and reduce tumor burdens (81.2 %). Dopamine 0-8 prolactin Homo sapiens 60-63 30967134-4 2019 Moreover, the activity of prolactin-producing lactotrophs also depends on other hormones which are regulated by the extra-pituitary activity of dopamine receptors, dopamine transporters, enzymes of neurotransmitter metabolism and other factors. Dopamine 164-172 prolactin Homo sapiens 26-35 32145165-6 2019 A slight decrease in total protein in the blood and a tendency to a decrease in the level of PRL with increasing age against the background of a negative correlations between the low degree of PRL and age (r=-0,20; p=0,01), total protein and age (r=-0,35; p=0,01) confirm the participation of PRL in protein metabolism, and also indirectly indicate changes in the regulatory effect of dopamine on prolactin synthesis and secretion. Dopamine 385-393 prolactin Homo sapiens 93-96 30740089-1 2018 Dopamine agonists such as bromocriptine and cabergoline are the predominant treatment drugs for prolactinoma by inhibiting prolactin secretion and shrinking tumor size. Dopamine 0-8 prolactin Homo sapiens 96-105 30660191-5 2019 On the basis of the patient"s serum concentration of prolactin, we diagnosed a prolactinoma and started dopamine agonist therapy with cabergoline. Dopamine 104-112 prolactin Homo sapiens 53-62 32145165-6 2019 A slight decrease in total protein in the blood and a tendency to a decrease in the level of PRL with increasing age against the background of a negative correlations between the low degree of PRL and age (r=-0,20; p=0,01), total protein and age (r=-0,35; p=0,01) confirm the participation of PRL in protein metabolism, and also indirectly indicate changes in the regulatory effect of dopamine on prolactin synthesis and secretion. Dopamine 385-393 prolactin Homo sapiens 193-196 32145165-6 2019 A slight decrease in total protein in the blood and a tendency to a decrease in the level of PRL with increasing age against the background of a negative correlations between the low degree of PRL and age (r=-0,20; p=0,01), total protein and age (r=-0,35; p=0,01) confirm the participation of PRL in protein metabolism, and also indirectly indicate changes in the regulatory effect of dopamine on prolactin synthesis and secretion. Dopamine 385-393 prolactin Homo sapiens 193-196 30828702-11 2019 Cabergoline (dopamine agonist) is employed to decrease prolactin production and its role in the progression of androgen-independent malignancy. Dopamine 13-21 prolactin Homo sapiens 55-64 31211288-8 2019 He was treated with cabergoline (dopamine agonist) treatment, which decreased the plasma prolactin 88%; by inhibiting the pituitary production of prolactin. Dopamine 33-41 prolactin Homo sapiens 89-98 31211288-8 2019 He was treated with cabergoline (dopamine agonist) treatment, which decreased the plasma prolactin 88%; by inhibiting the pituitary production of prolactin. Dopamine 33-41 prolactin Homo sapiens 146-155 31208951-4 2019 Prolactin level is affected by (and reflects) brain dopamine availability. Dopamine 52-60 prolactin Homo sapiens 0-9 30852578-2 2019 Herein we provide an overview of the evolution of dopamine agonists and their use in patients with PRL-secreting pituitary tumors, starting from the 1970s up to today, highlighting that normalization of PRL levels, restoration of eugonadism, and reduction of tumor mass can be achieved in the majority of patients by treatment with dopamine agonists. Dopamine 50-58 prolactin Homo sapiens 99-102 30347396-6 2019 They respond to medical treatment with dopamine agonists in terms of prolactin normalization, tumor shrinkage, and improvement in pituitary function. Dopamine 39-47 prolactin Homo sapiens 69-78 30852578-2 2019 Herein we provide an overview of the evolution of dopamine agonists and their use in patients with PRL-secreting pituitary tumors, starting from the 1970s up to today, highlighting that normalization of PRL levels, restoration of eugonadism, and reduction of tumor mass can be achieved in the majority of patients by treatment with dopamine agonists. Dopamine 50-58 prolactin Homo sapiens 203-206 30542321-18 2018 Conclusion: This study confirms that tumors resistant to dopamine agonists are more aggressive, since we did not have any microadenoma; treatment with high dose of cabergoline may reduce the size of the tumor without its disappearance, and that normalization of prolactin concentration rarely occurs. Dopamine 57-65 prolactin Homo sapiens 262-271 31328184-6 2019 This has been achieved with cabergoline (dopamine agonist; Dostinex) treatment of a patient that resulted in 88% decreased plasma prolactin, and terminated the malignancy. Dopamine 41-49 prolactin Homo sapiens 130-139 29620428-3 2018 As prolactin release is negatively regulated by dopamine, peripheral prolactin levels confirmed the efficacy of our manipulation. Dopamine 48-56 prolactin Homo sapiens 3-12 30613511-2 2018 Prolactin (PRL) secretion is stimulated by dopamine antagonism and thyroid-releasing hormone. Dopamine 43-51 prolactin Homo sapiens 0-9 30613511-2 2018 Prolactin (PRL) secretion is stimulated by dopamine antagonism and thyroid-releasing hormone. Dopamine 43-51 prolactin Homo sapiens 11-14 29168011-5 2018 Dopamine agonist treatment (n = 22) was safe and effective, leading to reductions in tumor size (p < 0.01) and prolactin levels (p < 0.01). Dopamine 0-8 prolactin Homo sapiens 114-123 28925774-8 2018 A prolactin-producing uterine leiomyoma should be considered as a possible cause of hyperprolactinemia resistant to dopamine agonists. Dopamine 116-124 prolactin Homo sapiens 2-11 29483903-9 2018 Dopamine is an effective inhibitor of PRL secretion due to either a direct influence on the hypophysis or stimulation of postsynaptic dopamine receptors in the hypothalamus, arousing the release of the PRL inhibitory factor. Dopamine 0-8 prolactin Homo sapiens 38-41 29483903-9 2018 Dopamine is an effective inhibitor of PRL secretion due to either a direct influence on the hypophysis or stimulation of postsynaptic dopamine receptors in the hypothalamus, arousing the release of the PRL inhibitory factor. Dopamine 0-8 prolactin Homo sapiens 202-205 28954263-7 2018 At the last assessment, his prolactin level was 21.5 ng/mL, recorded after 21 years of treatment with the dopamine agonist cabergoline at a dose as high as 4.5 mg per week. Dopamine 106-114 prolactin Homo sapiens 28-37 28130617-10 2017 Bromocriptine, a dopamine analog that suppresses PRL secretion, was associated with decreased lupus activity, prolonged lifespan, and restoration of immune competence in experimental model. Dopamine 17-25 prolactin Homo sapiens 49-52 30785690-4 2018 A greater imbalance in the content of dopamine in Aborigines compared with the European population was combined with a higher levels of prolactin, sex hormone binding globulin, antisperm antibodies and with lower concentrations of lutropine, progesterone, total and free testosterone. Dopamine 38-46 prolactin Homo sapiens 136-145 28828544-8 2017 In both men, dopamine agonist therapy markedly reduced serum prolactin. Dopamine 13-21 prolactin Homo sapiens 61-70 27815961-2 2016 We report a child with a prolactin secreting macroadenoma which was refractory to initial treatment with a dopamine antagonist. Dopamine 107-115 prolactin Homo sapiens 25-34 28459037-4 2017 Dopamine is the main endogenous inhibitor of prolactin synthesis and secretion in the anterior pituitary. Dopamine 0-8 prolactin Homo sapiens 45-54 28245452-5 2017 Very recently, dopamine agonists have been demonstrated to be efficacious in the treatment of some autoimmune disorders, placing PRL-mediated interactions as potential therapeutic targets for treating autoimmunity. Dopamine 15-23 prolactin Homo sapiens 129-132 27521731-10 2016 Sellar lesions with only moderate elevations in serum prolactin, particularly those that are refractory to medical management with a dopamine agonist, should prompt further investigation to confirm the diagnosis. Dopamine 133-141 prolactin Homo sapiens 54-63 27169416-0 2016 Serum prolactin as a biomarker for the study of intracerebral dopamine effect in adult patients with phenylketonuria: a cross-sectional monocentric study. Dopamine 62-70 prolactin Homo sapiens 6-15 27455388-4 2016 A dopamine agonist is a compound with high efficacy in lowering prolactin levels and restoring gonadal function. Dopamine 2-10 prolactin Homo sapiens 64-73 27169416-1 2016 BACKGROUND: It has been previously postulated that high phenylalanine (Phe) might disturb intracerebral dopamine production, which is the main regulator of prolactin secretion in the pituitary gland. Dopamine 104-112 prolactin Homo sapiens 156-165 27119847-2 2016 (2016) report that oscillating hypothalamic TIDA neurons, previously thought to be simple neurosecretory neurons controlling pituitary prolactin secretion, control dopamine output via autoregulatory mechanisms and thus could potentially regulate other physiologically important hypothalamic neuronal circuits. Dopamine 164-172 prolactin Homo sapiens 135-144 27335526-5 2016 Dopamine acts as a tonic inhibitor of prolactin secretion through the tubero-infundibular dopaminergic system. Dopamine 0-8 prolactin Homo sapiens 38-47 27093067-4 2016 It is well-known that dopamine constitutively inhibits prolactin (PRL) secretion via the dopamine receptor 2 (DR2D). Dopamine 22-30 prolactin Homo sapiens 66-69 27093067-5 2016 If dopamine is increased or if dopamine receptors hyperfunction, PRL may be reduced. Dopamine 3-11 prolactin Homo sapiens 65-68 27093067-10 2016 In this dopamine-PRL pathway-focused-hypothesis-driven review on the association of SCZ with T2D, we report a specific revision of what it is known about PRL and dopamine in relation to what we theorize is one of the missing links between the two disorders. Dopamine 8-16 prolactin Homo sapiens 17-20 29193914-4 2016 However secondary resistanceto dopamine agonists therapy has also been described in patients who wereinitially responsive to treatment, either with Cabergoline or Bromocriptinebut later develop dopamine agonist resistance, with elevated prolactin levelsand sometimes an enlarging tumor volume several years afterwards. Dopamine 31-39 prolactin Homo sapiens 237-246 26971354-9 2016 CONCLUSIONS: Treatments with dopamine agonists represent a beneficial strategy for patients with prolactinoma accompanied with bone loss, in addition to their established efficacy in shrinkage of the size of pituitary tumors, normalization of PRL levels, and improvement of metabolic disorders. Dopamine 29-37 prolactin Homo sapiens 243-246 26944776-2 2016 Cabergoline is a dopamine agonist that acts centrally to normalize serum prolactin that could improve orgasmic dysfunction. Dopamine 17-25 prolactin Homo sapiens 73-82 29193914-3 2016 Less than 10% of patientswith prolactinomas exhibit resistance to the action of dopamine agonists, asdefined by the lack of normalization of the serum prolactin levels despite long-term treatment at high doses of these drugs. Dopamine 80-88 prolactin Homo sapiens 30-39 26744030-8 2016 The effects of human epidermal growth factor (hEGF) and dopamine (DA) on the expression and secretion of PRL in BAPDL at passage 4 were also investigated. Dopamine 56-64 prolactin Homo sapiens 105-108 29193914-4 2016 However secondary resistanceto dopamine agonists therapy has also been described in patients who wereinitially responsive to treatment, either with Cabergoline or Bromocriptinebut later develop dopamine agonist resistance, with elevated prolactin levelsand sometimes an enlarging tumor volume several years afterwards. Dopamine 194-202 prolactin Homo sapiens 237-246 29193928-3 2016 Less than 10% of patientswith prolactinomas exhibit resistance to the action of dopamine agonists, asdefined by the lack of normalization of the serum prolactin levels despite long-term treatment at high doses of these drugs. Dopamine 80-88 prolactin Homo sapiens 30-39 29193928-4 2016 However secondary resistanceto dopamine agonists therapy has also been described in patients who wereinitially responsive to treatment, either with Cabergoline or Bromocriptinebut later develop dopamine agonist resistance, with elevated prolactin levelsand sometimes an enlarging tumor volume several years afterwards. Dopamine 31-39 prolactin Homo sapiens 237-246 29193928-4 2016 However secondary resistanceto dopamine agonists therapy has also been described in patients who wereinitially responsive to treatment, either with Cabergoline or Bromocriptinebut later develop dopamine agonist resistance, with elevated prolactin levelsand sometimes an enlarging tumor volume several years afterwards. Dopamine 194-202 prolactin Homo sapiens 237-246 26590188-8 2015 After 10 years of treatment with dopamine agonists, the prolactin levels decreased by 96.8%, there was an effective reduction in tumour size, and the neurological signs and symptoms resolved. Dopamine 33-41 prolactin Homo sapiens 56-65 26515614-1 2016 The introduction of dopamine agonists for treating tetrahydrobiopterin deficiency imposes the evaluation of peripheral prolactin as the sole reliable biochemical marker of dopaminergic homeostasis. Dopamine 20-28 prolactin Homo sapiens 119-128 26243714-5 2015 Dopamine agonist therapy is the first line of treatment for prolactinomas because of its effectiveness in normalizing serum prolactin levels and shrinking tumor size. Dopamine 0-8 prolactin Homo sapiens 60-69 26256063-8 2015 Dopamine agonist therapy remains the first line of treatment for prolactinomas, as it is effective in normalizing serum prolactin levels and reducing tumor size. Dopamine 0-8 prolactin Homo sapiens 65-74 26583049-2 2015 Normalization of prolactin (PRL) with dopamine agonists has been found to reverse these abnormalities. Dopamine 38-46 prolactin Homo sapiens 17-26 26583049-2 2015 Normalization of prolactin (PRL) with dopamine agonists has been found to reverse these abnormalities. Dopamine 38-46 prolactin Homo sapiens 28-31 26101377-1 2015 The hypothalamic control of prolactin secretion is different from other anterior pituitary hormones, in that it is predominantly inhibitory, by means of dopamine from the tuberoinfundibular dopamine neurons. Dopamine 153-161 prolactin Homo sapiens 28-37 26634176-7 2015 This review article explores a possible link between in-utero exposure to a high maternal prolactin/dopamine ratio and subsequent development of autism spectrum disorders. Dopamine 100-108 prolactin Homo sapiens 90-99 26101377-1 2015 The hypothalamic control of prolactin secretion is different from other anterior pituitary hormones, in that it is predominantly inhibitory, by means of dopamine from the tuberoinfundibular dopamine neurons. Dopamine 190-198 prolactin Homo sapiens 28-37 26101377-3 2015 Instead, it is regulated by short loop feedback, whereby prolactin itself acts in the brain to stimulate production of dopamine and thereby inhibit its own secretion. Dopamine 119-127 prolactin Homo sapiens 57-66 26074878-3 2015 A dopamine agonist (DA) (bromocriptine or cabergoline) is the treatment of choice that can normalize prolactin levels, reduce tumor size, and restore ovulation and fertility. Dopamine 2-10 prolactin Homo sapiens 101-110 25062894-1 2015 BACKGROUND: The management of giant prolactinomas remains a major challenge, despite dopamine agonists being the first line of treatment, owing to its efficacy to normalize prolactin levels and reduce tumor volume. Dopamine 85-93 prolactin Homo sapiens 36-45 25162753-4 2015 After stabilizing surgery, the patient responded to dopamine agonist therapy with normalization of serum prolactin levels and pronounced reduction in tumor volume. Dopamine 52-60 prolactin Homo sapiens 105-114 25014320-0 2015 Effect of dopamine infusion on thyroid hormone tests and prolactin levels in very low birth weight infants. Dopamine 10-18 prolactin Homo sapiens 57-66 25014320-1 2015 OBJECTIVE: To evaluate the effect of dopamine on thyroid hormone tests and prolactin (PRL) and to assess requirement for L-thyroxin (LT4). Dopamine 37-45 prolactin Homo sapiens 75-84 25732643-3 2015 Dopamine agonists are efficacious in about 80% to 90% of patients with prolactinoma, leading to reduction of serum prolactin levels and tumor dimensions. Dopamine 0-8 prolactin Homo sapiens 71-80 25707872-5 2015 According to the finding that dopamine is the natural inhibitor of prolactin (PRL) incretion, we introduced the use of peripheral PRL measurement as an index of dopaminergic homeostasis, so avoiding the need of repeated lumbar punctures in patients with BH4 deficiency. Dopamine 30-38 prolactin Homo sapiens 67-76 23928066-6 2014 Antipsychotic-drugs block these receptors and thus remove the inhibitory effect of dopamine on prolactin secretion. Dopamine 83-91 prolactin Homo sapiens 95-104 26587235-7 2015 LEARNING POINTS: Dopamine agonists such as cabergoline, which are a standard treatment for microprolactinomas, can have serious adverse effects such as psychosis or valvular heart disease.Aripiprazole is a well-tolerated atypical antipsychotic that, unlike other antipsychotics, is a partial dopamine agonist capable of suppressing prolactin levels.Adjunctive, low-dose aripiprazole has been utilized to reverse risperidone-induced hyperprolactinemia.This case report demonstrates how aripiprazole monotherapy, in doses ranging from 2 to 10 mg/day, was effective in suppressing prolactin in a woman with a microprolactinoma who developed psychiatric side effects from cabergoline. Dopamine 17-25 prolactin Homo sapiens 96-105 26587235-7 2015 LEARNING POINTS: Dopamine agonists such as cabergoline, which are a standard treatment for microprolactinomas, can have serious adverse effects such as psychosis or valvular heart disease.Aripiprazole is a well-tolerated atypical antipsychotic that, unlike other antipsychotics, is a partial dopamine agonist capable of suppressing prolactin levels.Adjunctive, low-dose aripiprazole has been utilized to reverse risperidone-induced hyperprolactinemia.This case report demonstrates how aripiprazole monotherapy, in doses ranging from 2 to 10 mg/day, was effective in suppressing prolactin in a woman with a microprolactinoma who developed psychiatric side effects from cabergoline. Dopamine 17-25 prolactin Homo sapiens 332-341 25230324-1 2014 Dopamine agonists are considered as the first line therapy in prolactin (PRL) secreting pituitary adenomas inducing a normalization of serum PRL and reduction of tumor size. Dopamine 0-8 prolactin Homo sapiens 62-71 25230324-1 2014 Dopamine agonists are considered as the first line therapy in prolactin (PRL) secreting pituitary adenomas inducing a normalization of serum PRL and reduction of tumor size. Dopamine 0-8 prolactin Homo sapiens 73-76 25230324-1 2014 Dopamine agonists are considered as the first line therapy in prolactin (PRL) secreting pituitary adenomas inducing a normalization of serum PRL and reduction of tumor size. Dopamine 0-8 prolactin Homo sapiens 141-144 24337778-2 2014 Dopamine serves as a tonic inhibitor of prolactin release in the anterior hypophysis. Dopamine 0-8 prolactin Homo sapiens 40-49 25187719-2 2014 Earlier studies have indicated that terguride, which is a partial dopamine agonist, reduces the prolactin levels that are induced by prolactinemia. Dopamine 66-74 prolactin Homo sapiens 96-105 24094029-2 2014 Increased serum prolactin level is frequently associated with dopamine blocking antipsychotics. Dopamine 62-70 prolactin Homo sapiens 16-25 23868656-2 2013 The objective of this analysis was to report the results of a population pharmacokinetic analysis and to describe the relationship between risperidone and 9-hydroxyrisperidone levels with dopamine (DA) D2-receptor occupancy, prolactin levels, and adverse events using data collected in 45 clinically stable schizophrenic patients receiving RBP-7000 in single ascending doses (risperidone) of 60, 90, and 120 mg. Dopamine 188-196 prolactin Homo sapiens 225-234 23590895-9 2013 As enhanced prolactin can increase dopamine release through a feedback mechanism, this could contribute to explaining how stress can trigger the outbreak of psychosis. Dopamine 35-43 prolactin Homo sapiens 12-21 23968123-0 2013 Treating symptomatic hyperprolactinemia in women with schizophrenia: presentation of the ongoing DAAMSEL clinical trial (Dopamine partial Agonist, Aripiprazole, for the Management of Symptomatic ELevated prolactin). Dopamine 121-129 prolactin Homo sapiens 26-35 23385474-11 2013 CONCLUSIONS: Our data support recent evidence that the serum PRL concentration is rarely >1000 mIU/l in males, or >2000 mIU/l in females, with non-functioning macroadenomas and that, once other contributing factors to the hyperprolactinemia have been excluded, a trial of dopamine agonist therapy for such lesions is indicated. Dopamine 278-286 prolactin Homo sapiens 61-64 23211297-8 2012 PRL synthesis and secretion is mainly regulated by the inhibitory influence of dopamine but other hormones are also involved in these mechanisms. Dopamine 79-87 prolactin Homo sapiens 0-3 24096218-3 2013 Newer antipsychotic aripiprazole, partial dopamine agonist, with neutral effect on prolactin level or even decreasing it, is associated with avoidance of sexual dysfunction. Dopamine 42-50 prolactin Homo sapiens 83-92 21660520-3 2012 She was treated with dopamine agonists for 10 years and after cessation of therapy her prolactin levels remain normal. Dopamine 21-29 prolactin Homo sapiens 87-96 21660520-6 2012 With decline of pituitary size, after starting dopamine agonists, the traction probably reduced resulting in a normal prolactin level. Dopamine 47-55 prolactin Homo sapiens 118-127 23392818-2 2013 Prolactin elevation is the result of a direct antagonistic D(2) effect blocking the tonic inhibition of prolactin release by dopamine. Dopamine 125-133 prolactin Homo sapiens 0-9 23392818-2 2013 Prolactin elevation is the result of a direct antagonistic D(2) effect blocking the tonic inhibition of prolactin release by dopamine. Dopamine 125-133 prolactin Homo sapiens 104-113 23404929-0 2013 Establishment of paediatric age-related reference intervals for serum prolactin to aid in the diagnosis of neurometabolic conditions affecting dopamine metabolism. Dopamine 143-151 prolactin Homo sapiens 70-79 23404929-1 2013 BACKGROUND: There are a number of inborn errors of dopamine biosynthesis for which prolactin measurement may be a useful screening tool. Dopamine 51-59 prolactin Homo sapiens 83-92 22127489-1 2012 OBJECTIVE: Dopamine agonists normalize prolactin (PRL) levels and reduce tumour size in responsive prolactinoma. Dopamine 11-19 prolactin Homo sapiens 50-53 22288612-7 2012 RESULTS: Dopamine agonists normalized prolactin levels in 73 3% and 65 2% of patients with micro- and macroprolactinomas, respectively. Dopamine 9-17 prolactin Homo sapiens 38-47 22105468-6 2012 Given that prolactin is under negative control by dopamine and positive control by serotonin, typical antipsychotics induce elevations in prolactin, while atypical antipsychotics do not. Dopamine 50-58 prolactin Homo sapiens 11-20 22828169-8 2012 Compared to no treatment, dopamine agonists significantly reduced prolactin level (weighted mean difference, -45; 95% confidence interval, -77 to -11) and the likelihood of persistent hyperprolactinemia (relative risk, 0.90; 95% confidence interval, 0.81 to 0.99). Dopamine 26-34 prolactin Homo sapiens 66-75 22828169-12 2012 CONCLUSION: Our results provide evidence to support the use of dopamine agonists in reducing prolactin levels and persistent hyperprolactinemia, with cabergoline proving more efficacious than bromocriptine. Dopamine 63-71 prolactin Homo sapiens 93-102 22520146-3 2012 Dopamine agonists and radiotherapy allowed control of prolactin secretion and pituitary remnant. Dopamine 0-8 prolactin Homo sapiens 54-63 19288176-10 2012 Measurement of serum prolactin can expedite a diagnosis and prevent delay of treatment with dopamine agonists. Dopamine 92-100 prolactin Homo sapiens 21-30 22333523-4 2012 OBJECTIVE: Since dopamine is a prolactin-inhibiting factor and dopamine imbalanced has been implicated in the pathophysiology of psychotic disorders, we investigated the probable relationship between hyperprolactinemia and the development of psychotic symptoms, in a patient with hypogonadism due to hyperprolactnemia and subsequent first episode of psychosis. Dopamine 17-25 prolactin Homo sapiens 31-40 21404115-0 2011 Clomipramine-induced serum prolactin as a marker for serotonin and dopamine turnover: results of an open label study. Dopamine 67-75 prolactin Homo sapiens 27-36 22333523-5 2012 Since dopamine is a prolactin-inhibiting factor and dopamine imbalance has been implicated in the pathophysiology of psychotic disorders, we investigated the probable relationship between hyperprolactinemia and the development of psychotic symptoms. Dopamine 6-14 prolactin Homo sapiens 20-29 22333523-3 2012 Dopamine is the most important prolactin-inhibiting factor, and dopaminergic hyperactivity has been implicated in the pathophysiology of psychosis. Dopamine 0-8 prolactin Homo sapiens 31-40 22654846-3 2011 Here we describe a patient initially diagnosed with a pure prolactin-secreting microadenoma, who experienced the progressive apparition of symptomatic autonomous GH secretion while on intermittent long term dopamine agonist therapy. Dopamine 207-215 prolactin Homo sapiens 59-68 20814333-2 2010 Recent studies have suggested that aripiprazole, a partial dopamine agonist, reduces the prolactin response to antipsychotics. Dopamine 59-67 prolactin Homo sapiens 89-98 20720166-8 2010 Moreover, the experiments showed that these actions of PRL within gonadotroph cells are controlled by dopamine, the main hypothalamic inhibitory regulator of PRL release in vivo. Dopamine 102-110 prolactin Homo sapiens 55-58 20720166-8 2010 Moreover, the experiments showed that these actions of PRL within gonadotroph cells are controlled by dopamine, the main hypothalamic inhibitory regulator of PRL release in vivo. Dopamine 102-110 prolactin Homo sapiens 158-161 19104942-3 2011 Treatment with dopamine agonist alleviated all symptoms, with concomitant suppression of plasma prolactin levels and a significant reduction in tumor mass. Dopamine 15-23 prolactin Homo sapiens 96-105 22001219-2 2011 Dopamine serves as a tonic inhibitor of prolactin release in the anterior hypophysis, thus the serum prolactin levels in occupationally Mn exposed workers has been found increased. Dopamine 0-8 prolactin Homo sapiens 40-49 22001219-2 2011 Dopamine serves as a tonic inhibitor of prolactin release in the anterior hypophysis, thus the serum prolactin levels in occupationally Mn exposed workers has been found increased. Dopamine 0-8 prolactin Homo sapiens 101-110 21175437-1 2010 AIMS: The tolerance to the prolactin response following administration of antipsychotic drugs has been modelled as a depletion of a prolactin pool (pool model) and a model where the tolerance is explained by a feedback loop including the dopamine interaction of prolactin release (agonist-antagonist interaction model, (AAI model)). Dopamine 238-246 prolactin Homo sapiens 27-36 21175437-9 2010 CONCLUSIONS: According to the analysis performed here, a previous analysis of several clinical studies and literature reports on prolactin concentrations, it appears that the dopamine feedback mechanism included in the AAI model is better than the storage depletion mechanism in the pool model to estimate the bio-rhythm of prolactin time-course and the tolerance development across different populations, drugs, treatment schedules and time. Dopamine 175-183 prolactin Homo sapiens 129-138 21175437-9 2010 CONCLUSIONS: According to the analysis performed here, a previous analysis of several clinical studies and literature reports on prolactin concentrations, it appears that the dopamine feedback mechanism included in the AAI model is better than the storage depletion mechanism in the pool model to estimate the bio-rhythm of prolactin time-course and the tolerance development across different populations, drugs, treatment schedules and time. Dopamine 175-183 prolactin Homo sapiens 324-333 20578590-10 2010 PRL levels elevation in these diseases might result from several factors: an increased release of prolactin from the anterior pituitary due to inflammatory cytokines or reduced production of suppressive dopamine, or, alternatively, an increased production of prolactin in immune system cells. Dopamine 203-211 prolactin Homo sapiens 0-3 20371569-1 2010 Human prolactin (PRL) is currently viewed as a hormone of pituitary origin, whose production (i.e. serum levels) is controlled by dopamine, whose biological actions relate exclusively to lactation and reproductive functions, for which any genetic disorder is yet to be identified, and whose unique associated pathology is hyperprolactinemia. Dopamine 130-138 prolactin Homo sapiens 6-15 20371569-1 2010 Human prolactin (PRL) is currently viewed as a hormone of pituitary origin, whose production (i.e. serum levels) is controlled by dopamine, whose biological actions relate exclusively to lactation and reproductive functions, for which any genetic disorder is yet to be identified, and whose unique associated pathology is hyperprolactinemia. Dopamine 130-138 prolactin Homo sapiens 17-20 20058099-3 2010 We present herein a giant prolactin-secreting pituitary adenoma in a middle-aged man that had responded partially to dopamine agonist therapy. Dopamine 117-125 prolactin Homo sapiens 26-35 18846427-5 2010 Dopamine agonist therapy was initiated with significant decline in PRL levels; however, nausea, fatigue, and anorexia developed. Dopamine 0-8 prolactin Homo sapiens 67-70 20578590-10 2010 PRL levels elevation in these diseases might result from several factors: an increased release of prolactin from the anterior pituitary due to inflammatory cytokines or reduced production of suppressive dopamine, or, alternatively, an increased production of prolactin in immune system cells. Dopamine 203-211 prolactin Homo sapiens 98-107 20152122-1 2010 Hypothalamic dopamine neurons inhibit pituitary prolactin secretion. Dopamine 13-21 prolactin Homo sapiens 48-57 20347273-2 2010 At doses lower than those needed to stimulate prolactin release directly, TRH almost completely antagonizes the inhibitory effect of dopamine on prolactin release. Dopamine 133-141 prolactin Homo sapiens 145-154 20170699-1 2010 Hyperprolactinemia is a frequent consequence of treatment with antipsychotic agents, partially because the prolactin response to antipsychotics is related to dopamine blockade. Dopamine 158-166 prolactin Homo sapiens 5-14 31569891-2 2009 The author analyses results of experimental and clinical investigations published in the literature with special reference to the role of estrogens, progesterone, and dopamine in control of prolactin secretion and its regulation under normal and pathological conditions. Dopamine 167-175 prolactin Homo sapiens 190-199 31569891-0 2009 [Interactions of estrogens, progesterone, and dopamine in regulation of prolactin secretion]. Dopamine 46-54 prolactin Homo sapiens 72-81 20043526-2 2009 Imipramine, a monoamine oxidase inhibitor stimulates prolactin production because it decreases dopamine which inhibits secretion of prolactin. Dopamine 95-103 prolactin Homo sapiens 53-62 19243891-3 2009 We tested whether such an interaction is also revealed by prolactin secretion, which is predominantly controlled by hypothalamic dopamine. Dopamine 129-137 prolactin Homo sapiens 58-67 21183909-6 2010 The increase of psychopathologic symptoms leads to lowering of prolactin level regardless of sex that confirms the dopamine theory of schizophrenia. Dopamine 115-123 prolactin Homo sapiens 63-72 19758960-4 2009 The first-line therapy of prolactinomas are the dopamine agonists, and the aims of the treatment are to normalize the prolactin level, restore fertility in child-bearing age, decrease tumor mass, save or improve the residual pituitary function and inhibit the relapse of the disease. Dopamine 48-56 prolactin Homo sapiens 26-35 19524180-15 2009 CONCLUSION: Dopamine agonists are effective in normalizing prolactin values, and inducing tumor shrinkage. Dopamine 12-20 prolactin Homo sapiens 59-68 20043526-2 2009 Imipramine, a monoamine oxidase inhibitor stimulates prolactin production because it decreases dopamine which inhibits secretion of prolactin. Dopamine 95-103 prolactin Homo sapiens 132-141 19412154-5 2009 However, dopamine has potentially detrimental effects on the release of pituitary hormones and especially prolactin, although the clinical relevance of these effects is unclear. Dopamine 9-17 prolactin Homo sapiens 106-115 18651225-7 2009 Our data showed that that patients treated with dopamine agonists prior to surgery experienced greater reductions in prolactin levels, had lower prolactin levels, were more likely to have normal prolactin levels at long term follow-up, and were less likely to require additional therapy to control their prolactin levels. Dopamine 48-56 prolactin Homo sapiens 117-126 22140413-3 2009 The raised prolactin level had led to oligomenorrhoea prompting her general practitioner (GP) to check pituitary hormone levels.Metoclopramide is a potent dopamine antagonist and dopamine acts as the physiological inhibitor of prolactin synthesis. Dopamine 155-163 prolactin Homo sapiens 11-20 22140413-3 2009 The raised prolactin level had led to oligomenorrhoea prompting her general practitioner (GP) to check pituitary hormone levels.Metoclopramide is a potent dopamine antagonist and dopamine acts as the physiological inhibitor of prolactin synthesis. Dopamine 179-187 prolactin Homo sapiens 11-20 22140413-3 2009 The raised prolactin level had led to oligomenorrhoea prompting her general practitioner (GP) to check pituitary hormone levels.Metoclopramide is a potent dopamine antagonist and dopamine acts as the physiological inhibitor of prolactin synthesis. Dopamine 179-187 prolactin Homo sapiens 227-236 22140413-4 2009 Thus, the dopamine antagonism led to elevated prolactin level and the symptom of oligomenorrhoea.Following curtailment of the metoclopramide, the prolactin level normalised very quickly and the patient was reassured.Consideration should be given to non-pathological causes of hyperprolactinaemia, including physiological states such as pregnancy and concurrent medication. Dopamine 10-18 prolactin Homo sapiens 46-55 22140413-4 2009 Thus, the dopamine antagonism led to elevated prolactin level and the symptom of oligomenorrhoea.Following curtailment of the metoclopramide, the prolactin level normalised very quickly and the patient was reassured.Consideration should be given to non-pathological causes of hyperprolactinaemia, including physiological states such as pregnancy and concurrent medication. Dopamine 10-18 prolactin Homo sapiens 146-155 18791324-1 2009 BACKGROUND/AIMS: Prolactin (PRL) secretion and its gene expression are inhibited by dopamine. Dopamine 84-92 prolactin Homo sapiens 17-26 19358813-8 2009 Noteworthy, the neurotoxin-induced increase of prolactin secretion returns with time to a normal level due to the stimulation of DA synthesis by the tuberoinfundibular most probably monoenzymatic neurons. Dopamine 129-131 prolactin Homo sapiens 47-56 18651225-7 2009 Our data showed that that patients treated with dopamine agonists prior to surgery experienced greater reductions in prolactin levels, had lower prolactin levels, were more likely to have normal prolactin levels at long term follow-up, and were less likely to require additional therapy to control their prolactin levels. Dopamine 48-56 prolactin Homo sapiens 145-154 18651225-7 2009 Our data showed that that patients treated with dopamine agonists prior to surgery experienced greater reductions in prolactin levels, had lower prolactin levels, were more likely to have normal prolactin levels at long term follow-up, and were less likely to require additional therapy to control their prolactin levels. Dopamine 48-56 prolactin Homo sapiens 145-154 18651225-7 2009 Our data showed that that patients treated with dopamine agonists prior to surgery experienced greater reductions in prolactin levels, had lower prolactin levels, were more likely to have normal prolactin levels at long term follow-up, and were less likely to require additional therapy to control their prolactin levels. Dopamine 48-56 prolactin Homo sapiens 145-154 18651225-9 2009 In fact, pretreatment with dopamine agonist drugs, possibly by inducing tumor regression, seemed to improve the surgeon"s ability to resect a greater percentage of the tumor and led to better control of the prolactin level. Dopamine 27-35 prolactin Homo sapiens 207-216 18848860-12 2008 The prolactin-normalizing effects of aripiprazole are likely caused by the unique characteristics of the dopamine partial agonist with its high affinity for dopamine D2 receptors. Dopamine 105-113 prolactin Homo sapiens 4-13 18633321-3 2008 Among the 40 patients with PRL-producing pituitary adenoma, 16 had been preoperatively treated with the dopamine agonist bromocriptine. Dopamine 104-112 prolactin Homo sapiens 27-30 18720422-1 2008 It has previously been reported that the glutamate ionotropic antagonist phencyclidine directly inhibits the release of prolactin in anterior pituitary cells in culture, suggesting that phencyclidine has a dopamine (DA)-like action on prolactin-releasing cells. Dopamine 206-214 prolactin Homo sapiens 120-129 18720422-1 2008 It has previously been reported that the glutamate ionotropic antagonist phencyclidine directly inhibits the release of prolactin in anterior pituitary cells in culture, suggesting that phencyclidine has a dopamine (DA)-like action on prolactin-releasing cells. Dopamine 216-218 prolactin Homo sapiens 120-129 18797434-10 2008 MANAGEMENT: Steroid replacement, careful control of fluid and electrolyte balance and conservative nonsurgical management with the dopamine agonist cabergoline resulted in resolution of the patient"s headache, improvement of the third nerve palsy and subsequent normalization of the prolactin level, with reduction in size of the prolactinoma on MRI scan. Dopamine 131-139 prolactin Homo sapiens 283-292 18096663-0 2008 Dopamine inhibits basal prolactin release in pituitary lactotrophs through pertussis toxin-sensitive and -insensitive signaling pathways. Dopamine 0-8 prolactin Homo sapiens 24-33 18332900-1 2008 Dopamine-agonist cabergoline (CB) reduces prolactin (PRL) secretion and tumor size in 80% of patients with prolactin-secreting adenomas (PRL-omas) by binding type 2 dopamine receptor (DRD2). Dopamine 0-8 prolactin Homo sapiens 42-51 18332900-1 2008 Dopamine-agonist cabergoline (CB) reduces prolactin (PRL) secretion and tumor size in 80% of patients with prolactin-secreting adenomas (PRL-omas) by binding type 2 dopamine receptor (DRD2). Dopamine 0-8 prolactin Homo sapiens 107-116 18579277-0 2008 Association between dopamine-related polymorphisms and plasma concentrations of prolactin during risperidone treatment in schizophrenic patients. Dopamine 20-28 prolactin Homo sapiens 80-89 18579277-1 2008 Hyperprolactinemia is an inevitable consequence of treatment with antipsychotic agents to some extent because prolactin response to antipsychotics is related to dopamine blockade. Dopamine 161-169 prolactin Homo sapiens 5-14 18579277-3 2008 Thus, we studied the effects of major polymorphisms of dopamine-related genes on plasma concentration of prolactin. Dopamine 55-63 prolactin Homo sapiens 105-114 18096663-4 2008 Here we show that the dopamine agonist-induced inhibition of spontaneous Ca(2+) influx and release of prestored PRL was preserved when cAMP levels were elevated by forskolin treatment. Dopamine 22-30 prolactin Homo sapiens 112-115 18096663-9 2008 Thus, dopamine inhibits basal PRL release by blocking voltage-gated Ca(2+) influx through the PTX-sensitive signaling pathway and by desensitizing Ca(2+) secretion coupling through the PTX-insensitive and protein kinase C-sensitive signaling pathway. Dopamine 6-14 prolactin Homo sapiens 30-33 18477617-2 2008 Dopamine (DA) holds a predominant role in the regulation of prolactin (PRL) secretion. Dopamine 0-8 prolactin Homo sapiens 60-69 18477617-2 2008 Dopamine (DA) holds a predominant role in the regulation of prolactin (PRL) secretion. Dopamine 10-12 prolactin Homo sapiens 60-69 18477618-3 2008 Prolactin is secreted from the anterior pituitary gland under the influence of dopamine, which exerts a tonic inhibitory effect on prolactin secretion. Dopamine 79-87 prolactin Homo sapiens 0-9 18477618-3 2008 Prolactin is secreted from the anterior pituitary gland under the influence of dopamine, which exerts a tonic inhibitory effect on prolactin secretion. Dopamine 79-87 prolactin Homo sapiens 131-140 18393218-2 2008 We hypothesized that women with chronic anovulation should show exacerbated secretion of prolactin (PRL) after thyrotropin-releasing hormone (TRH) stimulation test, having more chances for dopamine inhibitory dysfunction due to alterations in the structure of DRD3. Dopamine 189-197 prolactin Homo sapiens 89-98 17590551-3 2008 It has been reported that serum prolactin levels are elevated in patients with PTPS deficiency indicating that inhibition of prolactin secretion by dopamine is insufficient and is negatively correlated with the CSF level of HVA. Dopamine 148-156 prolactin Homo sapiens 125-134 17329276-8 2007 Suppression of TSH, T(4) and PRL was observed in dopamine-treated newborns from 12 h of treatment onwards, whereas levels of growth hormone reduced significantly only at 12 h and 36 h of treatment (p<0.01). Dopamine 49-57 prolactin Homo sapiens 29-32 17329276-9 2007 TSH, T(4) and PRL rebound was observed from the first day onwards after stopping dopamine. Dopamine 81-89 prolactin Homo sapiens 14-17 17329276-12 2007 Dopamine reduces serum levels of TSH, T(4) and PRL in VLBW infants but such suppression is quickly reversed after treatment is stopped. Dopamine 0-8 prolactin Homo sapiens 47-50 17195425-4 2006 She was treated for over 2 years with dopamine agonists, with which her prolactin level normalized, but she remained infertile. Dopamine 38-46 prolactin Homo sapiens 72-81 17521855-4 2007 Dopamine has numerous potential deleterious effects on local circulations (pulmonary, cerebral, coronary and cutaneous), respiratory function, gastroduodenal motility, endocrine function (further depression of the hypothalamic-pituitary axis induced by stress) and immunity (partially due to decreased production of prolactin). Dopamine 0-8 prolactin Homo sapiens 316-325 17557033-8 2007 Normalization of PRL levels during therapy with dopamine agonists was significantly more frequent in patients with monomeric hyperprolactinemia than in subjects with macroprolactinemia (78.6% vs 32%, P=0.0006). Dopamine 48-56 prolactin Homo sapiens 17-20 17058022-0 2007 Low dose of dopamine may stimulate prolactin secretion by increasing fast potassium currents. Dopamine 12-20 prolactin Homo sapiens 35-44 17058022-3 2007 Surprisingly, at concentrations approximately 1000 lower, DA can stimulate prolactin secretion. Dopamine 58-60 prolactin Homo sapiens 75-84 17308959-2 2007 During therapy with a dopamine agonist, prolactin levels usually normalize and the tumors shrink substantially. Dopamine 22-30 prolactin Homo sapiens 40-49 17308959-12 2007 We conclude that in patients with massive prolactin hypersecretion, therapy with a dopamine agonist will lead to tumor shrinkage and improvement of mass effects, but usually does not normalize prolactin or testosterone. Dopamine 83-91 prolactin Homo sapiens 42-51 17519641-6 2007 These results suggest that the blockade of higher dopamine activity in the paranoid schizophrenia corresponds to the prolactin increase, more than in the schizoaffective and disorganized subtypes. Dopamine 50-58 prolactin Homo sapiens 117-126 17641533-1 2007 BACKGROUND: Plasma prolactin levels are sensitive to dopamine and serotonin function, and fatigue. Dopamine 53-61 prolactin Homo sapiens 19-28 16675366-14 2006 The dopamine agonists used to treat Parkinson"s disease--bromocriptine, pergolide, pramipexole, ropinerole--usually reverse antipsychotic-induced prolactin increases without compromising psychiatric effectiveness. Dopamine 4-12 prolactin Homo sapiens 146-155 17024154-1 2006 Resistance to dopamine agonists occurs in a subset of patients with prolactin-secreting pituitary tumors. Dopamine 14-22 prolactin Homo sapiens 68-77 17024156-3 2006 Currently, therapeutic management of hyperprolactinemia relies on dopamine agonists, since dopamine is the primary physiological suppressor of pituitary prolactin production. Dopamine 66-74 prolactin Homo sapiens 42-51 17024156-3 2006 Currently, therapeutic management of hyperprolactinemia relies on dopamine agonists, since dopamine is the primary physiological suppressor of pituitary prolactin production. Dopamine 91-99 prolactin Homo sapiens 42-51 17024156-7 2006 These findings have renewed the interest in finding alternative strategies to suppress prolactin actions when dopamine agonists are ineffective. Dopamine 110-118 prolactin Homo sapiens 87-96 16482082-2 2006 We tested the hypothesis that, independent of the antipsychotic-induced rise in prolactin, the incidence of TD would be associated with the incidence of prolactin-related sexual disturbances (PRSD), which would be suggestive of a common pathology involving multiple dopamine tracts. Dopamine 266-274 prolactin Homo sapiens 153-162 16480723-4 2006 Circulating prolactin levels were suppressed using cabergoline (Dostinex: Pfizer), a long acting dopamine (D2) agonist with minimal behavioural side-effects. Dopamine 97-105 prolactin Homo sapiens 12-21 19338911-4 2006 Serum prolactin levels were high, and she was treated with carbegoline, a dopamine agonist, which suppressed the prolactin secretion and led to rapid cessation of lactation. Dopamine 74-82 prolactin Homo sapiens 113-122 16772199-10 2006 Approximately 40% of patients in the macroprolactin group were treated with a dopamine agonist, 28% of whom had normalization of the total prolactin level. Dopamine 78-86 prolactin Homo sapiens 42-51 16288952-4 2006 These pituitary tumours may produce an excessive amount of prolactin or disrupt the normal delivery of dopamine from the hypothalamus to the pituitary; prolactin secretion from the pituitary is inhibited by dopamine released from neurones in the hypothalamus. Dopamine 207-215 prolactin Homo sapiens 152-161 16288952-8 2006 Pharmacological intervention should be considered the first line therapy and involves the use of dopamine agonists to reduce tumour size and prolactin levels. Dopamine 97-105 prolactin Homo sapiens 141-150 16288952-15 2006 Surgery should be considered only in certain circumstances, and for the majority of patients, dopamine agonists will be sufficient to alleviate symptoms and restore normal prolactin levels. Dopamine 94-102 prolactin Homo sapiens 172-181 16508259-1 2006 BACKGROUND: Previous studies demonstrated that dopamine infusion reduces plasma concentration of thyroxine (T4), thyroid stimulating hormone (TSH), prolactin (PRL), and growth hormone (GH) in adults, children, and infants. Dopamine 47-55 prolactin Homo sapiens 148-157 16711341-1 2006 A large proportion of prolactin secreting tumours of the pituitary gland are treatable by dopamine agonist drugs. Dopamine 90-98 prolactin Homo sapiens 22-31 16328513-0 2006 Morphologic changes of prolactin-producing pituitary adenomas after short treatment with dopamine agonists. Dopamine 89-97 prolactin Homo sapiens 23-32 16328513-1 2006 Treatment of patients with prolactin (PRL)-producing pituitary adenomas with dopamine agonists has proved successful for most cases. Dopamine 77-85 prolactin Homo sapiens 27-36 16328513-1 2006 Treatment of patients with prolactin (PRL)-producing pituitary adenomas with dopamine agonists has proved successful for most cases. Dopamine 77-85 prolactin Homo sapiens 38-41 16328513-2 2006 Dopamine agonists inhibit PRL secretion, suppress cell proliferation, and may induce apoptosis to adenoma cells. Dopamine 0-8 prolactin Homo sapiens 26-29 16328513-3 2006 Dopamine agonists induce striking morphologic changes in the majority of treated PRL-producing adenomas. Dopamine 0-8 prolactin Homo sapiens 81-84 16328513-6 2006 The purpose of this report is to describe the morphologic changes seen in PRL-producing adenomas after short-term dopamine agonist treatment. Dopamine 114-122 prolactin Homo sapiens 74-77 16328513-7 2006 We present two cases of PRL-producing macroadenomas, both from male patients who received treatment with dopamine agonists, the first for 5 and the second for 8 days. Dopamine 105-113 prolactin Homo sapiens 24-27 16508259-1 2006 BACKGROUND: Previous studies demonstrated that dopamine infusion reduces plasma concentration of thyroxine (T4), thyroid stimulating hormone (TSH), prolactin (PRL), and growth hormone (GH) in adults, children, and infants. Dopamine 47-55 prolactin Homo sapiens 159-162 16508259-2 2006 OBJECTIVES: The purpose of this prospective observational study was to evaluate the relationship between dopamine infusion and the dynamics of T4, TSH, PRL, and GH in preterm newborns weighing less than 1,500 g (very low birth weight infants, VLBW) admitted in a neonatal intensive care unit of a university hospital over a one year period. Dopamine 105-113 prolactin Homo sapiens 152-155 16508259-6 2006 RESULTS: Among the VLBW newborns who were given dopamine, the four pituitary hormones had different dynamics: a reduction of T4, TSH, and PRL levels was noticed since the first day of treatment, and a rebound of their levels was evident since the first day after its interruption. Dopamine 48-56 prolactin Homo sapiens 138-141 16508259-9 2006 CONCLUSIONS: The results suggest that dopamine infusion reduces T4, TSH, and PRL plasma levels in preterm VLBW infants and have no effect on postprandial GH rate. Dopamine 38-46 prolactin Homo sapiens 77-80 16357488-1 2006 BACKGROUND/AIMS: In animal models, prolactin increases tuberoinfundibular dopamine turnover, which has been demonstrated to suppress both hypothalamic GnRH and pituitary TSH secretion. Dopamine 74-82 prolactin Homo sapiens 35-44 15356045-2 2004 The release of PRL by the pituitary is tonically inhibited by dopamine through activation of the dopamine D2 receptor (D2R) of lactotroph cells, and obese humans appear to have reduced D2R-binding sites in their brain. Dopamine 62-70 prolactin Homo sapiens 15-18 16566383-7 2005 In the identification of hyperprolactinemia not only simple measurements of the prolactin serum level are used, the dynamic tests with the use of dopamine antagonists have a special role as well. Dopamine 146-154 prolactin Homo sapiens 30-39 15988468-1 2005 In humans, mu- and kappa-opioid receptor agonists lower tuberoinfundibular dopamine, which tonically inhibits prolactin release. Dopamine 75-83 prolactin Homo sapiens 110-119 15988468-2 2005 Serum prolactin is, therefore, a useful biomarker for tuberoinfundibular dopamine. Dopamine 73-81 prolactin Homo sapiens 6-15 16311416-3 2005 It is well known that dopamine agonists, such as bromocriptine, pergolide, quinagolide, cabergoline, and lisuride, can inhibit PRL secretion by binding to the D(2) dopamine receptors located on normal as well as tumorous pituitary cells. Dopamine 22-30 prolactin Homo sapiens 127-130 15856525-3 2005 Firstly, there had been long experience of use of dopamine antagonists (that increase prolactin) in human medicine and no evidence of an increase in breast cancer incidence or risk had been reported. Dopamine 50-58 prolactin Homo sapiens 86-95 15856525-4 2005 Secondly, dopamine agonists (that lower prolactin) had been shown to have no effect in human breast cancer treatment. Dopamine 10-18 prolactin Homo sapiens 40-49 15939210-2 2005 We hypothesized that environmental Pb exposure can interact with prolactin (PRL) secretion, regulated by calcium and dopamine, during pregnancy and in fetus. Dopamine 117-125 prolactin Homo sapiens 65-74 15939210-2 2005 We hypothesized that environmental Pb exposure can interact with prolactin (PRL) secretion, regulated by calcium and dopamine, during pregnancy and in fetus. Dopamine 117-125 prolactin Homo sapiens 76-79 16379032-11 2005 These data suggest that, in male macro- and giant prolactinomas, dopamine agonists represent the first-line therapy effective in reducing PRL, restoration of libido and potency, improvement of VFD and determining tumor shrinkage. Dopamine 65-73 prolactin Homo sapiens 138-141 15064918-1 2004 RATIONALE: Alteration in serum prolactin (PRL) levels may reflect changes in central dopamine activity, which modulates the behavioral effects of cocaine. Dopamine 85-93 prolactin Homo sapiens 31-40 15064918-1 2004 RATIONALE: Alteration in serum prolactin (PRL) levels may reflect changes in central dopamine activity, which modulates the behavioral effects of cocaine. Dopamine 85-93 prolactin Homo sapiens 42-45 16509147-14 2006 CONCLUSIONS: Dopamine agonist medications are effective as a first-line therapy for invasive giant prolactinomas, because they can significantly shrink tumor volume and control the PRL level. Dopamine 13-21 prolactin Homo sapiens 181-184 16279371-9 2005 Treatment with the non-selective dopamine agonist pergolide caused a significant reduction of serum PRL concentration with a remarkable decrease of body weight. Dopamine 33-41 prolactin Homo sapiens 100-103 15994755-11 2005 CONCLUSIONS: Novel dopamine-somatostatin chimeric molecules with differing, enhanced activity at sstr2, sstr5 and DAD2, consistently produced significatly greater suppression of GH and PRL than either octreotide or single-receptor-interacting ligands in tumors from patients classified as only partially responsive to octreotide therapy. Dopamine 19-27 prolactin Homo sapiens 185-188 15814850-6 2005 Such compounds are thus candidates to counteract the undesired actions of PRL, not only in tumors, but also in dopamine-resistant prolactinomas. Dopamine 111-119 prolactin Homo sapiens 74-77